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Abstract 
Core myopathies are a diverse group of congenital muscle diseases, which 
typically present with proximal muscle weakness, hypotonia and delayed 
motor milestones. Biopsies from affected individuals display ‘core’ areas that 
lack mitochondrial staining; despite cores being a pathological hallmark for 
these diseases, their formation and development is not well understood. In 
this thesis I have explored the involvement of mitochondrial dysfunction in 
core myopathy pathology by studying different models with mutations of 
proteins involved in intracellular calcium (Ca2+) homeostasis. 
The first model discussed is a new mouse sub-line carrying the I4898T 
mutation in RYR1. RYR1 codes for a Ca2+ release channel on the 
sarcoplasmic reticulum (SR) called Ryanodine Receptor 1 (RyR1), and given 
that mitochondria localise close to the SR, a faulty RyR1 is likely to upset the 
Ca2+ balance that is required for mitochondrial function. In contrast to studies 
of other RyR1 I4898T models, I did not observe reduced SR-stimulated Ca2+ 
release in myotubes or myofibres isolated from the heterozygous mice. 
Consequently, no defects in mitochondrial localisation, respiration or 
biogenesis were identified. 
The second model discussed is fibroblasts from a patient with a mutation in 
STAC3, which codes for an adaptor protein that is thought to be involved in 
excitation-contraction coupling. While histamine-induced Ca2+ signals were 
elevated in the patient fibroblasts, resting mitochondrial membrane potential 
was reduced. As STAC3 is predominantly expressed in skeletal muscle, 
these results are difficult to interpret and highlight the need for a future 
skeletal muscle model. 
The final model consists of fibroblasts from individuals that have loss-of-
function mutations in MICU1, which codes for a Ca2+ sensor that regulates 
the opening of the Mitochondrial Ca2+ Uniporter. The mitochondria in these 
MICU1-deficient fibroblasts are fragmented, exhibit accelerated mitochondrial 
Ca2+ uptake and are Ca2+-loaded at rest. While mitochondrial membrane 
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potential and respiration appear normal, there is evidence for a futile Ca2+ 
cycle across the mitochondrial membrane, which illustrates the bioenergetic 
cost of mitochondrial Ca2+ accumulation.  
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Chapter 1 Introduction 
Mitochondria play significant roles in cell and tissue physiology, including 
energy homeostasis, Ca2+ signalling and redox balance. They are regulators 
of not only cell life but cell death, and mitochondrial dysfunction contributes 
to a wide range of human diseases. In this thesis I have explored the 
proposition that mitochondrial dysfunction contributes to the pathophysiology 
of core myopathies. First, I have provided a broad overview of skeletal 
muscle physiology, core myopathy research and mitochondrial biology. I 
have then presented functional data from three different core myopathy cell 
models, which are finally discussed and evaluated in line with my research 
hypothesis. 
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1.1 Skeletal muscle physiology 
1.1.1 Skeletal muscle structure 
The skeletal muscles are the effector organs of the locomotor system, or 
musculoskeletal system, which is responsible for movement. They consist of 
bundles of multinucleated cells, called myofibres, which run roughly parallel 
to the line of muscle action (Figure 1.1) (Sciote & Morris 2014). Within each 
individual myofibre are protein filaments called myofibrils, which are 
subdivided into contractile elements known as sarcomeres (Figure 1.1). 
Sarcomeres work co-operatively so that when muscle contraction occurs, 
tension develops along the axis of the myofibrils and therefore along the 
myofibre itself. Sarcomeres are also directionally aligned across the 
myofibrils, giving the muscle a distinct ‘striated’ appearance consisting of 
light and dark bands. These bands are named after their birefringent 
properties under the light microscope: the light band is isotropic (I band) and 
the dark band is anisotropic (A band) (Jones & Round 1990) (Figure 1.1). 
Each myofibril is a bundle of contractile protein filaments called 
myofilaments. There are two major types of myofilaments: thick filaments and 
thin filaments, which are large polymers of myosin II and actin, respectively. 
While the myosin (thick) filaments make up the A band, the actin (thin) 
filaments make up the I band. The thick and thin filaments interdigitate to 
form a hexagonal lattice (Lieber 1992). The thin filaments of each sarcomere 
overlap at the ‘Z lines’, which define the area of each sarcomere (Figure 1.1). 
The region where there is no actin-myosin overlap is called the H zone 
(Figure 1.1).  
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Figure 1.1: Hierarchy of skeletal muscle organisation 
Figure taken from (Bloom & Forcett 1968). 
Each thin filament comprises two helical strands made up of G-actin 
monomers, which each have a myosin binding site. Tropomyosin winds 
along the groove of this actin double helix and effectively ‘hides’ the actin-
myosin binding sites when the muscle is relaxed. Associated with 
tropomyosin is a protein complex called troponin, which is made up of three 
subunits: Tn-T, which binds to tropomyosin and regulates the interaction of 
the troponin complex with the thin filaments; Tn-C, which binds Ca2+ released 
during excitation-contraction coupling (discussed in 1.1.3), triggering a 
conformational change in the tropomyosin-troponin complex that exposes the 
myosin binding sites and permits actin-myosin interaction; and Tn-I, which 
exerts an inhibitory influence on tropomyosin when Ca2+ is not present 
(Lieber 1992).  
Figure removed due to copyright restrictions 
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Myosins are motor proteins that interact with actin molecules and use ATP 
hydrolysis to ‘walk’ along the actin filament. In skeletal muscle, each myosin 
II molecule consists of two identical heavy chains wound around each other 
to form a rod portion that points to the centre of the sarcomere as well as two 
heads that extend laterally (Figure 1.1). The myosin heads of the thick 
filaments are able to bind actin in the thin filaments, forming attachments 
called cross bridges. ATP hydrolysis allows the cross bridges to generate 
force through a power stroke movement (Figure 1.2). As long as ATP and 
Ca2+ are present in the cytoplasm of the myofibre, repeated ATP hydrolysis 
and power strokes occur in what is known as the cross bridge cycle (Figure 
1.2). The resulting effect is that the thin filament is being ‘pulled’ by the 
myosin heads of the thick filament, causing both filaments to slide past each 
other. This reduces the size of the sarcomeres, shortening the myofibres 
(and the entire muscle) into a contracted state.  
Figure 1.2: Cross bridge cycle 
When no nucleotide is bound, the myosin head binds actin tightly in a ‘rigor’ state. 
When ATP binds (1), the interaction between the myosin head and actin weakens, 
causing the cross bridge to detach. The myosin head then hydrolyses the ATP (2), 
causing a conformational change that moves it to a new position where it can bind a 
different actin molecule. As phosphate (Pi) dissociates from the ATP binding pocket 
(3), the myosin head undergoes the power stroke, which restores myosin to the rigor 
state and forces the myosin to move the actin filament. ADP is then released (4). 
Diagram adapted from figure 18.25 in (Lodish et al. 2000). 
Figure removed due to copyright restrictions 
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1.1.2 Skeletal muscle fibre types 
Skeletal muscle fibres are generally classified according to the type of 
myosin heavy chain that is predominantly expressed. While type I fibres 
contain mostly slow-contracting myosins, type II fibres are made up of fast-
contracting myosins. For this reason, type I and II fibres are also referred to 
as slow-twitch and fast-twitch fibres, respectively. Type II fibres can be 
classified further according to their metabolic properties: type IIa (fast-twitch 
oxidative fibres) and IIb (fast-twitch glycolytic fibres). These three main fibre 
types are adapted for different purposes and so have different properties 
(summarised in Table 1.1 below). 
 Type I Type IIa Type IIb 
Contraction time Slow Moderately fast Fast 
Muscle fibre diameter Small Intermediate Large 
Oxidative capacity High Intermediate Low 
Fatigue resistance High Intermediate Low 
Power produced Low Medium High 
Mitochondrial content High High Low 
Myoglobin content High High Low 
Myosin heavy chain I IIa IIb 
Myosin ATPase activity Low High High 
Table 1.1: Characteristics of different muscle fibre types  
1.1.3 Skeletal muscle innervation 
Unlike cardiac and smooth muscles, skeletal muscles are under voluntary 
control. The stimulus for physiological skeletal muscle activity is always 
derived from an electrical impulse, or action potential, which comes from the 
neurons that innervate the skeletal muscle (the motorneurons). When a 
motorneuron in the brain stem or spinal cord is activated, the generated 
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action potential travels down its myelinated axon to its branches in the 
muscle. Myelin insulation does not cover the entire length of the axon; there 
are periodic gaps called nodes of Ranvier. The concentration of voltage-
dependent sodium channels in the axon membrane at each node, and 
electrical insulation of the fatty myelin sheath, ensure that action potentials 
rapidly jump from node to node by a process known as saltatory conduction 
(ffrench-Constant et al. 2004).  
Collectively, a motorneuron and the muscle fibres it innervates are called a 
‘motor unit’. Once a motorneuron is activated, all of the muscle fibres in one 
motor unit will contract at the same time, producing a synchronous electrical 
discharge (action potential) and generation of force (twitch) (Jones & Round 
1990). The number of muscle fibres per motor unit varies from muscle to 
muscle. The smallest motor units, containing as few as 3-10 muscle fibres, 
are found in muscles used for intricate fine movements (Hopkins 2006), for 
example in a small hand muscle. Much larger motor units, containing up to 
several hundred muscle fibres, are predominant in larger muscles used for 
gross vigorous movements (Hopkins 2006), such as the quadriceps. Motor 
units also differ in the type of muscle fibres they innervate; motor units that 
innervate small type I fibres are generally referred to as slow motor units, 
whereas the motor units that innervate type II fibres are called fast motor 
units. 
The neuromuscular junction is the synaptic connection between the axon 
branch of the motorneuron and the skeletal muscle fibre (Figure 1.3). Upon 
the arrival of an action potential at the presynaptic terminal, voltage-
dependent calcium channels open and there is an influx of Ca2+ from the 
extracellular fluid into the cytosol of the presynaptic bulb. This increase in 
Ca2+ concentration causes vesicles containing the neurotransmitter 
acetylcholine (ACh) to fuse with the presynaptic membrane and release their 
contents into the synaptic cleft (Jones & Round 1990). The ACh molecules 
diffuse across the cleft and fit into acetylcholine receptors (AChRs) in the 
postsynaptic muscle fibre membrane, referred to as the motor endplate, 
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which is invaginated to increase the surface area exposed to the synaptic 
cleft (Figure 1.3). 
Binding of ACh to the AChRs causes a depolarisation of the muscle fibre 
membrane (referred to as the sarcolemma) (Figure 1.3). A regenerative 
action potential is initiated and propagates down the length of the muscle 
fibre. The sarcolemma is characterised by deep invaginations called 
transverse tubules (t-tubules) that allow the action potential to reach the 
fibre’s interior. The t-tubule system is closely associated with the longitudinal 
sarcoplasmic reticulum (SR), which is the primary intracellular Ca2+ 
storage/release organelle found in striated muscles.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: Neuromuscular junction 
When an action potential reaches the presynaptic terminal, Ca2+ channels open 
causing vesicles containing ACh (purple) to fuse with the presynaptic membrane 
and release ACh into the synaptic cleft. Binding of ACh to AChRs (green) in the 
sarcolemma triggers the opening of cationic channels thus regenerating the action 
potential. Figure taken from (Swaiman et al. 2011). 
Figure removed due to copyright restrictions 
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1.1.4 Skeletal muscle ryanodine receptor 
The principal Ca2+ release channel on the SR is called the ryanodine 
receptor (RyR). The RyR family consists of three isoforms: RyR1, which was 
first identified in skeletal muscle (Takeshima et al. 1989; Zorzato et al. 1990), 
RyR2 in cardiac muscles (Nakai et al. 1990; Otsu et al. 1990), and RyR3, 
which was first found in the brain (Hakamata et al. 1992). Although RyR1 and 
RyR2 are predominantly expressed in skeletal muscle and cardiac muscle, 
respectively, all three isoforms are found in a wide range of tissues (Lanner 
et al. 2010). The RyR family are named after the plant alkaloid ryanodine, 
which locks the channels in an open subconductance state at nanomolar 
concentrations and inhibits at high concentrations (>100μM) (Lanner et al. 
2010). 
RyRs form homotetramers with a total molecular mass of >2MDa (Lai et al. 
1988; Inui et al. 1987). This enormous size has made structural analysis 
challenging, but recent technological advancements in single particle cryo-
electron microscopy have allowed three groups to independently solve the 
structure of RyR1. The tetrameric complex has a mushroom-like shape, with 
each monomer consisting of an extensive cytoplasmic N terminus on a short 
stalk (Figure 1.4), which is made up of six transmembrane segments (Zalk et 
al. 2015; Efremov et al. 2015; Yan et al. 2015). 
Figure 1.4: Structure of the RyR1 channel 
Cross-sectional arrangement of the RyR1 channel in the closed conformation (left) 
and in the presence of Ca2+ (right). Purple dots illustrate Ca2+-binding EF hands. 
Figure removed due to copyright restrictions 
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Black arrow indicates movement of each monomer during channel opening. Figure 
adapted from (Kuo & Ehrlich 2015). 
The N terminal domain of RyR1 can directly interact with a voltage-
dependent Ca2+ channel called the dihydropyridine receptor (DHPR). DHPRs 
are situated within the t-tubules, which are flanked on each side by the 
RyR1-studded terminal cisternae of the SR (forming a ‘triad’). The physical 
link between RyR1 and DHPR is important for excitation-contraction (EC) 
coupling, which converts the incoming action potential into a mechanical 
event via intracellular Ca2+ release (Figure 1.5); Ca2+ binds Tn-C and triggers 
a conformational change in the tropomyosin-troponin complex, which allows 
actin-myosin interaction to occur and cross-bridge cycling to take place (see 
section 1.1.1). 
Figure 1.5: EC coupling in a skeletal muscle cell 
Action potentials propagate along the sarcolemma from the neuromuscular junction 
to the t-tubules, where they activate voltage-sensitive DHPRs and cause a 
conformational change that allosterically activates RyR1. The resulting SR Ca2+ 
release activates neighbouring RyR1 channels and amplifies the Ca2+ signal across 
the skeletal muscle fibre. This Ca2+ signal triggers actin-myosin contraction, 
increases mitochondrial metabolism and causes glycogen breakdown via 
phosphorylase kinase (PhK) activation. When the nerve impulse stops and the 
sarcolemma repolarises, Sarco/Endoplasmic Reticulum ATPase (SERCA) actively 
pumps Ca2+ back into the SR, gradually decreasing [Ca2+]c until relaxation occurs. 
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The opening of these physically coupled RyR1 channels is referred to as 
‘depolarisation-induced Ca2+ release’ (DIPR). Since RyR1 itself can be 
activated by Ca2+ - a process known as Ca2+-induced Ca2+ release (CICR) – 
the DIPR signal can be rapidly amplified across the large skeletal muscle 
fibre. More than half of the RyR1 channel population are not coupled to 
DHPRs, meaning they are available to participate in the CICR process (Fill & 
Copello 2002).  
The resulting rise in cytosolic calcium concentration ([Ca2+]c) activates 
phosphorylase kinase, which then activates glycogen phosphorylase to 
release glucose-1-phosphate from glycogen stores (Brostrom et al. 1971) 
(Figure 1.5). A rise in [Ca2+]c is also associated with an increase in 
mitochondrial calcium concentration ([Ca2+]m), which in turn stimulates 
mitochondrial dehydrogenases (described in more detail in section 1.4.1). 
The consequence of these two processes is an increase in ATP generation, 
thus ensuring that energy supply is matched with demand. 
1.2 RYR1-associated diseases 
1.2.1 Core myopathy disease 
Core myopathies are a clinically and genetically heterogeneous group of 
congenital muscle diseases for which no curative treatments are currently 
available (Jungbluth et al. 2011). They were first described in 1956 by Shy 
and Magee, who identified areas devoid of stains for oxidative enzyme 
activity (and thus lacking in mitochondria) in the myofibres of a family with 
congenital hypotonia and non-progressive proximal muscle weakness 
(MAGEE & SHY 1956). These areas were subsequently given the name 
‘cores’, and as they were mostly centrally located in the myofibres, the 
condition was termed central core disease (CCD) (Figure 1.6A & C). A 
spectrum of disorders have since been characterised, including multi-
minicore disease (MmD), which differs to CCD in that numerous cores are 
seen in the myofibres, and these do not usually extend the whole length of 
the fibre (Brislin & Theroux 2013) (Figure 1.6B & D). While central cores are 
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typically found in the mitochondria-rich type I myofibres, minicores may affect 
both type I and type II fibres (Jungbluth 2007a; Jungbluth 2007b). Although 
these diseases all share the same histopathological core hallmark, the 
number and position of cores within each muscle fibre varies from patient to 
patient, and can even vary between muscles of the same patient (Dubowitz & 
Roy 1970). 
In 1990, linkage analysis mapped the CCD locus to chromosome 19q13 
(Haan et al. 1990), which was later found to be the site of skeletal muscle 
specific gene, RYR1 (Quane et al. 1993; Mulley et al. 1993). Mutations in 
RYR1 are the most common cause of core myopathies (Jungbluth et al. 
2011). While CCD-associated RYR1 mutations are dominantly inherited 
(Jungbluth 2007a), MmD-associated RYR1 mutations are recessively 
inherited (Jungbluth 2007b).  
 
Figure 1.6: Oxidative stain abnormalities in core myopathy disease 
Muscle biopsy sections from patients with RYR1-related CCD (A,C), Selenoprotein 
N1-related MmD (B), and RYR1-related MmD (D) stained with NADH tetrazolium 
reductase. Adapted from (Jungbluth et al. 2011). 
Figure removed due to copyright restrictions 
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Although most patients with RYR1 mutations present clinical signs in infancy 
or early childhood, there have been reports of late-onset cases, suggesting 
that there could be a synergistic effect between certain RYR1 mutations and 
the ageing process (Jungbluth et al. 2009). Typical symptoms of RYR1 
related myopathies include delayed motor milestones, hypotonia (or ‘floppy 
infant syndrome’), proximal muscle weakness (particularly in the hip girdle) 
and orthopaedic complications such as scoliosis and hip dislocation (Zhou et 
al. 2007). Axial muscle weakness, opthalmaplegia, and respiratory 
impairment, which can lead to secondary cardiac failure, can additionally 
present in MmD (Jungbluth 2007b). The degree of disability varies greatly 
between core myopathy patients, even those within the same family. While 
cases at the severe end of the clinical spectrum present with fetal akinesia 
syndrome and usually do not survive the neonatal period (Romero et al. 
2003), most cases are non-progressive and even improve over time; the 
majority of CCD patients do achieve the ability to walk independently 
(Jungbluth 2007a).  
The prevalence of congenital myopathies is estimated to be one tenth of all 
cases of neuromuscular disorders, and although the core myopathies are 
thought to be the most common of congenital myopathies, little is known 
about their exact epidemiology (Jungbluth 2007a). A regional study in 
northern England estimated a prevalence of CCD of 1:250,000 (Norwood et 
al. 2009), thus classifying it as an ‘ultra-rare’ disease (Beck 2012). 
Nevertheless, the variable phenotypic expression and non-progressive 
nature of CCD makes it likely that several cases go undiagnosed (Quinlivan 
et al. 2003). In Japan, the carrier frequency for heterozygous RYR1 
mutations is reported to be as high as 1:2000 (Wu et al. 2006). 
1.2.2 Malignant hyperthermia susceptibility 
Mutations in the RYR1 gene also result in malignant hyperthermia 
susceptibility (MHS), meaning patients with a core myopathy carry a high risk 
of MHS (Brislin & Theroux 2013). MHS is defined as a pharmacogenetic 
disorder that manifests as a life-threatening hypermetabolic response to 
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inhalational anaesthetics, the depolarising muscle relaxant succinylcholine, 
and rarely, in humans, to stressors such as vigorous exercise and heat 
(Rosenberg et al. 2015). MHS exhibits an autosomal dominant mode of 
inheritance. While the frequency of malignant hyperthermia (MH) reactions 
ranges from 1:5000 to 1:100,000 anaesthetic procedures, the prevalence of 
the genetic abnormalities may be as great as 1:3000 individuals (Rosenberg 
et al. 2015). The ‘gold standard’ for diagnosis of MHS is currently an in vitro 
contracture test (IVCT), which checks to see if contracture occurs upon 
addition of halothane or caffeine to isolated strips of skeletal muscle. As it 
requires a muscle biopsy, the IVCT is relatively invasive. A more attractive 
option, for both clinicians and researchers, might be to establish a primary 
fibroblast cell line from a small skin biopsy, which can then be converted to 
the muscle lineage via an induced pluripotent stem cell (iPSC) route or by 
viral transduction with a Myogenic Differentiation 1 (MyoD) transgene. This 
would not only give an insight into the pathophysiology of MHS but would 
also allow for investigation of novel treatments (Fernandez-Fuente et al. 
2014).   
1.2.3 Mutations in RYR1 disrupt EC coupling 
The ability to sequence the entire RYR1 coding sequence has meant more 
and more genotype-phenotype correlations are emerging, which will help not 
only with diagnosis but also with providing advice to affected families. 
Historically, it has been reported that mutations associated with MHS and 
CCD are localised at ‘hot spot’ regions within the N terminal, central and C 
terminal domains of RyR1 (Figure 1.7). While the channel-forming C 
terminus is a mutation hot spot for classical CCD, the N terminal and central 
domains are predominantly associated with a MHS phenotype (Jungbluth et 
al. 2011). However, as the amount of data collated increases the borders of 
these hot spot regions are gradually expanding, which suggests that the hot 
spots originally described may have resulted from screening bias (Robinson 
et al. 2006). Recessively inherited mutations linked to MmD are more 
widespread through the RYR1 gene and are often associated with reduced 
RyR1 protein levels rather than RyR1 malfunction itself, which may explain 
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why recessive RYR1-related myopathies are usually more severe (Zhou et 
al. 2007).  
Figure 1.7: Mutation hot spots within the RyR1 protein 
Mutations associated with MHS (blue) are predominantly situated in the N terminal 
region (1-600 amino acids (aa)) and a central region (2100-2500aa) of the RyR1 
protein sequence, while mutations causing classical CCD (green) are found near the 
C terminus (3900-5000aa). 
Previous work on core myopathy models has led to two distinct hypotheses 
as to how RYR1 mutations can lead to muscle weakness. The first is the 
‘leaky channel’ hypothesis, which proposes that mutations increase the open 
probability of the RyR1 channel, making it constitutively active and allowing 
the depletion of SR Ca2+ stores (Zhang et al. 1993). Alternatively, RYR1 
mutations can lead to ‘EC uncoupled’ channels, meaning SR Ca2+ release is 
no longer triggered by sarcolemmal excitation (Quane et al. 1993). Both of 
these mechanisms result in less Ca2+ being released per action potential, 
leading to reduced contractile activity. A reduction in SR Ca2+ release can 
also affect signals for muscle maintenance and metabolism, such as the 
activity of Ca2+ dependent effectors (De Koninck & Schulman 1998) and the 
Nuclear Factor of Activated T-cells (NFAT) family of transcription factors 
(Hogan et al. 2003). So far, mutations that result in CCD without MHS e.g. 
the I4898T mutation (discussed later in Chapter 2) have been linked to the 
EC uncoupled functional phenotype (Guerrero-Hernández et al. 2014) 
(Figure 1.5). Since these CCD-only mutations usually lie near the selectivity 
filter of the C terminus, the underlying molecular mechanism is though to be 
diminished Ca2+ permeation in the mutant channels (Avila et al. 2001; 
Zvaritch et al. 2007; Loy et al. 2011). 
Mutations related to MHS are associated with a leaky RyR1 channel; the 
severity of the SR leak may dictate whether a CCD phenotype is seen in 
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addition to MHS (Figure 1.8). There is evidence to suggest that 
compensatory mechanisms, such as increased SERCA expression, are 
active in MHS-only models (Tong et al. 1999; Dirksen & Avila 2004), 
meaning SR Ca2+ content is normal and depolarisation-evoked Ca2+ release 
is not affected. Thus RYR1 patients with MHS alone only have a muscle 
phenotype when in the presence of triggering anaesthetics. During an MH 
episode, the RyR1 channel remains open and evokes supraphysiological 
levels of SR Ca2+ release; this leads to excessive contractile activity, heat, 
ATP depletion, metabolic stimulation and rhabdomyolysis (Hopkins 2011). 
The skeletal muscle relaxant, dantrolene, is the only known drug to 
specifically treat MH; although its mechanism of action is not fully understood 
it is thought to bind to RyR1 and inhibit SR Ca2+ release (Krause et al. 2004). 
MH-related mortality has declined since the introduction of dantrolene but 
remains as high as 35%, according to a study using data from the North 
American MH registry (Larach et al. 2010).  
Figure 1.8: Schematic depicting distinct cellular consequences of mutations 
in RyR1 that result in CCD-only, CCD with MHS, and MHS-only 
Mutations that give rise to CCD in the absence of MHS (CCD-only) are thought to 
cause muscle weakness through EC uncoupling. Mutations that give rise to a CCD 
phenotype with MHS (MH+CCD) result in a hyperactive, leaky RyR1 channel, which 
Figure removed due to copyright restrictions 
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reduces SR Ca2+ content and thus the amount of Ca2+ available for muscle 
contraction. Mutations associated with MHS alone (MH-only) also result in a leaky 
channel but the activity of compensatory mechanisms mean that SR Ca2+ store 
content is normal. Diagram taken from (Dirksen & Avila 2004). 
1.3 STAC adaptor proteins 
Three isoforms make up the STAC family of adaptor proteins, so named 
because they consist of SRC Homology three (SH3) and cysteine-rich 
domains. Although they have been characterised as 14-3-3 binding proteins 
(Satoh et al. 2006), little is known about their function. While both STAC and 
STAC2 are expressed in dorsal root ganglia neurons (Legha et al. 2010), 
STAC3 is predominantly expressed in skeletal muscle (Bower et al. 2012; 
Reinholt et al. 2013). 
STAC3 and EC couplingStudies of STAC3 mutant zebrafish and KO mouse 
models have suggested that STAC3 plays a role in EC coupling. In response 
to depolarisation-evoked Ca2+ transients, the mutant zebrafish muscles 
exhibit reduced contraction and the KO mouse muscles completely fail to 
contract (Horstick et al. 2013; Nelson et al. 2013). Both models, however, 
contract normally in response to RyR1 agonists, proving that the RyR1-
mediated Ca2+ release pathway and contractile apparatus are still functional.  
STAC3 has been shown to co-localise with EC coupling proteins, DHPR and 
RyR1, in the triads (Horstick et al. 2013). Immunoprecipitation data suggests 
that STAC3 forms a molecular complex with DHPR and RyR1, which both 
contain numerous SH3 binding sequences in their predicted cytoplasmic 
portions (Horstick et al. 2013). The relationship between these proteins and 
STAC3, however, is not well understood. Suggested functions include 
modulating the channel properties of DHPR and/or RyR1, helping to organise 
their positioning at triadic junctions between the t-tubules and SR, or 
regulating the amount of DHPR and/or RyR1 present in the triads by 
controlling their trafficking or stability (Horstick et al. 2013). 
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Recent evidence suggests that STAC3 does indeed control the trafficking of 
the muscle-specific CaV1.1 subunit of DHPR. When CaV1.1 was expressed 
alone in tsA201 cells, which are of non-muscle origin, it was retained 
intracellularly (Polster et al. 2015). However, when STAC3 was expressed 
alongside CaV1.1, the two proteins trafficked together to the plasma 
membrane (Polster et al. 2015). Moreover, despite the fact that they do not 
express RyR1, the L-type Ca2+ currents in tsA201 cells co-expressing STAC3 
and CaV1.1 were functionally similar to those in myotubes (Polster et al. 
2015). 
1.3.1 STAC3 in skeletal muscle development 
STAC3 was first identified as a nutritionally regulated gene involved in 
skeletal muscle growth of Atlantic salmon (Bower & Johnston 2010). It has 
been suggested to be involved in several signalling pathways controlling cell 
cycle progression, cell migration and cytoskeletal organisation, which are all 
important in myogenesis (Bower et al. 2012). 
In vitro studies have produced conflicting answers as to the exact role of 
STAC3 in myogenesis. Bower et al. observed an increase in STAC3 
expression during differentiation of the C2C12 myogenic cell line and showed 
that myotubes fail to form when STAC3 is knocked down (Bower et al. 2012). 
In contrast, Ge et al. showed that STAC3 has an inhibitory role in myoblast 
differentiation and fusion in both C2C12 and primary mouse embryonic 
myoblasts (Ge et al. 2014). A study using bovine satellite cells also indicated 
that STAC3 is a negative regulator of differentiation, although - somewhat 
contradictorily - its expression increased during the differentiation process 
(Zhang et al. 2014). 
In vivo models do not support the conclusion drawn by Bower et al. that 
STAC3 is essential for myotube formation; myofibers are clearly formed in 
STAC3 KD and KO zebrafish, and STAC3 KO mice (Horstick et al., 2013; 
Nelson et al., 2013; Reinholt et al., 2013). Nevertheless, several skeletal 
muscle abnormalities were observed in homozygote KO mice, including 
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centrally-positioned nuclei, fewer yet larger myofibers, and fewer, smaller 
and less organised myofibrils within the myofibers (Reinholt et al. 2013). 
Musculoskeletal defects were also reported (Nelson et al. 2013). While the 
heterozygotes were grossly normal in appearance and behaviour, the 
homozygotes were born paralysed, with abnormal spinal curvature and wrist 
drop, and died shortly after birth due to asphyxia (Nelson et al. 2013; 
Reinholt et al. 2013). 
1.3.2 STAC3 and congenital myopathy in humans 
Native American Myopathy (NAM) is an autosomal recessive congenital 
myopathy first reported in the Lumbee Indian people (Bailey & Bloch 1987; 
Stewart et al. 1988). Clinical features of NAM include congenital onset of 
muscle weakness, cleft palate, short stature, dysmorphic facial features, 
scoliosis and MHS. 36% of affected individuals die by the age of 18 (Demetra 
S Stamm et al. 2008). Homozygosity mapping of 5 Lumbee families with 
NAM identified a common genetic locus on chromosome 12q13-14 (D S 
Stamm et al. 2008). It was later shown that human STAC3 maps to this 
region, leading to the identification of 5 NAM families sharing the same G>C 
missense mutation of base pair 1046 in exon 10 of STAC3 (Horstick et al. 
2013). Carriers were heterozygous for this mutation, while affected 
individuals were homozygous.  
The NAM mutation results in a tryptophan (W) to serine (S) substitution at 
amino acid 284 in the first SH3 domain of STAC3 (Figure 1.9) (Horstick et al. 
2013). This W is highly conserved across SH3 domains and is important for 
binding specificity (Hou et al. 2012). Expression of STAC3 W284S in a 
STAC3-null zebrafish reduced skeletal muscle Ca2+ signals during touch-
evoked swimming, suggesting that at least one of the SH3 domains in 
STAC3 forms important interactions with DHPR and/or RyR1 (Horstick et al. 
2013). 
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Figure 1.9: NAM mutation affects the first SH3 domain of STAC3 
The domain architecture of STAC3 consists of a region containing 11 successive 
glutamic acid residues (Poly-E), a Protein Kinase C (PKC) C1 domain and two SH3-
protein interaction domains (Nelson et al. 2013). Arrow indicates site of W284S 
NAM mutation. Numbers indicate amino acid position. 
1.4 Mitochondrial biology 
1.4.1 Mitochondrial Ca2+ uptake links energy demand with supply 
Mitochondria are able to take up Ca2+ via an electrogenic mitochondrial Ca2+ 
uniporter (MCU) found in the inner mitochondrial membrane (IMM). Since 
three rate-limiting mitochondrial dehydrogenases are Ca2+-sensitive, 
mitochondrial Ca2+ uptake provides a cellular mechanism for coupling 
stimulatory cytosolic Ca2+ signals with oxidative phosphorylation and ATP 
production. This is particularly important for energy demanding tissues such 
as skeletal muscle, where EC coupling during contraction is linked to 
increased mitochondrial metabolism. 
The first of these Ca2+-sensitive dehydrogenases is the Pyruvate 
Dehydrogenase Complex (PDHC), which irreversibly converts the end 
product of glycolysis, pyruvate, into a high-energy intermediate called acetyl 
coenzyme A (acetyl co-A). As it represents ‘the point of no return’ in 
carbohydrate metabolism, PDHC is subject to stringent regulation; its activity 
is directly affected by end-product inhibition through increasing ratios of 
acetyl co-A/pyruvate and NADH/NAD+, as well as by reversible 
phosphorylation of three sites in its E1 subunits (Denton 2009). The 
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phosphatase responsible for keeping PDH in its active form is activated by 
Ca2+ (Figure 1.10). 
 
 
 
 
 
 
 
 
 
 
Figure 1.10: Regulation of the PDHC 
PDHC is activated by Ca2+-dependent Pyruvate Dehydrogenase Phosphatase 
(PDP). PDHC is inactivated by the phosphorylating action of Pyruvate 
Dehydrogenase Kinase (PDK). PDK is inhibited by increases in NAD+, ADP and 
pyruvate (pyr). 
Acetyl co-A produced by PDHC and fatty acid β-oxidation is subsequently 
oxidised by a series of enzymes that make up the citric acid cycle (Figure 
1.11). Two of these enzymes - α-ketoglutarate dehydrogenase and isocitrate 
dehydrogenase - are Ca2+-sensitive. Like the PDHC, they are inhibited by 
increasing ATP/ADP and NADH/NAD+ ratios (Denton 2009) but the activation 
mechanism by Ca2+ is different. Ca2+ apparently binds directly, resulting in 
variations in the kinetics of both substrates and inhibitory metabolites 
(Balaban 2009). 
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Figure 1.11: Glycolysis and the citric acid cycle 
Glycolysis in the cytosol produces pyruvate, which is transported across the IMM by 
the Mitochondrial Pyruvate Carrier (MPC) and converted to acetyl co-A by PDHC in 
the mitochondrial matrix. Acetyl co-A is then oxidised by a series of enzymes (blue) 
that make up the citric acid cycle. This provides important reducing agents (pink) for 
the electron transport chain, as well as small carbon units for making amino acids. 
Adapted from Figure 1.17.15 within (Berg et al. 2002). 
Figure removed due to copyright restrictions 
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Glycolysis, fatty acid oxidation and the citric acid cycle feed important 
reducing power in the form of NADH and FADH2, into the electron transport 
chain of the IMM (Figure 1.12). NADH supplies electrons to Complex I 
(NADH dehydrogenase), which subsequently shuttles them to the quinone 
(Q) pool of electron carriers. FADH2 also supplies electrons to the Q pool via 
Complex II (succinate dehydrogenase), which is the only membrane bound 
enzyme of the citric acid cycle. Electrons then move from the Q pool to 
cytochrome c (cyt c) through Complex III (ubiquinone:cyt c oxidoreductase). 
The final stage of the electron transport chain is the oxidation of reduced cyt 
c by Complex IV (cyt c oxidase), which passes electrons to O2 and results in 
the formation of water. 
Figure 1.12: Oxidative phosphorylation 
Electrons (green arrows) are shuttled though the electron transport chain (orange) 
before reducing the final electron acceptor, oxygen (O2). The energy released 
through this process allows Complex I, III and IV to pump protons (blue arrows) into 
the intermembrane space (IMS), setting up a proton gradient across the inner 
mitochondrial membrane (IMM). Protons then preferentially flow back into the matrix 
through Complex V (pink) and ATP is produced. 
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As electrons pass down this long chain of donor and acceptor molecules, 
they fall to successively lower energy states (Berg et al. 2002). Complex I, III 
and IV use the energy released by this process to pump protons from the 
matrix into the intermembrane space (IMS). This proton pumping sets up a 
gradient called the protonmotive force (PMF), which is dictated by a chemical 
component (ΔpH) and an electrical component (Δm) (Mitchell 1961). In 
mammalian mitochondria, Δm (also called mitochondrial membrane 
potential) is usually around 180mV (negative to the IMS and cytosolic 
exterior) and ΔpH is approximately 1 unit (the matrix is more alkaline than the 
IMS and cytosolic exterior) (Skulačev et al. 1981). 
The PMF drives ATP production by allowing protons to travel back into the 
matrix via the ATP synthase (also referred to as Complex V) (Figure 1.12). 
The ATP synthase essentially converts the energy of this proton movement 
into the mechanical movement of its transmembrane rotor ring, which in turn 
rotates a matrix-protruding stalk domain. On the end of the stalk sits a 
stationary bulbous head domain containing binding sites for ADP and 
inorganic phosphate (Pi). Rotation of the stalk repeatedly causes 
conformation changes within the head (Boyer 1993; Abrahams et al. 1994), 
rapidly driving the formation of 100 ATP molecules a second (Alberts et al. 
2002). The number of protons translocated for each synthesised ATP 
(H+/ATP ratio) is an important parameter for the mechanism of the enzyme 
and energy transduction in cells; the H+/ATP ratio can vary among different 
species and may be determined by the number of subunits within the 
catalytic head domain (Petersen et al. 2012). 
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1.4.2 A history of mitochondrial Ca2+ uptake 
In the early 1960s, it was shown that rat kidney mitochondria accumulate 
large amounts of Ca2+ in the presence of ATP (Deluca & Engstrom 1961; 
VASINGTON & MURPHY 1962). Two models were proposed to explain this 
process: the first being that Ca2+ transport is directly and stoichiometrically 
coupled to the generation of a high energy phosphorylated chemical 
intermediate by the electron transport chain (Chance 1965), and the second 
being that there must exist a specific Ca2+ carrier which passively transports 
Ca2+ across the membrane in response to a electrochemical gradient 
generated by electron transport (Lehninger 1970). Although the latter model 
appeared more feasible at the time, it was not until the general acceptance of 
Mitchell’s chemiosmotic theory that the major driving force for Ca2+ 
accumulation was realised to be the Δm (Moyle & Mitchell 1977). Thus Ca
2+ 
enters the mitochondrial matrix down its electrochemical gradient, which can 
either be generated by electron flow through the respiratory chain, or if 
oxidisable substrates are lacking or the respiratory chain is blocked, by the 
reversal of the ATP synthase (and ATP hydrolysis) (Drago et al. 2011).  
After some debate, it was agreed that the unknown mitochondrial Ca2+ 
carrier must function as a uniporter, and not a H+/Ca2+ antiporter, as the net 
positive charge transported across the mitochondrial membrane during Ca2+ 
import was found to be 2 (Brand et al. 1976). Since there is no counteracting 
ion exchange, the process of mitochondrial Ca2+ import effectively acts like 
an inward current, and a transient depolarisation of Δm is witnessed 
(Duchen 1992; Duchen 2000). In theory, electrochemical equilibrium should 
be reached if mitochondrial Ca2+ accumulation depends solely on Δm. 
However, according to the Nernst equation, a Δm value of -180mV would 
imply about a million fold accumulation of Ca2+ in the matrix, which has never 
been witnessed in cells and does not comply with general physiological 
concepts (Drago et al. 2011). This paradox was eventually solved upon the 
discovery of mitochondrial Ca2+ efflux pathways, such as via the Na+/Ca2+ 
exchanger (NCLX) (Palty et al. 2010) and the H+/Ca2+ exchanger. The 
activity of these antiporters, in addition to matrix calcium buffering 
 40 
mechanisms, is important in the regulation of [Ca2+]m and thus the prevention 
of detrimental mitochondrial Ca2+ overload (described in more detail in 1.4.5). 
The establishment of fluorescent cytosolic Ca2+ indicators during the 1980s 
seeded doubts regarding the significance of mitochondria in Ca2+ 
homeostasis. The Ca2+ concentrations measured under resting (≈ 0.1 μM) or 
stimulated (1-3μM at the peak) conditions seemed too low for substantial 
uptake through the low affinity mitochondrial Ca2+ uniporter (Rizzuto et al. 
2012). Surprisingly, the development of mitochondrial-targeted aequorin 
(mtAEQ) in the early 1990s showed that the rise in [Ca2+]m closely follows a 
stimulated increase in [Ca2+]c (Rizzuto et al. 1992; Rizzuto et al. 1993). 
Furthermore, the use of low affinity variants of mtAEQ showed that peak 
[Ca2+]m can actually exceed 100μM in some cell types (Montero et al. 2000). 
The discrepancy between the amplitude of [Ca2+]m rises and the low affinity 
of the mitochondrial Ca2+ uniporter was later explained by the observation 
that mitochondria position themselves close to the Ca2+ release channels 
that evoke the rise in [Ca2+]c i.e. IP3Rs in the ER (Rizzuto et al. 1998; 
Csordás et al. 1999), RyRs in the SR (Szalai et al. 2000) and voltage-
operated channels and store-operated channels in the plasma membrane 
(David et al. 1998; Glitsch et al. 2002). Thus, these microdomains of high 
[Ca2+]c are rapidly dissipated by the mitochondria without causing harmful 
Ca2+ overload and/or futile Ca2+ cycling across the mitochondrial membrane 
(Rizzuto et al. 2012). In this way, mitochondria act as high capacity Ca2+ 
buffers, which can influence the spatiotemporal properties of Ca2+ signals 
(Tinel et al. 1999; Boitier et al. 1999) and regulate the activity of Ca2+ 
channels themselves. 
Although more and more was being understood about the role of 
mitochondrial Ca2+ uptake in cell physiology, the identity of the mitochondrial 
Ca2+ uniporter eluded scientists for decades. It was not until 2010 that the 
first molecular component was discovered; Perocchi et al. used a targeted 
RNA interference (RNAi) screening approach to highlight the necessity of a 
gene called CBARA1 (which they renamed as Mitochondrial Ca2+ Uptake 1 
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(MICU1)) in mitochondrial Ca2+ uptake (Perocchi et al. 2010). The presence 
of two EF hands indicated that MICU1 was a Ca2+ sensor, but was unlikely to 
be part of the pore-forming channel as it was predicted to have only one 
membrane-spanning domain. It was suggested that its role could be in gating 
the activity of the bona fide channel, which was actually not far from the truth. 
1.4.3 Mitochondrial Ca2+ uniporter 
The discovery of MICU1 helped reignite the search for the mitochondrial Ca2+ 
uniporter, which came to a remarkable conclusion in 2011 when two papers 
reporting the identification of the same protein using different approaches 
were published side by side in Nature (Baughman et al. 2011; De Stefani et 
al. 2011). Both groups agreed that the Mitochondrial Ca2+ Uniporter (MCU) 
(previously called CCDC109A) was a 40kDa protein ubiquitously expressed 
in all mammalian tissues and in most eukaryotes, and its down regulation 
caused considerably reduced mitochondrial Ca2+ uptake in living cells 
stimulated with Ca2+ mobilising agonists, permeabilised cells perfused with 
buffered Ca2+ and isolated mitochondria. The presence of two 
transmembrane domains strongly suggested that the MCU oligomerised in 
the IMM to form a gated ion channel, which is now believed to exist as a 
tetramer (Raffaello et al. 2013). 
While its overexpression sensitised cells to apoptotic stimuli, silencing of the 
MCU was originally shown to have little effect on mitochondrial respiration, 
membrane potential or basic morphology (Baughman et al. 2011; De Stefani 
et al. 2011), which might seem surprising given its role in satisfying energy 
demands. A more recent study, however, showed that MCU knockdown (KD) 
in pancreatic islet cells decreased respiratory chain activity by affecting the 
expression of its components (Quan et al. 2015). 
Interestingly, it is possible to create viable mice in which the MCU is globally 
knocked out (MCU-KO) (although only when using an outbred strain; MCU 
deletion is embryonic lethal on the inbred C57BL/6 strain (Murphy et al. 
2014)). Despite a complete lack of any capacity for mitochondrial Ca2+ 
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accumulation, the MCU-KO mice showed no change in basal metabolism, 
mitochondrial morphology or autophagy (Pan et al. 2013). Although MCU-KO 
mitochondria from these mice lacked evidence for Ca2+-induced 
mitochondrial permeability transition pore (mPTP) opening, the absence of 
MCU did not protect against in vitro cell death or ischaemia-reperfusion (IR) 
injury in the heart (Pan et al. 2013). Besides being slightly smaller than their 
wild type littermates, the only reported physiological difference was that 
MCU-KO mice showed reduced maximal skeletal muscle power output, 
suggesting that altering matrix Ca2+ in vivo maybe important in response to 
exercise (Pan et al. 2013). It is also worth noting that in the MCU-KO mice, 
mitochondrial Ca2+ levels were reduced but were not zero, so alternative 
entry mechanisms may have been active. One possible mechanism could be 
the rapid mode of Ca2+ uptake (RaM), which has been observed in isolated 
mitochondria with kinetics much faster than the MCU (Sparagna et al. 1995; 
Buntinas et al. 2001) but currently has no molecular identity. 
Recent work using a conditional, cardiac-specific MCU-KO mouse shows 
that while it may be indispensible for homeostatic cardiac function, the MCU 
is required to match metabolic output with contractile demand during stress 
(Luongo et al. 2015; Kwong et al. 2015). In addition, these mice had reduced 
activation of the mPTP, which protected them against mitochondrial Ca2+ 
overload during myocardial IR injury (Luongo et al. 2015; Kwong et al. 2015). 
This suggests that the global KO mouse may have developed adaptations 
where mPTP opening was prevented but cell death at reperfusion wasn’t 
reduced. 
Another recent study has shown that MCU-dependent mitochondrial Ca2+ 
uptake controls muscle size in mice through two major trophic pathways. 
Skeletal muscle specific silencing of the MCU after birth led to a reduction in 
PGC1α4 expression and IGF1-Akt/PKB signalling, subsequently triggering 
atrophy, whereas MCU overexpression had the opposite effect and resulted 
in hypertrophy (Mammucari et al. 2015). Furthermore, MCU overexpression 
was protective against denervation-induced atrophy (Mammucari et al. 
2015). Interestingly, MCU-overexpressing and MCU-silenced myofibres 
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showed respective increases and decreases in mitochondrial volume, 
suggesting that mitochondrial Ca2+ homeostasis might have a role in 
organelle biogenesis and morphology (Mammucari et al. 2015).  
1.4.4 Mitochondrial Ca2+ uniporter complex 
Alongside the channel-forming MCU, a number of regulatory proteins have 
been identified that form a mitochondrial Ca2+ uniporter complex (Figure 
1.13). Their exact stoichiometry, role and interaction within the complex are 
still under scrutiny. Essential MCU Regulator (EMRE) is a 10kDa protein 
containing a single transmembrane domain, which has been reported to 
interact with MCU and other regulators MICU1 and MICU2 (Sancak et al. 
2013) (Figure 1.13). Solute carrier 25A23 (SLC25A23), a Mg-ATP / Pi carrier 
in the IMM, also interacts with MCU and MICU1 (Hoffman et al. 2014) (Figure 
1.13). KD of either of these proteins has been shown to reduce mitochondrial 
Ca2+ uptake (Sancak et al. 2013; Hoffman et al. 2014). 
The MCU paralogue MCUb (previously known as CCDC109b) has been 
found to act as a dominant negative subunit of the MCU channel (Figure 
1.13). The MCU/MCUb ratio appears to vary across different tissues, 
potentially providing a molecular mechanism to regulate levels of 
mitochondrial Ca2+ uptake (Raffaello et al. 2013). 
Mitochondrial Ca2+ Uptake Regulator 1 (MCUR1, previously known as 
CCDC90A) was originally reported to be essential for MCU function, as its 
KD diminished mitochondrial Ca2+ uptake and compromised cellular 
bioenergetics (Mallilankaraman, Cárdenas, et al. 2012) (Figure 1.13). A 
subsequent study, however, concluded that MCUR1 is involved in the 
assembly of Complex IV and does not directly regulate the MCU; the 
observed reduction in mitochondrial Ca2+ uptake was shown to be a 
consequence of altered Δm (Paupe et al. 2015). The authors of the first 
study have recently challenged the observations of Paupe et al. by showing 
that MCUR1 KD does not affect Δm or decrease the expression of subunit II 
of Complex IV (Vais et al. 2015).  
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Figure 1.13: Mitochondrial Ca2+ uniporter complex 
Mitochondrial take up Ca2+ through the MCU when a threshold [Ca2+]c is reached i.e. 
during a robust intracellular Ca2+ signal. The opening of the MCU is controlled by 
SLC25A23, MCUR1, EMRE, MICU1 and MICU2, which all form part of the uniporter 
complex. 
The most documented regulators of the MCU are the Mitochondrial Ca2+ 
Uptake (MICU) family of proteins. MICU1 was the first identified member of 
the mitochondrial uniporter complex (even before the MCU itself), and when 
initially characterised it was described as indispensable for mitochondrial 
Ca2+ uptake (Perocchi et al. 2010). However, subsequent studies have found 
this not to be the case. It is now widely agreed that MICU1 acts as a 
gatekeeper of the MCU by setting the threshold concentration of intracellular 
Ca2+ for mitochondrial Ca2+ uptake (Mallilankaraman, Doonan, et al. 2012; 
Csordás et al. 2013).  
The precise localisation of MICU1 is still under debate; some studies show 
that it senses Ca2+ on the matrix side of the IMM (Mallilankaraman, Doonan, 
et al. 2012; Hoffman et al. 2013), while others demonstrate that it resides in 
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the IMS (Csordás et al. 2013; Hung et al. 2014; Lam et al. 2014; Patron et al. 
2014). The significance of MICU1’s Ca2+ binding EF hands is also not well 
understood; one model suggests that MICU1 inhibits the MCU in the Ca2+-
bound state (Mallilankaraman, Doonan, et al. 2012), while another model 
involves MICU1 inhibition in the apo-state (Csordás et al. 2013). The latter 
model also proposes that Ca2+ binding to MICU1 is responsible for the 
cooperative activation of the MCU (Csordás et al. 2013).  
Although it is widely recognised that MICU1 is an important regulator of 
mitochondrial Ca2+ uptake, there are still some discrepancies in the literature 
concerning mitochondrial Ca2+ levels at rest and after stimulation in the 
absence of MICU1. The studies by Mallilankaraman et al. and Patron et al. 
found that mitochondria were constitutively Ca2+ loaded in MICU1 KD cells 
(Mallilankaraman, Doonan, et al. 2012; Patron et al. 2014), whereas other 
studies did not observe a change in resting mitochondrial Ca2+ levels 
(Perocchi et al. 2010; Csordás et al. 2013; de la Fuente et al. 2014). Some 
groups also noted diminished mitochondrial Ca2+ uptake in response to 
agonist-induced ER-mediated Ca2+ release (Perocchi et al. 2010; Csordás et 
al. 2013), which was not observed by Mallilankaraman et al. 
While MICU1 KD does not seem to affect Δm or the resting rate of O2 
consumption, other bioenergetic differences have been reported. 
Mallilankaraman et al. showed that O2 consumption was enhanced upon 
10μM histamine stimulation in MICU1 KD cells but not in controls. However, 
upon stimulation with 100μM histamine, a similar increase in O2 consumption 
was observed in both control and MICU1 KD cells. The results of Csordas et 
al. partly agreed with this; compared to controls, MICU1 KD hepatocytes 
showed increased O2 consumption in response to low Ca
2+ (0.2mM CaCl 
added) but reduced O2 consumption in response to high Ca
2+ (10mM CaCl 
added). Mallilankaraman et al. also showed that pyruvate dehydrogenase 
was hypophosphorylated (i.e. more active) in MICU1 KD cells, reflecting 
enhanced Ca2+-dependent activity of pyruvate dehydrogenase phosphatase. 
In contrast, Perocchi et al. described a reduced increase in NADH 
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fluorescence in response to 150μM histamine, suggesting that matrix 
dehydrogenases were less active.  
The discovery of MICU2 has added another level of complexity to the 
regulation of MCU. MICU2 shares 27% sequence identity with MICU1, 
contains two EF hands and has been shown to form heterodimers with 
MICU1 in the IMS (Patron et al. 2014). The silencing of MICU1 leads to a 
loss of MICU2 at the protein level, indicating that MICU2 requires the 
presence of MICU1 for stability, but not vice versa (Patron et al. 2014; Kamer 
& Mootha 2014). Biochemical studies also show that association of MICU2 
and MCU requires the presence of MICU1 (Kamer & Mootha 2014). These 
observations therefore complicate interpretation of previous MICU1 KD 
studies where the expression levels of MICU2 may have been altered. 
Work by Patron et al. suggests that MICU2 is actually the gatekeeper of the 
MCU, and MICU1 instead acts as an activator of the MCU. Whether 
overexpressing or knocking down MICU1, or knocking down MICU2 alone, 
the authors saw elevated agonist-induced matrix Ca2+ (Patron et al. 2014). 
This was attributed to a reduction in MICU1-MICU2 heterodimers and the 
predominance of MICU1-MICU1 homodimers, meaning less MCU inhibition 
and more activation, respectively. Furthermore, electrophysiological 
experiments using planar bilayer membranes demonstrated that purified 
MICU1 failed to have an effect on MCU open probability until Ca2+ was 
raised from 0-1μM (Patron et al. 2014). MICU2, on the other hand, 
completely inhibited MCU channel activity in the absence of Ca2+. 
In contrast, the Mootha group, who originally identified MICU1, believe that 
MICU1 and MICU2 play nonredundant gatekeeping roles. Both MICU1 and 
MICU2 KO cells lost a normal threshold for mitochondrial Ca2+ uptake, and 
mutation of either protein’s EF hands abolished uptake altogether (Kamer & 
Mootha 2014). The authors concluded that MICU2 function requires MICU1 
but the converse is not true. Somewhat curiously, their data also showed that 
EF hand mutant MICU1 was able to rescue the gatekeeping function that 
was compromised in cells lacking MICU2, whereas wild type MICU1 could 
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not (Kamer & Mootha 2014). Although the authors did not explain this 
observation, they thought it likely that MICU1 has a different [Ca2+] threshold 
to MICU2; perhaps the EF hands of each MICU protein have a different 
functionality in the regulation of MCU. 
While MICU1 and MICU2 share similar tissue expression patterns with MCU, 
MICU3 is found mainly in the nervous system with some expression in 
skeletal muscle (Plovanich et al. 2013). Very little is known about the 
functionality of MICU3, but its distinct pattern of expression suggests tissue-
specific differences in the regulation of mitochondrial Ca2+ uptake. 
1.4.5 Mitochondrial Ca2+ overload 
Though mitochondrial Ca2+ accumulation is important for metabolism, too 
much of it can be detrimental. An excessive increase in [Ca2+]m  can trigger 
mitochondrial permeability transition, which has been implicated in cell death 
associated with ischaemia reperfusion injury (Crompton & Andreeva 1993; 
Halestrap et al. 1997), neurodegenerative disorders (Rao et al. 2014), 
diabetes (Fujimoto et al. 2010) and various forms of myopathy (Palma et al. 
2009). Permeability transition is the formation of a non-specific high 
conductance channel (the mPTP) in the IMM, which permits unrestricted 
movement of solutes up to 1.5kDa in size (Haworth & Hunter 1979; Hunter & 
Haworth 1979). Persistent mPTP opening irreversibly commits cells to death 
by a series of events: depolarisation of the IMM, which uncouples oxidative 
phosphorylation and decreases ATP production; matrix swelling and cristae 
unfolding, and the eventual rupture of the OMM, releasing Ca2+ and pro-
apoptotic proteins (Rasola & Bernardi 2011). The uncoupling of oxidative 
phosphorylation not only stops mitochondria from making ATP, but also 
means that the proton-translocating ATP synthase will run in reverse and 
cause ATP depletion (Halestrap 2009). Increased [Ca2+]m alone may not be 
sufficient to induce mPTP opening; additional factors including oxidative 
stress, adenine nucleotide depletion, elevated phosphate concentrations and 
mitochondrial depolarisation are also thought to be critical (Halestrap 2009).  
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Mitochondrial Ca2+ overload could also result in a futile Ca2+ cycle (Bhosale 
et al. 2015). An increase in [Ca2+]m will inevitably lead to activation of Ca
2+ 
efflux pathways – most notably via the mitochondrial Na+/Ca2+ exchanger 
(NCX). This will raise matrix Na+, which will in turn activate Na+/H+ exchange 
and allow protons back into the matrix without going through the ATP 
synthase (Figure 1.14). Hence, the processes that balance Ca2+ influx may 
cause loss of PMF at the expense of ATP production. 
 
 
Figure 1.14: Futile Ca2+ cycling across the inner mitochondrial membrane 
Constitutive mitochondrial Ca2+ accumulation carries an energetic cost through the 
activation of the NCX-mediated efflux pathway. 
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1.4.6 Mitochondrial ROS production 
Reactive Oxygen Species (ROS) are molecules originating from O2 that can 
readily oxidise other molecules. Most intracellular ROS are derived from 
superoxide (O2
-), which is produced by the one electron reduction of O2 
(Sena & Chandel 2012). O2
- can be detoxified to the less reactive H2O2 by 
superoxide dismutases, and then to O2 and H2O by antioxidants (Brand 
2010). However, there are limits to these antioxidant defence systems, and 
O2
- that escapes them will damage lipids, proteins and DNA (Brand 2010).  
Mitochondria are believed to be major producers of O2
- as electrons can leak 
out of the respiratory chain. According to Harman’s free radical theory of 
aging, mitochondrial ROS (mROS) generation is the inevitable outcome of 
oxidative ATP production and the major cause of macromolecular damage 
(HARMAN 1972). Some ROS-induced damage may not be repaired thus 
leading to the gradual decline of the cell’s machinery, which has been linked 
to multiple pathologies including neurodegenerative diseases, diabetes and 
cancer. On the other hand, mROS production is now understood to be an 
important signalling pathway in a number of physiological processes, 
including adaptation to hypoxia, autophagy, immunity, differentiation and 
longevity (Sena & Chandel 2012).  
Seven sites of mROS production have been identified, which are, in order of 
descending capacity: the ubiquinone binding sites of complex I and complex 
III, glycerol-3-phosphate dehydrogenase, the flavin in complex I, the electron 
transferring flavoprotein Q oxidoreductase of fatty acid β-oxidation, and PDH 
and α-ketoglutarate dehydrogenase (Brand 2010). All of these appear to 
produce mROS in the matrix, which makes the mtDNA particularly vulnerable 
to damage. Furthermore, mtDNA lacks the protection conferred by histones 
characteristic of nuclear DNA and mitochondria have an inadequate repair 
system for mtDNA mutations (Adhihetty et al. 2003). This means tissues with 
high oxidation rates e.g. skeletal muscle may be particularly susceptible to an 
(age or disease related) increase in ROS-induced mtDNA mutations, leading 
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to dysfunctional OXPHOS and a feed forward cycle of progressive 
deterioration (Adhihetty et al. 2003).  
Skeletal muscle cells experience a high level of ROS generation during 
contractile activity, though mitochondria may not be the primary source 
(Barbieri & Sestili 2012). Muscle inactivity also increases mROS production, 
which could be due to disrupted intracellular Ca2+ handling, augmented 
mitochondrial levels of fatty acid hydroperoxides, impaired protein import into 
mitochondria or an increase in mitochondrial fission (Powers et al. 2012). 
It is sometimes theorised that Ca2+ uptake into the mitochondria should result 
in enhanced mROS generation by the stimulation of the citric acid cycle and 
OXPHOS, which make the mitochondrion work faster and consume more O2. 
In practice, however, it does not appear that simple; observations in the 
literature vary greatly, which may be due to differences in the specific 
inhibitors used, the presence of uncouplers, the source and the metabolic 
state of the mitochondria (Brookes et al. 2004). On the whole it appears that 
Ca2+ reduces mROS from complexes I and III under normal conditions but 
augments mROS when the complexes are inhibited (Brookes et al. 2004).  
1.4.7 Mitochondrial biogenesis 
Mitochondria have their own genome, which is maternally inherited and 
consists of double stranded circular DNA (mtDNA). mtDNA contains 37 
genes; 13 of which code for essential subunits of respiratory complexes I,III, 
IV and V, while the remaining genes encode transfer RNAs and ribosomal 
RNAs required for translating the respiratory subunit mRNAs in the 
mitochondrial matrix. The limited coding capacity of mtDNA means that 
mitochondria are genetically semi-autonomous; they are dependent on the 
expression of nuclear genes for all their biological functions (Scarpulla 2011). 
For mitochondrial biogenesis to occur, the expression of nuclear and 
mitochondrial genomes must be carefully co-ordinated. Peroxisome 
Proliferator-Activated Receptor (PPAR)-γ Co-activator 1α (PGC1α) appears 
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to be at the centre of this co-ordinated response by binding to a large 
complement of transcription factors and subsequently triggering a complex 
signalling cascade (Wu et al. 1999). Two such transcription factors are 
Nuclear Respiratory Factors (NRF) 1 and 2, which contribute to the 
expression of many genes required for the maintenance and function of the 
mitochondrial respiratory apparatus (Figure 1.15) (Scarpulla 2008). NRF-1 
and NRF-2 directly promote the expression of nuclear-encoded respiratory 
chain subunits but indirectly promote the expression of mitochondrial-
encoded subunits through the activation of proteins involved in mtDNA 
transcription and replication (Figure 1.15). This includes Mitochondrial 
Transcription Factor A (TFAM), which is essential for mammalian 
mitochondrial biogenesis and embryonic development (Larsson et al. 1998). 
Figure 1.15: Summary of the nuclear control of mitochondrial functions by 
NRF-1 and NRF-2 
NRFs act on genes encoding cytochrome c (cyt c), the majority of nuclear subunits 
of respiratory complexes I-V and the rate-limiting heme biosynthetic enzyme, 5-
aminolevulinate synthase. In addition, NRFs promote the expression of key 
components of the mitochondrial transcription and translation machinery, which 
includes TFAM, a number of mitochondrial ribosomal proteins and tRNA 
synthetases. NRFs are also involved in the expression of important constituents of 
Figure removed due to copyright restrictions 
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the mitochondrial protein import and assembly machinery. Figure taken from 
(Scarpulla 2008). 
In muscle, PGC1α plays a role in the determination of fibre type. There are 
two main types of muscle fibre: slow twitch (type I), which are much higher in 
mitochondrial content and are more dependent on oxidative metabolism, and 
fast twitch (type II), which contain less mitochondria and rely more on 
glycolysis (Berchtold et al. 2000). Transgenic mice with a skeletal muscle 
specific overexpression of PGC1α show a predominance of slow twitch 
fibres, as well as fatigue resistance and an increased expression of 
mitochondrial genes (Lin et al. 2002).  
Mitochondrial biogenesis can be modulated by a number of physiological 
conditions. While aging has been linked to reduced biogenesis, there is 
evidence that calorie restriction can prevent these age-related changes 
(Picca et al. 2013). In skeletal muscle, mitochondrial biogenesis can be 
activated by adaptive thermogenesis in response to low temperature or 
excessive calorific intake (Wu et al. 1999), as well as by chronic contractile 
activity e.g. endurance training (Hood 2001). Large Ca2+ fluxes within the 
contracting muscle cell activate a number of Ca2+-sensitive enzymes, such 
as Ca2+-calmodulin kinase II (CaMKII), protein kinase C (PKC) and 
calcineurin, which are ultimately translocated to the nucleus to affect the 
activity of transcription factors like PGC1 (Hood 2001). The increased rate of 
ATP turnover i.e. increased rates of ATP synthesis and degradation during 
moderate-intensity exercise has also been linked to increased biogenesis 
through increased AMP-activated Protein Kinase (AMPK) signalling and 
partial mitochondrial uncoupling (Hood 2001). 
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1.4.8 Mitochondrial dynamics 
Mitochondria are dynamic organelles that undergo constant cycles of 
morphological remodelling in response to changing intracellular requirements 
and extracellular cues. The balance of fission and fusion events determines 
the overall appearance of mitochondria, which reflects the cell’s physiological 
state (Figure 1.16). Typically, dominance of fusion or suppression of fission 
activity leads to branched, tubular networks; conversely, dominance of fission 
or suppression of fusion activity causes mitochondria to fragment into short 
rods or spheres (Jeyaraju et al. 2009). Mitochondrial dynamics and structure 
can vary between tissues and cell types; for example, mitochondria in 
cultured primary rat myotubes derived from Flexor Digitorium Brevis (FDB) 
muscle show an elongated shape like those in adult rat FDB fibres, but 
because they are not restricted by precisely organised myofilaments, they 
are more motile and can undergo more fusion events (Eisner et al. 2014). 
The mitochondrial fusion machinery includes Mitofusin (Mfn) 1, 2 and optic 
atrophy 1 (OPA1). OPA1 is a dynamin-related GTPase that is anchored on 
the IMM and mediates IMM fusion (van der Bliek et al. 2013). OPA1 activity 
is controlled by OMA1, a protease in the IMM that is rapidly activated by low 
membrane potential and low ATP levels; this provides a quality control 
mechanism to prevent damaged mitochondria from re-joining the 
mitochondrial network (Youle & van der Bliek 2012). Mfn1 and Mfn2 are large 
GTPases in the outer mitochondrial membrane (OMM) that tether adjacent 
mitochondria together by forming homo- and hetero-dimers (Chen et al. 
2003). Transgenic mice carrying specific deletions of Mfn1 and Mfn2 in 
skeletal muscle displayed severe mitochondrial dysfunction, compensatory 
mitochondrial biogenesis and muscle atrophy (Chen et al. 2010). These 
abnormalities were preceded by a severe loss of mtDNA and a rapid 
accumulation of mtDNA mutations, highlighting the importance of 
mitochondrial fusion for mtDNA fidelity and for maintaining respiratory activity 
in cells carrying a mix of wild type and mutant mtDNA i.e. heteroplasmic cells 
(Chen et al. 2010) (Figure 1.16). Fusion also allows the mitochondria to act 
as electrically unified systems, meaning a membrane potential generated in 
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the cell periphery can be dissipated over a large area and produce ATP in 
remote parts of the cell (Skulachev 2001) (Figure 1.16). This is particularly 
important in skeletal muscle, where mitochondrial filaments connect the 
oxygen-poor mitochondria in the core of the fibre with the oxygen rich 
peripheral mitochondria (Glancy et al. 2015). 
Central to mitochondrial fission events is dynamin-related protein 1 (Drp1 in 
mammals). Drp1 is a large cytosolic GTPase that self-assembles into a 
multimeric scission complex at punctate sites on the OMM upon fission 
initiation (Jeyaraju et al. 2009). A number of OMM proteins including 
Mitochondrial Fission protein 1 (Fis1) have been reported to be important for 
Drp1 recruitment during fission (Losón et al. 2013). Drp1-dependent 
mitochondrial fragmentation is controlled by phosphorylation at two 
conserved sites, serine 616 (activating) and 637 (inhibiting). S616 is 
phosphorylated by protein kinase C (PKC) δ, Rock kinase, CDK1/cyclin B or 
CaMKIα, and S637 is phosphorylated by PKA (van der Bliek et al. 2013). 
While S616 phosphorylation promotes fission during mitosis, the 
dephosphorylation of S637 by Ca2+-dependent calcineurin is involved in 
apoptotic mitochondrial fragmentation (Cribbs & Strack 2007). Opposing 
effects of PKA and calcineurin on the same site may serve as a switch to 
translate Ca2+ signals of different strength and duration into different 
mitochondrial morphologies i.e. PKA takes precedence during physiological 
Ca2+ transients but long-lasting Ca2+ plateaus will fully activate calcineurin 
(Cereghetti et al. 2008). Besides mitosis and apoptosis, fission is also 
important for trafficking mitochondria by cytoskeletal-mediated transport, 
which is crucial for large extended cells like neurons (Figure 1.16).  
Expression of the fission machinery is sufficient to cause muscle wasting in 
mice by triggering mitochondrial dysfunction, energy stress and AMPK 
activation (Romanello et al. 2010). AMPK triggers activation of the Forkhead 
box O (FoxO) class of transcription factors, which drive protein degradation 
during atrophy via the ubiquitin-proteasome and autophagy-lysosome 
pathways (Romanello & Sandri 2010). In contrast, inhibition of mitochondrial 
fission prevents muscle loss during denervation, showing that disruption of 
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the mitochondrial network is an essential amplifying loop of the muscle 
atrophy program (Romanello et al. 2010; Romanello & Sandri 2010).  
 
 
Figure 1.16: Mitochondrial dynamics in various intracellular processes  
Mitochondria undergo frequent cycles of fusion and fission that allow the cell to 
produce several heterogeneous mitochondria or interconnected mitochondrial 
networks, depending on physiological requirements. Fission is necessary for 
mitochondrial inheritance during cell division, apoptosis, intracellular mitochondrial 
distribution and mitochondrial turnover (mitophagy). Fused mitochondrial networks 
are important for the dissipation of metabolic energy and for the complementation of 
mtDNA gene products in heteroplasmic cells to counteract decline of respiratory 
functions in ageing (X and Y represent alleles of different mitochondrial genes). 
Figure adapted from (Westermann 2010). 
 
Figure removed due to copyright restrictions 
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1.4.9 Mitochondrial autophagy 
Autophagy is a conserved lysosomal degradation pathway that plays an 
important part in the breakdown and recycling of cellular components, 
including damaged organelles. The selective autophagic removal of 
mitochondria is often referred to as mitophagy. This turnover process is co-
ordinated with biogenesis and morphological remodelling to maintain the 
steady state population of mitochondria. 
Fission is required to isolate damaged mitochondria so they can be removed 
by mitophagy. A study of mitochondrial dynamics in fibroblasts showed that 1 
in 5 daughter mitochondria is depolarised and eradicated by mitophagy (Twig 
et al. 2008). In most fission events, one daughter mitochondrion is transiently 
hyperpolarised while the other is transiently depolarised, suggesting that 
fission serves as a ‘stress test’ that can push a daughter mitochondrion to 
completely depolarise if it is functionally compromised (Youle & van der Bliek 
2012). 
Two gene products mutated in familial Parkinson’s disease, PTEN-induced 
putative kinase 1 (PINK1) and Parkin, have given an insight into the 
molecular mechanism for mitophagy. PINK1 kinase is maintained at low 
levels on healthy mitochondria by constitutive import into the IMM and 
degradation by a protease called Presenilin-associated Rhomboid-like 
protein (PARL) (Youle & van der Bliek 2012). When a mitochondrion 
becomes damaged to the point of uncoupling, protein import to the IMM is 
prevented and PINK1 accumulates on the OMM (Youle & van der Bliek 
2012). The kinase activity of PINK1 then recruits Parkin, an E3 ubiquitin 
ligase that ubiquitinates OMM proteins and initiates the signal for autophagic 
removal. However, a recent study has shown that PINK1 is capable of 
initiating mitophagy in the absence of Parkin, suggesting that PINK1 is 
actually the signal initiator and Parkin instead acts as a signal amplifier 
(Lazarou et al. 2015). The PINK1 and Parkin pathway also prevents 
damaged mitochondria from fusing and contaminating the mitochondrial 
network through the ubiquitination of Mfn1 and Mfn2 and the phosphorylation 
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of mitochondrial-motor protein Miro, subsequently marking them for 
degradation (Youle & van der Bliek 2012).  
Upon initiation of the mitophagy signal, a double membrane structure called 
the isolation membrane (or phagophore) is recruited to the mitochondria and 
grows around it, essentially engulfing it. The resulting autophagosome then 
fuses with a lysosome, allowing degradation of the mitochondrial cargo and 
the inner bilayer of the double membrane, which can be reused or 
catabolised (Youle & Narendra 2011). A marker for mammalian autophagy is 
Microtubule-associated Protein 1 Light Chain 3 (MAP1LC3, hereafter 
referred to as LC3), which exists in two forms: LC3-I, which has a cytosolic 
distribution and is 18kDa in size, and LC3-II, a lipid-conjugated 16kDa 
version, which is integrated into the isolation membrane upon autophagy 
induction (Kabeya et al. 2000). 
FoxO3, a transcription factor that is active during muscle atrophy, enhances 
the transcription of autophagy-related genes including LC3 (Mammucari et al. 
2007).  The master regulator of mitochondrial biogenesis, PGC1α, is 
protective against atrophy as it inhibits FoxO3-dependent transcription 
(Sandri et al. 2006), but its role in autophagy and mitophagy is not well 
understood. Some atrophy studies have shown increased autophagic flux 
upon PGC1α overexpression (Vainshtein et al. 2015), whereas others have 
seen a reduction in autophagy (Cannavino et al. 2014). Nevertheless, there 
is a clear link between mitochondrial biogenesis and autophagy, and the 
balance between these two pathways is crucial in determining the quality and 
quantity of mitochondria. 
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1.5 What is known about mitochondrial function in core 
myopathies? 
To date, the majority of core myopathy literature has focussed on the study 
of mouse models, which may reflect the difficulties in accessing patient 
muscle samples or perhaps practical difficulties in producing muscle cell 
models from patient fibroblasts. How well these mouse models reflect the 
human form of CCD varies considerably; for example, the RyR1 T4825I 
mutation has only been associated with MHS in humans, however, in mouse, 
it also causes core-like regions (Table 1.2) (Yuen et al. 2011). 
While most of these mouse models show characteristic, mitochondria-
deficient cores, fibres isolated from the RyR1 T4826I mouse also displayed 
unusual accumulations of mitochondria in subsarcolemmal areas peripheral 
to the cores, suggesting that cores are a result of abnormal mitochondrial 
migration (Yuen et al. 2011). Moreover, fibres from the RyR1 Y522S mouse 
showed a small but significant increase in the average distance between the 
mitochondria and the triads (Durham et al. 2008). 
Various alterations in mitochondrial morphology have also been reported. 
Although there were variations from fibre to fibre and area to area, a 
significant number of FDB fibres from heterozygous RyR1 Y522S mice 
showed a large number of mitochondria that were abnormally shaped, 
swollen, and sometimes severely disrupted (Durham et al. 2008). The 
prevalence of these deteriorations seemed to increase with age. Changes 
noted included widening and loss of matrix density, an increase in overall 
size, loss/disorganisation of the internal cristae, disruption of the external 
membrane and vacuolisation (Durham et al. 2008). Similar abnormalities 
have been reported in the RyR1 T4826I mouse (Yuen et al. 2011) and the 
calsequestrin 1 (CASQ1) KO mouse (Paolini et al. 2015), but not in the RyR1 
I4895T model (Zvaritch et al. 2007; Zvaritch et al. 2009) (Table 1.2), which 
will be discussed in more detail in the following chapter.  
  
Table 1.2: Summary of available core myopathy mouse models 
CCD= central core disease, MHS= malignant hyperthermia susceptibility, HOM= homozygote, HET= heterozygote, ED= embryonic day, NA= 
not applicable, * though the N244G mutation in CASQ1 causes a vacuolar myopathy (Rossi et al. 2014) 
 RyR1 I4895T RyR1 Y522S RyR1 R163C RyR1 T4826I CASQ1 KO 
Human disease CCD CCD & MHS CCD & MHS MHS None* 
Viability HOM die at birth 
HET viable 
HOM die ED17 
HET viable 
HOM die ED17/18 
HET viable 
HOM & HET viable Viable 
MHS - + + + + 
Core-like regions + + - + + 
Nemaline rods + - - - - 
Myofibrillar 
disorganisation 
+ + Unknown + + 
Mitochondrial swelling 
/ degeneration 
- + Unknown + + 
Location in RyR1 C terminal N terminal N terminal C terminal NA 
RyR1 phenotype EC uncoupled Leaky Leaky Leaky Leaky 
 
References 
(Zvaritch et al. 2007; 
Zvaritch et al. 2009; 
Boncompagni et al. 
2010; Loy et al. 2011) 
(Chelu et al. 2006; 
Durham et al. 2008; 
Boncompagni et al. 
2009) 
(Yang et al. 2006; 
Giulivi et al. 2011) 
 
(Yuen et al. 2011; 
Barrientos et al. 
2012) 
(Paolini et al. 2007; 
Dainese et al. 2009; 
Paolini et al. 2015) 
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A study using the CASQ1 KO mouse has suggested that mitochondrial 
biogenesis may be affected in core myopathies. The authors reported a two-
fold increase in PGC1α expression in EDL muscle homogenates from adult 
CASQ1 KO mice, which was consistent with increased mitochondrial volume 
and increased oxidative fibre content (Paolini et al. 2015). This PGC1α 
upregulation could be linked to Ca2+ deregulation, as free myoplasmic Ca2+ 
levels were increased at physiological temperature in CASQ1 KO fibres 
(Dainese et al. 2009). 
Although their mutations are more closely associated with MHS in humans, 
the RyR1 Y522S and CASQ1 KO mice present evidence that increased 
oxidative stress contributes to mitochondrial damage and possibly core 
development. Both mutations result in elevated resting myoplasmic Ca2+, 
which increases mitochondrial ROS and Reactive Nitrogen Species (RNS) 
production (Durham et al. 2008; Paolini et al. 2015). This then creates a 
feed-forward mechanism where the ROS and RNS cause activity-enhancing 
modifications to RyR1, leading to further SR Ca2+ leak and enhanced Ca2+ 
release in response to heat stress (Durham et al. 2008). In support of this, 
treatment with potent antioxidant, N-acetylcysteine, reduced oxidative stress 
and improved muscle function in both models (Durham et al. 2008; Paolini et 
al. 2015). In agreement with these murine studies, cultured myotubes from 
patients with RYR1-related myopathies have been shown to exhibit oxidative 
stress (Dowling et al. 2012). This was attributed to increased mitochondrial 
ROS production and could also be treated with N-acetylcysteine (Dowling et 
al. 2012). 
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1.6 Research hypothesis 
The ‘health’ of muscle mitochondria is crucial for maintaining normal muscle 
function and to provide the energy for force generation, as emphasized by 
the predominantly muscle phenotype of patients with mitochondrial DNA 
mutations. As has been described in earlier sections of this thesis, 
mitochondrial biology and intracellular Ca2+ homeostasis have an intricate 
relationship. Ca2+ plays a central role in the modulation of mitochondrial 
function through several pathways that ultimately converge to promote 
oxidative phosphorylation. On the other hand, excessive mitochondrial Ca2+ 
uptake can cause mitochondrial damage and potentially cell death. This 
delicate balancing act means it is not surprising that an alteration in 
intracellular Ca2+ signalling can result in a mitochondrial phenotype. In spite 
of this, the literature has somewhat overlooked the possibility that disruptions 
to intracellular Ca2+ homeostasis may cause mitochondrial dysfunction and 
altered bioenergetics, which could contribute to the muscle weakness 
observed in core myopathy patients. Therefore my research hypothesis is as 
follows: 
Mitochondria are contributing to core myopathy pathology by suffering Ca2+-
related dysfunction. 
I will test this hypothesis by characterising mitochondrial function in three 
core myopathy models with mutations in RYR1, STAC3 and MICU1, all of 
which play a role in muscle Ca2+ homeostasis (Figure 1.17). More 
specifically, I aim to complete the following objectives in each model: 
1. Characterise intracellular Ca2+ homeostasis, which is known to be 
disrupted in core myopathies 
2. Examine possible mitochondrial defects, including alterations in 
bioenergetics and mitochondrial distribution/morphology 
3. Compare my results to previous literature 
4. Discuss and evaluate my results in line with the above research 
hypothesis 
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Figure 1.17: Proteins involved in muscle Ca2+ homeostasis  
Mutations in RyR1, STAC3 and MICU1 proteins (red) result in a core myopathy 
phenotype. I will answer my research hypothesis by characterising mitochondrial 
function in three models with mutations in these proteins. 
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Chapter 2 Assessing mitochondrial function in a new RyR1 
I4895T mouse model 
2.1 Introduction 
2.1.1 I4898T mutation in RYR1 
The I4898T mutation has been associated with the dominant inheritance of 
CCD in at least seven unrelated families around the world (Robinson et al. 
2006). The degree of severity within each family varies from mild to severe, 
but a lethal de novo case of the mutation has also been reported in newborn 
twins (Hernandez-Lain et al. 2011). In addition to central cores, muscle 
biopsies from these twins showed nemaline rods, which have never been 
seen in I4898T-affected humans before. 
The I4898T mutation is situated in the C-terminal ‘hotspot’ region of RyR1 
(see Introduction 1.2.3), or more specifically, the transmembrane/luminal 
domain (or selectivity filter) (Lynch et al. 1999). Whether this mutation 
resulted in a ‘leaky’ or ‘EC-uncoupled’ RyR1 channel was not clear from early 
in vitro studies. The group that identified the first I4898T-affected family 
showed that transient expression of both normal and mutant channels 
(mimicking the patient heterozygosity) in HEK cells resulted in increased 
resting [Ca2+]c through RyR1 leak, which may have been due to a reduction 
in the Ca2+ concentration required for channel activation (Lynch et al. 1999). 
However similar experiments in dyspedic (RyR1 KO) mouse myotubes by 
Avila et al. did not show a change in resting or luminal Ca2+ concentrations; 
instead the authors observed a reduction in electrically-evoked Ca2+ 
transients, which may have been due to an uncoupling of sarcolemma 
excitation from SR Ca2+ release (Avila et al. 2001). 
2.1.2 RyR1 I4895T knock-in mouse 
The generation of a knock-in mouse line carrying the analogous murine 
I4895T mutation in RyR1 provided a valuable in vivo insight into the 
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pathogenesis caused by this RYR1 mutation. Homozygous mice are born 
with skeletal muscle paralysis, are unable to breathe, and die perinatally 
(Zvaritch et al. 2007). Analysis of the homozygote foetuses showed abnormal 
myogenesis and skeletal and cardiovascular development, suggesting that 
RyR1-mediated Ca2+ signalling is important in embryogenesis. Although 
muscle triad architecture and channel assembly was deemed normal in the 
mice, primary mutant myotubes were completely unresponsive to electrical 
and drug stimulation. Zvaritch et al. interpreted this as a defect in Ca2+ 
permeation/gating rather than a leaky channel, since resting [Ca2+]c and SR 
Ca2+
 
content were no different to that in wild type (WT) myotubes. 
Although heterozygous RyR1 I4895T mice also undergo neonatal respiratory 
stress, they recover from this and go on to exhibit a slowly progressive 
myopathy with varying degrees of severity (Zvaritch et al. 2009). Phenotypic 
features include impaired locomotion, dorsal kyphosis and in some mice, 
complete hind limb paralysis. Grip strength and hanging tasks showed that 4-
5 month old adult heterozygotes have a significant reduction in in vivo 
muscle strength (Loy et al. 2011). Single skeletal muscle fibres from these 
mice exhibited a significant reduction in the magnitude and rate of cytosolic 
Ca2+ signals during electrically evoked EC coupling and 4-chloro-m-cresol 
induced RyR1 activation, but did not have altered SR store content or RyR1 
channel sensitivity thus agreeing with Zvaritch’s diminished Ca2+ permeation 
theory (Loy et al. 2011). It is now widely agreed that the I4895T mutation 
causes RyR1 to become ‘EC uncoupled’, while other mutations result in an 
over-sensitive, ‘leaky’ channel (see Table 2.1, Introduction 1.5). 
It has been shown that heterozygous RyR1 I4895T myofibres undergo an 
age-dependent transition from small, compacted focal areas resembling 
minicores in younger mice, to cores and nemaline rods in adult and aged 
animals (Zvaritch et al. 2009). In areas of structural disorganisation, the 
mitochondria were displaced but did not show signs of swelling or 
degeneration as seen in other core myopathy mouse models (Table 2.1, 
Introduction 1.5). In the RyR1 I4895T and Y522S models, spatial 
inhomogeneity in local Ca2+ releases was proposed as a possible 
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mechanism for the formation of localised alterations in muscle structure 
(Zvaritch et al. 2009; Boncompagni et al. 2009). Functional heterogeneity in 
WT:mutant RyR tetramers could be the cause of such nonuniform Ca2+ 
release, which would result in shearing forces and possible disruption to 
sarcotubular and mitochondrial systems over time (Zvaritch et al. 2009). 
Genetic background appears to have a strong influence over the disease 
phenotype of the RyR1 I4895T knockin mouse. When the mutation was bred 
on a congenic 129S2/SvPasCrl background, it resulted in a variable but 
severe phenotype; 80% of HET mice exhibited some degree of motor 
dysfunction by 10 months old and 14% suffered complete hind limb paralysis 
at 12 months (Zvaritch et al. 2009). However, RyR1 I4895T mice on a mixed 
129S6/SvEvTac and 129S2/SvPasCrl background had a much milder 
disease phenotype (Boncompagni et al. 2010). The mixed sub-line showed 
mild structural alterations with relatively little mitochondrial involvement, 
whereas widespread areas of mitochondria-deficient contracture (localised 
regions of severe sarcomere shortening) were a prominent feature of the 
congenic sub-line.  
A study of MmD patients has reported a correlation between variations in 
clinical phenotype and RyR1 expression levels, demonstrating that 
epigenetic allele silencing can play an important role in disease presentation 
(Zhou et al. 2006; Zhou et al. 2007). However, it is unlikely that this applies to 
the I4895T mouse models, as the same study also showed that the RYR1 
mouse orthologue does not undergo genetic imprinting. In agreement with 
this, Zvaritch et al. found that WT and mutant alleles were expressed at 
similar levels in their congenic colony (Zvaritch et al. 2009). Nevertheless, 
other factors such as differences in epigenetic modulators or stability of the 
mutant protein might explain the phenotypic variation between I4895T mouse 
strains (Boncompagni et al. 2010). 
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2.1.3 Aims 
The degree of mitochondrial involvement varies considerably between 
different core myopathy mouse models (see Introduction 1.5) and even 
between sub-lines of mice carrying the same RyR1 mutation. The Duchen 
laboratory has created a new sub-line of RyR1 I4895T mice on a mixed 
129S2/SvPasCrl and C57BL/6J genetic background. In line with the 
objectives set out in 1.6, the aim of this chapter is to characterise the 
phenotype of this new sub-line by assessing Ca2+ homeostasis and 
mitochondrial function in a primary muscle cell model.  
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2.2 Methods 
2.2.1 Animal handling 
RyR1 I4895T knock-in mice on a 129S2/SvPasCrl background were kindly 
provided by the Hamilton laboratory, Texas, USA. These founder mice were 
rederived using C57BL/6J mice as this strain is reliable for breeding. This 
resulted in a new sub-line with a mixed genetic background (approximately 
50% 129S2/SvPasCrl and 50% C57BL/6J after rederivation). Since 
homozygotes have a perinatal lethal phenotype (Zvaritch et al. 2007), 
heterozygotes (HET) were crossed with wild type (WT) littermates or 
C57BL/6J mice (Charles River) to maintain the colony. At least five such 
crosses had occurred before my experiments. Ear snips from adult mice and 
tail snips from sacrificed neonates were retained for genotyping.  
2.2.2 Animal genotyping 
DNA was extracted from tissue samples using the Extract-N-Amp kit (Sigma) 
and PCR was used to amplify the fragment covering the mutation site. 
Forward and reverse primers were 5’-
GGTCTTCCTGTCTCAATAACCCGATCTAGAAAC-3’ and 5’-
GATGGAGAAACCAAAGCTCAGAGAGACCAC-3’ respectively. PCR 
reactions were made up to 25μL and contained the following: 1X Green 
GoTaq® reaction buffer (ProMega), 0.2mM PCR nucleotide mix (ProMega), 
3mM MgCl2 (ProMega), 1μM forward and 1μM reverse primers (Sigma), 1.25 
units of GoTaq® Hot Start polymerase (ProMega) and 1μL DNA template. 
PCR was performed in an Eppendorf MasterCycler using the cycling profile: 
95°C for 2mins, followed by 35 cycles at 95°C for 30secs, 60°C for 30secs, 
72°C for 1min.  2.5 units of Age I (NEB) was added to each amplified sample 
and incubated at 37°C for 2 hrs. 5μL of 1kB DNA marker (NEB) and 10μL of 
each restriction digest was loaded onto a 3% agarose gel (made with 1X 
TAE buffer and 0.5μg/mL ethidium bromide) and electrophoresis was carried 
out at 75V until the dye line was approximately 70% of the way down the gel. 
DNA was then visualised under UV light on a transilluminator (Figure 2.1). 
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Figure 2.1: Example of genotyping restriction digest 
Since the inserted mutation site also contains an Age I target sequence, only 
samples containing the mutated allele undergo Age I digestion. Therefore HET mice 
show two lower ‘cut’ bands in addition to the ‘uncut’ WT band. With hindsight, a 
negative (no DNA template) control should have been included in each PCR 
experiment to check for extraneous DNA contamination. 
2.2.3 Chemicals 
All chemicals were purchased from Sigma unless otherwise stated. 
2.2.4 Cell culture 
Primary myotube cultures were produced from postnatal (P) day P2-P7 WT 
and HET littermates. As genotype was unknown at time of dissection, each 
mouse and its subsequent myoblast population were processed separately. 
Pups were sacrificed by cervical dislocation and the hind limbs dissected. 
Muscles were minced finely and shaken for 1 hr at 37°C in a digestion mix 
containing 1mg/mL collagenase (from Clostridium histolyticum, Sigma) and 
3.5mg/mL dispase (Invitrogen) diluted in Iscove’s Modified Dulbecco’s 
Medium (IMDM) containing Glutamax (cat. no. 31980030, Invitrogen). 
Centrifugation and filtration were used to remove large debris, and then the 
cell suspension was pre-plated for 3-4 hrs to remove fibroblasts and purify 
the myoblast population. During this time, 22mm glass coverslips, 35mm 
imaging dishes (FluoroDish, WPI) or 96 well imaging plates (BD Biosciences) 
were coated with Matrigel (BD Biosciences, diluted 1:100 in ice-cold IMDM) 
for at least 1 hr at RT before washing with IMDM. After 3-4 hrs pre-plating, 
 69 
myoblasts were centrifuged and resuspended in proliferation media 
consisting of IMDM, 20% Fetal Bovine Serum (FBS) (Invitrogen), 1% chicken 
embryo extract (MP Biomedicals), and 0.05mg/mL gentamycin (Sigma), and 
plated on the Matrigel-coated cultureware. When myoblasts started to 
spontaneously fuse after 3-4 days, the proliferation media was removed and 
concentrated Matrigel (diluted 1:2 in ice-cold IMDM) was carefully pipetted on 
top of the cells and left to set for 30 mins at 37°C. Differentiation media 
consisting of IMDM, 2% horse serum (HS) (Invitrogen), 100ng/mL rat agrin 
(R&D Systems) and 0.05mg/mL gentamycin was then added to the Matrigel-
coated cells. Myotubes were imaged at days 8-10 of agrin differentiation. 
2.2.5 Myofiber isolation 
6-7 month old female WT and HET mice were sacrificed by CO2 inhalation 
and FDB muscles were dissected. This muscle was selected because its 
small size was optimal for tituration (see below). FDBs were digested for 1.5 
hrs at 37°C in 2mg/mL collagenase type I (Sigma) before being transferred to 
Dulbecco’s Modified Eagle’s Medium (DMEM) containing Glutamax (cat. no. 
10569010, Invitrogen), 10% FBS, 1% PS and left at 37°C 5% CO2 for at least 
15mins. Individual myofibers were released by titurating the muscles with a 
range of fire-polished glass bore pipettes decreasing in diameter. Tituration 
steps were carried out directly on Matrigel (diluted 1:10 in ice-cold DMEM) 
coated 35mm imaging dishes and 24-well imaging plates (iBidi). Plating 
medium consisted of DMEM, 20% controlled serum replacement (Sigma), 
1% HS and 1% PS. Myofibers were imaged within 24 hrs of plating. 
2.2.6 Immunofluorescence 
Primary mouse myotubes were fixed in PBS/3.7% paraformaldehyde for 15 
mins, washed with PBS, permeabilised with PBS/0.25% Triton X-100 for 10 
mins and blocked in PBS containing 3% BSA and 10% donkey serum 
(Sigma) for 30 mins at room temperature (RT). Primary anti-RyR1 antibody 
(mouse IgG1, Abcam) was used at 1:200 dilution in PBS/0.25% Triton X-
100/3% BSA for 2 hrs RT. Secondary anti-mouse AlexaFluor647 antibody 
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(donkey, Invitrogen) was used at 1:500 dilution in PBS/0.25% Triton X-
100/3% BSA for 30 mins RT. Cells were washed with PBS and incubated 
with 2μg/mL Hoechst stain for 10 mins RT. Cells were then washed with 
PBS, covered in Fluoromount (Sigma) and left to air dry before imaging on a 
Zeiss 700 CLSM. A secondary control (no primary antibody incubation) was 
used to establish acquisition settings so that background staining was 
excluded.  
ImageJ (NIH) was used for image analysis. Differentiated myotubes were 
identified as cells containing more than one nucleus (using the Hoechst 
image). Myotubes with a stripy RyR1 patterning as in (Falcone et al. 2014) 
were scored as ‘striated’. 
2.2.7 Cytosolic Ca2+ imaging 
Myotubes and myofibres, cultured in 96 well and 24 well imaging plates, 
respectively, were loaded with recording buffer (RB) (150mM NaCl, 4.25mM 
KCl, 4mM NaHCO3, 1.25mM NaH2PO4, 1.2mM MgCl2, 1.2mM CaCl2, 10mM 
D-glucose, 10mM HEPES pH7.4) containing 5μM fura-2 AM (Molecular 
Probes) for 40 mins at 37°C. 0.002% pluronic acid was also included in the 
loading buffer to aid solubilisation and loading of the AM ester. Cells were 
washed with RB before being imaged on an Olympus IX71 inverted 
epifluorescence microscope using a 20x objective. Stock concentrations of 
caffeine and 4-chloro-m-cresol were made up in RB. Potassium chloride 
(KCl) solutions were made up so the final total ionic strength remained as 
154.25mM ([K+] + [Na+]). Fura-2 was sequentially excited at 340nm and 
380nm, while emission was measured at 510nm. Images were acquired 
using a CCD camera (Hamamatsu Corporation) and were recorded and 
analysed in the MetaFluor 7.8 software (Universal Imaging). 
Background was subtracted from both 340nm and 380nm images and 
regions of interest (ROIs) were drawn around individual myotubes and 
myofibres. Myotubes were defined as cells with more than one nucleus. 
Damaged or contracted myofibres were excluded from analysis. The ratio of 
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the background-corrected fluorescence intensities detected at 510nm 
(hereafter referred to as fura-2 ratio) was used to illustrate cytosolic Ca2+ 
levels in each cell. By using the ratio of fluorescence intensities produced by 
excitation at two wavelengths, factors such as uneven dye loading and 
photobleaching are minimised as they should affect both measurements to a 
similar extent. fura-2 was calculated as the difference between the average 
resting fura-2 ratio and the peak ratio following stimulation. Only ‘responding’ 
cells i.e. that showed a ≥10% increase in fura-2 ratio following stimulation, 
were analysed. Data originating from the same mouse was pooled together 
to give an average value, which was then used in statistical analysis. 
2.2.8 Measurements of resting Δm 
Isolated myofibres were equilibrated with RB containing 25nM 
tetramethylrhodamine methyl ester (TMRM) for 15 mins at 37°C. Confocal z 
stacks were then acquired on a Zeiss 510 UV-VIS CLSM using a 40x oil 
objective. RB containing only 25nM TMRM was present throughout imaging. 
Fluorescence was excited at 543nm and measured at >560nm.  
ImageJ was used for image analysis. Damaged or contracted myofibres were 
excluded from analysis. ROIs were drawn around individual myofibres and 
images were thresholded to quantify the mean of mitochondria-localised 
signal intensities within each ROI. Maximum intensity projections were used 
for quantification to avoid bias in the focal plane. Identical acquisition settings 
and threshold values were used in repeat experiments. 
2.2.9 Resting NADH measurements 
Isolated myofibres were imaged as a z stack using a Zeiss 510 UV-VIS 
CLSM with a 40x oil objective. Fluorescence was excited using the 351nm 
line of an argon laser and was measured between 435-485nm. The pinhole 
was kept wide open to maximise NADH signal. 
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ImageJ was used for image analysis. Damaged or contracted myofibres were 
excluded from analysis. ROIs were drawn around individual myofibres and 
images were thresholded to quantify the mean of mitochondria-localised 
signal intensities within each ROI. Maximum intensity projections were used 
for quantification to avoid bias in the focal plane. Identical acquisition settings 
and threshold values were used in repeat experiments. 
2.2.10 Respirometry of permeabilised muscle fibres 
5 month old female WT and HET mice were sacrificed by CO2 inhalation. 
EDL and soleus muscles were dissected and put in ice-cold Biopsy 
Preservation Solution (BIOPS) (2.77mM CaK2EGTA, 7.23mM K2EGTA, 
5.7mM Na2ATP, 6.56mM MgCl2.6H2O, 20mM taurine, 15mM Na2Phospho-
creatine, 20mM imidazole, 0.5mM dithiothreitol, 50mM MES, pH7.1). 
Muscles and fibre bundles were kept on ice at all times prior to respirometry 
measurement. After removing connective tissue and tendon, muscles were 
gently separated into 6-8 fibre bundles of roughly equal size using a pair of 
needles. To maximise muscle surface area, individual fibres within each 
bundle were teased apart with needles. Fibre bundles were permeabilised in 
ice-cold BIOPS containing 25μg/mL saponin for 30 mins with gentle agitation, 
before being washed with ice-cold Mitochondrial Respiration medium 5 
(Miro5) (0.5mM EGTA, 3mM MgCl2.6H2O, 60mM K-lactobionate, 20mM 
taurine, 10mM KH2PO4, 20mM HEPES, 110mM sucrose, 1g/L BSA, pH7.1) 
for 10 mins with gentle agitation. 3 bundles of roughly equal size were 
transferred to a Miro5-filled chamber of a high-resolution Oxygraph 
(Oroboros Oxygraph-2K) maintained at 37°C. The chambers were then 
hyper-oxygenated to at least 500μM [O2] by injecting a 95% O2 / 5% CO2 
medical gas mixture (Figure 2.2). Complex I substrates, 10mM glutamate 
and 2.5mM malate, were added to measure the leak state (non-
phosphorylating resting state of intrinsic uncoupled respiration), followed by 
2.5mM ADP to observe the active state. 10μM cyt c was used to test the 
intactness of the OMM (Pesta & Gnaiger 2012). 10mM succinate was then 
added to assess respiration in the presence of both complex I & II substrates. 
Maximal oxidative capacity was determined in the presence of 0.25μM 
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FCCP, complex II-driven respiration measured in the presence of 0.5μM 
rotenone and non-mitochondrial (background) O2 consumption determined in 
the presence of 2.5μM Antimycin A. 
As the instrument contained two measuring chambers, WT and HET samples 
were assessed simultaneously in one experiment. To minimise any possible 
variation between the chambers, WT and HET samples swapped chambers 
in repeat experiments. 
At the end of each experiment, muscle bundles were removed from the 
chambers and frozen at -80°C. The bundles were homogenised using a 
hand-operated Kontes Pellet Pestles grinder (Kimble) and lysed in RIPA 
buffer (150mM NaCl, 0.5% sodium deoxycholic acid, 0.1% SDS, 1% Triton 
X-100, 50mM Tris pH8, 1mM PMSF) for 30 mins on ice. Samples were 
subsequently centrifuged at 16,000g at 4°C and protein concentrations 
determined using Pierce BCA assay (Thermo Scientific). These values were 
then input into DatLab5 (Oroboros Oxygraph-2K) to normalise O2 flux to total 
protein content of each sample. Average O2 consumption rates were 
calculated by manually selecting a region where the signal was relatively 
stable (Figure 2.2). These rates were then corrected for background/non-
mitochondrial respiration by deducting the value for average O2 flux in the 
presence of Antimycin A. 
  
 
 
Figure 2.2: Example of O2 consumption measurements of permeabilised muscle fibres 
Blue line indicates O2 concentration inside the chamber, while the red line shows O2 flux per mg protein i.e. O2 consumption normalised to total 
protein content.  After inserting the fibre bundles, the chambers were hyperoxygenated and glutamate and malate were added to kick-start 
mitochondrial respiration. ADP, cyt c, succinate, FCCP (titrated), and rotenone were added in succession to observe transition between different 
respiratory states. A final addition of Antimycin A was used to measure non-mitochondrial respiration (NMR). Green bars indicate regions over 
which average respiratory state values were calculated.
7
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2.2.11 Western blotting 
6-8 month old female WT and HET mice were sacrificed by CO2 inhalation 
and dissected of EDL and soleus muscles, which were then frozen at -80°C. 
These muscles were chosen to see if the pathological impact of the I4895T 
mutation varies in different muscle types (in human CCD type I fibres are 
predominantly affected (Jungbluth 2007a)). The muscles were homogenised, 
lysed and had total protein concentration determined as above (section 
2.2.10). 25μg of protein was heated to 55°C for 5 mins in NuPAGE 4X LDS 
sample buffer (Invitrogen) containing 5% β-mercapethanol. Proteins were 
separated using 4-12% NuPAGE Bis-Tris gels (Invitrogen) with MOPS 
running buffer (Invitrogen) and transferred onto Immobilon PVDF membranes 
(Millipore) using NuPAGE transfer buffer (Invitrogen) supplemented with 20% 
methanol. Membranes were washed with PBS-T and blocked with 5% dried 
skimmed milk in PBS-T for 1 hour at RT, before being incubated with primary 
antibody solution overnight at 4°C. Following 3 x 10 min washes in PBS-T, 
membranes were incubated with secondary antibody solution for 1-1.5 hrs at 
RT. After 3 x 5 min washes in PBS-T, the membranes were developed using 
Amersham ECL reagent (GE Healthcare) and imaged with a ChemiDoc 
system (BioRad). Densitometry analysis was carried out using ImageJ. 
Primary antibodies used were total OXPHOS rodent antibody cocktail 
(mouse, MitoSciences; 1:1000), anti-TFAM (rabbit, Abcam; 1:1000) and anti-
GAPDH (rabbit, Sigma; 1:5000). The total OXPHOS antibody cocktail 
contains antibodies against the following complex subunits: CI subunit 
NDUFB8, CII-30kDa, CIII-core protein 2, CIV subunit I and CV alpha subunit. 
Secondary antibodies used were goat anti-mouse and goat anti-rabbit HRP 
conjugated IgGs (both from Thermo Scientific and diluted 1:4000). 
2.2.12 Statistics 
Values are presented as mean ± standard error. Statistical analysis was 
performed using Prism 6 (GraphPad). Unpaired two-tailed t-tests were 
applied to test significance to a P value of 0.05. Significant differences are 
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indicated with asterisks (* if P<0.05, ** if P<0.01, *** if P<0.001). N indicates 
number of mice used for statistics (unless otherwise stated). 
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2.3 Results 
2.3.1 Agrin-treated primary mouse myotubes do not exhibit striated 
triads but are a functional muscle model 
Skeletal muscle has an intricate striated architecture in vivo, which has been 
replicated with some success in in vitro culture systems (Cooper et al. 2004; 
Cusimano et al. 2009; Flucher et al. 1991). A recent study has reported using 
agrin to grow myotubes with the striated pattern of transversal triads 
(Falcone et al. 2014), essentially mimicking mature myofibres. Agrin is a 
large proteoglycan that induces clustering of acetylcholine receptors and aids 
the formation of neuromuscular junctions (Patthy & Nikolics 1993). Falcone 
et al. showed that up to 80% of their primary myotubes had organised triads 
after 10 days of agrin-supported differentiation, compared to only 20% in 
non-treated cultures (Falcone et al. 2014) (Figure 2.3b). Given that the triads 
are where EC coupling takes place, and EC coupling has been shown to be 
defective in the RyR1 I4895T mouse model, it seems important to attain 
triadic striations in my primary muscle cultures. Despite following the same 
protocol as Falcone et al., I did not find any striated myotubes in my cultures 
(Figure 2.3a & c).  
Figure 2.3: Quantification of striated myotubes in agrin-treated cultures 
Figures removed due to copyright restrictions 
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After 10 days of agrin-supported differentiation, myotubes were fixed and 
immunostained for RyR1 (a). Myotubes exhibiting a distinct, striped RyR1 patterning 
were scored as ‘striated’ (b). Image in (b) is adapted from (Falcone et al. 2014). 
Scorings indicate pooled myotubes from 3 different WT and HET mice (c). Scale 
bars 10μm. 
Exposing fura2-loaded myotubes to the RyR1 agonist caffeine resulted in 
robust cytosolic Ca2+ signals (Figure 2.4) associated with contraction. This 
suggests that although there is a lack of triadic structure, RyR1 is still present 
and functional in these myotubes, making them an adequate model for 
studying EC coupling and how it affects mitochondrial function. 
 
 
 
 
 
 
 
 
Figure 2.4 Agrin-treated myotubes are caffeine sensitive 
Addition of 5mM caffeine (arrow) triggers SR Ca2+ release in agrin-treated myotubes 
loaded with fura-2 AM. This increase in [Ca2+]c is observed as an increase in 
fluorescence intensity at 340nm (Ca2+ bound) and a decrease in fluorescence at 
380nm (Ca2+ free) i.e. an increase in the ratio of 340nm/380nm (Fura-2 ratio). Trace 
represents the initial stage of the Ca2+ response of >25 myotubes originating from 4 
different WT mice (n=4). Errors bars indicate SEM.  
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2.3.2 Ca2+ homeostasis is unaltered in primary HET myotubes 
Previously, it has been shown that mature myofibres isolated from two 
different strains of HET RyR1 I4895T mice have reduced Ca2+ transients in 
response to RyR1 activation (Boncompagni et al. 2010; Loy et al. 2011). To 
see if this is also the case in my model, I applied different concentrations of 
caffeine to myotubes loaded with fura-2 AM and measured the change in 
fura-2 ratio (fura-2). No significant differences in fura-2 were identified 
between WT and HET myotubes stimulated with 1mM (P=0.928), 2mM 
(P=0.607) or 5mM caffeine (P=0.454) (Figure 2.5a). It has also been 
suggested previously that the I4898T mutation in RyR1 causes chronic Ca2+ 
leak from the SR and elevated resting [Ca2+]c (Lynch et al. 1999). In 
disagreement with this, no significant difference in resting cytosolic Ca2+ was 
observed (P=0.257) (Figure 2.5b). 
Figure 2.5: Average resting and agonist-induced cytosolic Ca2+ levels are 
similar between WT and HET mouse myotubes 
Myotubes were loaded with fura-2 AM and stimulated with different concentrations 
of caffeine (a). Average fura-2 ratios prior to stimulation were used as a measure of 
resting cytosolic Ca2+ (b). fura-2 was calculated as the difference between the 
average resting fura2 ratio and the peak ratio following caffeine addition. n ≥ 4 mice, 
with at least 3 myotubes measured per mouse (and thus per caffeine experiment). 
Myotube measurements from one mouse were averaged to give the mean value for 
that particular mouse. Therefore values shown are mean of means ± standard error. 
Given that the I4895T mutation is associated with an ‘EC uncoupled’ RyR1 
phenotype, I was surprised that caffeine-induced Ca2+ transients were not 
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significantly reduced in myotubes produced from the HET mouse. This may 
reflect the fact that they do not have the same triadic structure as a mature 
muscle fibre, which may be important for replicating physiological Ca2+ 
signals. 
2.3.3 Single myofibres isolated from adult HET mice produce slightly 
higher Ca2+ transients in response to depolarisation 
Given that myotubes are an immature form of a myofibre, I decided to also 
characterise Ca2+ homeostasis in mature myofibres isolated from the FDB 
muscle of adult WT and HET mice. As caffeine and 4-chloro-m-cresol did not 
seem to be reliable stimuli for this model, KCl was used to depolarise the 
myofibres, triggering EC coupling and Ca2+ release from the SR. fura-2 in 
response to 50mM KCl was significantly larger in HET myofibres (0.769 ± 
0.00645) than in WTs (0.714 ± 0.0125) (P=0.0181), though this difference 
was relatively small (Figure 2.6a). Quantification of the number of fibres that 
responded to the KCl stimulus suggested that HET fibres are more likely to 
respond, though this result was not statistically significant (P=0.421) (Figure 
2.6b). In agreement with my measurements in myotubes, resting cytosolic 
Ca2+ levels were not significantly different (P=0.0839) between WT and HET 
myofibres (Figure 2.6c). 
Figure 2.6: Average depolarisation-induced cytosolic Ca2+ rise is significantly 
higher in HET mutant fibres 
FDB myofibres isolated from 6-7 month old mice were loaded with fura-2 AM and 
depolarised with 50mM KCl (a). The number of myofibres that produced a cytosolic 
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Ca2+ response to KCl was quantified (b). Average fura-2 ratio prior to stimulation 
was used as a measure of resting cytosolic Ca2+ (c). n=3 mice, with at least 5 
myofibres measured per mouse. Measurements from one mouse were averaged to 
give the mean value for that particular mouse. Therefore values shown are mean of 
means ± standard error. 
 
2.3.4 Mitochondrial distribution and Δm are unchanged in HET 
myofibres 
Δm is a key bioenergetic parameter that determines respiratory rate, ATP 
synthesis and ROS generation. To assess whether Δm was affected in the 
mixed background mouse model, WT and HET FDB myofibres were imaged 
in the presence of TMRM, a cell-permeant cationic dye that is readily 
sequestered by active mitochondria (Figure 2.7a & b). Quantification of 
average basal TMRM fluorescence showed no significant difference between 
WT and HET myofibres (P=0.827) (Figure 2.7c).  
Qualitative analysis of the same TMRM z stacks did not show a difference in 
mitochondrial distribution between WT and HET myofibres (Figure 2.7a & b). 
Previous work on the RyR1 I4895T and the RyR1 Y522S mouse models 
have shown the presence of contracture cores (localised regions of severe 
sarcomere shortening) where mitochondria are absent (Zvaritch et al. 2009; 
Boncompagni et al. 2009). I was unable to identify such contractures in the 
HET myofibres, though there is the possibility that during image collection I 
may have overlooked such structures as damage sustained to the fibre 
during the isolation process.  
  
 
 
 
 
 
 
Figure 2.7: Resting Δm is similar between WT and HET myofibres 
FDB myofibres isolated from 6-7 month old mice were loaded with TMRM and imaged from one end to the other through a z stack series (inset 
montages, a & b).  Maximal projection images were used for intensity analysis (right hand image, a & b). Average TMRM fluorescence of HET 
myofibres was normalised to WT average on each experimental day (c). Scale bars 10μm. n=4 mice, with at least 7 myofibres measured per 
mouse. Measurements from one mouse were averaged to give the mean value for that particular mouse. Therefore values shown are mean of 
means ± standard error. 
8
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2.3.5 HET myofibres are not bioenergetically compromised 
NADH (but not NAD+) is fluorescent, absorbing light of about 350nm in 
wavelength and emitting fluorescence at 460nm. To get a rough indication of 
cellular redox state and energy metabolism in this new RyR1 I4895T mouse 
model, resting NADH fluorescence was measured in single WT and HET 
myofibres (Figure 2.8a). Quantification of average fluorescence showed no 
significant difference between WT and HET myofibres (P=0.224) (Figure 
2.8b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.8: Resting NADH levels are similar between WT and HET myofibres 
Representative maximal projections of NADH fluorescence in FDB myofibres 
isolated from 6-7 month old WT and HET mice (a). Average NADH fluorescence of 
HET myofibres was normalised to WT average on each experimental day (b). Scale 
bars 10μm. n=2 mice, with at least 12 myofibres measured per mouse. 
Measurements from one mouse were averaged to give the mean value for that 
particular mouse. Therefore values shown are mean of means ± standard error. 
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Basal NADH signal is difficult to interpret in terms of cell redox state; the 
NADH/NAD+ pool may differ between two separate biological preparations. 
For example, two samples with identical resting NADH levels may have 
considerably different NAD+ levels. Thus to directly compare the redox state 
of two specimens, the dynamic range of NADH fluorescence should be 
measured (Duchen 2004). This can be done using drug treatments to 
maximally reduce and maximally oxidise mitochondrial NAD (Figure 2.9). I 
did trial such an experiment on the isolated mouse myofibres but concluded 
that it was practically too difficult to carry out; there was usually only one fibre 
in a field and it often moved upon drug addition. In addition, each mouse 
preparation gave a relatively low yield of healthy fibres, thus limiting the 
number of different experiments I could carry out. 
Figure 2.9: Quantifying the dynamic range of NADH fluorescence 
Example of an experiment for quantifying the dynamic range of NADH fluorescence. 
Basal NADH fluorescence was measured at t=0. Addition of uncoupler FCCP 
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caused a decrease in fluorescence, as the mitochondrial NADH pool became 
maximally oxidised i.e. 0% NADH redox level. Addition of complex I inhibitor 
rotenone caused an increase in fluorescence, as the mitochondrial NADH pool 
became maximally reduced i.e. 100% NADH redox level. Basal fluorescence was 
then calibrated to these minimum and maximum values to give a measure of NADH 
redox level. 
Respirometry measurements also give an indication of cellular bioenergetics 
and the functionality of the electron transport chain. Rather than isolating 
mitochondria, which requires a lot of muscle tissue, muscle fibres can be 
gently permeabilised to allow for the exchange of soluble molecules between 
the cytosolic phase and the external medium without permeabilisation of the 
mitochondrial membranes. If the mitochondrial membranes have become 
damaged by the permeabilisation process, addition of cytochrome c causes a 
substantial rise in O2 consumption (Pesta & Gnaiger 2012). Having 
previously optimised the permeabilisation procedure, no effect of cyt c was 
ever seen in my experiments (see figure 2.2 for example trace and figures 
2.10 & 2.11 for average values). Respirometry measurements were carried 
out on both fast-twitch (Figure 2.10) and slow-twitch (Figure 2.11) muscles 
but there was no significant difference between WT and HET muscles in any 
respiratory state in either muscle type.  
  
 
 
 
 
 
 
Figure 2.10: Mitochondrial O2 consumption in permeabilised HET EDL muscle fibres is comparable to WT EDL 
High-resolution respirometry was used to measure O2 consumption of permeabilised WT and HET EDL fibres in the leak state (only glutamate 
and malate present), active state (ADP also present), complex II driven state (succinate), maximal state (FCCP) and under complex I inhibition 
(rotenone). Raw O2 consumption measurements (pmol s
-1 mg protein-1) from each experimental day are shown in the table. The mean averages 
of these measurements are shown in the bar graph (error bars SEM). n=4 mice (one on each experimental day), with 3 fibre bundles measured 
per mouse. 
 
Leak ADP Cyt c Succinate FCCP Rotenone 
WT HET WT HET WT HET WT HET WT HET WT HET 
Day 1 4.6 23.9 23.2 89.3 20.6 69.6 42.1 106.1 49.7 109.1 29.8 62.3 
Day 2 34.0 12.4 93.0 45.2 81.0 43.3 115.3 84.1 119.2 83.4 72.0 60.4 
Day 3 3.9 21.6 32.9 54.4 30.5 47.3 58.0 72.8 68.4 76.0 43.7 45.3 
Day 4 27.8 16.4 124.3 115.6 113.8 104.7 126.7 129.5 162.2 164.9 97.6 99.3 
Mean 17.6 18.6 68.4 76.2 61.5 66.2 85.5 98.1 99.9 108.4 60.8 66.8 
S.D. 15.6 5.16 48.4 32.4 43.7 28.1 41.7 25.1 50.9 40.3 30.2 22.9 
P 
value 0.909 0.799 0.861 0.624 0.802 0.760 
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Figure 2.11: Mitochondrial O2 consumption in permeabilised HET soleus muscle fibres is comparable to WT soleus 
High-resolution respirometry was used to measure O2 consumption of permeabilised WT and HET soleus fibres in the leak state (only 
glutamate and malate present), active state (ADP also present), complex II driven state (succinate), maximal state (FCCP) and under complex I 
inhibition (rotenone). Raw O2 consumption measurements (pmol s
-1 mg protein-1) from each experimental day are shown in the table. The mean 
averages of these measurements are shown in the bar graph (error bars SEM). n=4 mice (one on each experimental day), with 3 fibre bundles 
measured per mouse. 
 
Leak ADP Cyt c Succinate FCCP Rotenone 
WT HET WT HET WT HET WT HET WT HET WT HET 
Day 1 6.2 37.1 19.9 61.8 12.0 40.6 46.8 77.3 49.5 70.1 30.7 47.0 
Day 2 25.3 12.6 106.0 60.2 98.8 57.0 138.5 86.8 127.5 98.8 79.3 48.4 
Day 3 13.1 34.3 47.3 86.4 45.6 60.8 69.7 93.8 72.9 101.2 50.1 58.6 
Day 4 12.0 4.4 35.8 42.8 32.4 46.5 75.1 107.8 77.8 113.8 46.0 63.1 
Mean 14.1 22.1 52.2 62.8 47.2 51.2 82.5 91.4 81.9 96.0 51.5 54.2 
S.D. 8.03 16.1 37.6 18.0 37.1 9.31 39.3 12.8 32.8 18.5 20.3 7.83 
P 
value 0.411 0.630 0.841 0.681 0.484 0.811 
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2.3.6 Levels of expression of complex III and IV subunits are reduced 
in fast-twitch muscle from HET adult mice 
Alterations in electron transport chain assembly can lead to respiratory 
deficiency, as demonstrated in many mitochondrial disorders. To assess 
relative levels of electron transport chain subunits in this RyR1 I4895T 
mouse model, western blotting analysis was carried out on EDL and soleus 
homogenates using a commercial antibody cocktail (Figure 2.12a & d). 
Quantification showed that the relative levels of complex III were significantly 
reduced in HET fast-twitch EDL muscle (WT 0.548 ± 0.039; HET 0.432 ± 
0.015; P=0.0331) (Figure 2.12b). A significant reduction in the relative levels 
of complex IV was also observed (WT 0.752 ± 0.036; HET 0.570 ± 0.025; 
P=0.00629) (Figure 2.12b). Although there was a trend for reduced 
expression of each complex subunit in HET slow-twitch soleus muscle, the 
differences were not statistically significant (Complex V: P=0.564, complex 
IV: P=0.314, complex III: P=0.532, complex II: P=0.204, complex I: P= 0.470) 
(Figure 2.12c). 
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Figure 2.12: Levels of complex III and IV subunits are reduced in HET EDL 
muscle 
Muscle homogenates from EDL (a) and soleus (d) were immunoblotted for the 
following complex subunits: complex I NDUFB8 (20kDa), complex II SDHB (30kDa), 
complex III UQCRC2 (48kDa), complex IV MTCO1 (40kDa), complex V ATP5A 
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2.3.7 Mitochondrial biogenesis appears normal in skeletal muscle of 
HET adult mice 
Down regulation of electron transport chain subunits at the protein level could 
suggest that HET mice have fewer mitochondria in their skeletal muscle, 
which could be a consequence of reduced mitochondrial biogenesis. To test 
this theory, western blotting analysis was carried out on EDL and soleus 
homogenates using an antibody targeted to TFAM (Figure 2.13a & b), which 
is a major transcription factor driving the expression of mitochondrial-
encoded proteins. Densitometry analysis showed no significant differences 
between WT and HET mice, in either fast-twitch EDL (P=0.811) (Figure 
2.13c) or slow-twitch soleus muscle (P=0.653) (Figure 2.13d). 
 
 
 
 
 
Figure 2.13: TFAM protein levels are similar in WT and HET skeletal muscle 
Muscle homogenates from EDL (a) and soleus (b) were immunoblotted for TFAM. 
Band intensities were normalised to GAPDH loading control (c & d). n≥4 mice 
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2.4 Discussion 
In this chapter, I have characterised the RyR1 and mitochondrial phenotype 
of a new sub-line of RyR1 I4895T mice by using two different muscle cell 
models. The first consisted of myotubes produced from neonates, which 
were treated with agrin in an attempt to replicate the striated triadic structure 
seen in mature myofibres. Despite following the same protocol used by 
Falcone et al., I could not identify any striated myofibres in my primary 
cultures at day 10 of agrin-supported differentiation. Instead the myotubes 
had diffuse RyR1 staining, similar to that described by Falcone et al. at day 5 
of agrin-supported differentiation. This suggests that my myotubes may have 
been slower to mature and perhaps needed longer in culture. I did try 
extending the differentiation period but it was too difficult to quantify striations 
as most of the cells had detached themselves from the coverslips by day 12 
(probably through natural cell death or increased spontaneous contractions).  
2.4.1 RyR1 phenotype 
As a skeletal muscle model, primary myotubes may not be structurally 
accurate but stimulation with caffeine proved that they have a functional 
RyR1 and are contractile. Previous studies have shown that the I4895T 
mutation in RyR1 causes a reduction in stimulated SR Ca2+ release (Avila et 
al. 2001; Boncompagni et al. 2010; Loy et al. 2011). In contrast, I found that 
HET myotubes behaved similarly to controls and did not show reduced 
cytosolic Ca2+ transients in response to any caffeine concentration tested. 
Although these myotubes did show spontaneous twitching in culture, it is 
unlikely that they experienced the same frequency and intensity of contractile 
activity that would occur in vivo. Perhaps if a regular in vitro activity regime 
were implemented, such as applying caffeine or electrical stimulation, 
abnormalities in Ca2+ homeostasis and mitochondrial function might be 
revealed in the HET cells.  
As I was unable to show a RyR1-related Ca2+ defect in the HET myotubes, I 
decided to switch to a more mature muscle cell model, which consisted of 
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isolated FDB myofibres from adult mice. Initially, I attempted to measure 
cytosolic Ca2+ signals in myofibres loaded with fura-2 and stimulated with 
10mM caffeine or 500uM 4-chloro-m-cresol (another RyR1 agonist) (as in 
2.2.7). Unfortunately these RyR1 agonists failed to reliably produce Ca2+ 
signals in even isolated WT fibres so I proceeded to use KCl-induced 
depolarisation as an alternative stimulus for muscle contraction. My results 
showed a very small but significant increase in depolarisation-induced Ca2+ 
release in the HET myofibres. This result was surprising as previous mouse 
studies have shown reduced Ca2+ transients in response to electrical 
stimulation (Boncompagni et al. 2010; Loy et al. 2011). Although depolarising 
with KCl has not been tested in HET I4895T myofibres before, it should in 
theory stimulate RyR1-mediated Ca2+ release in the same way as an 
electrical stimulus, so it’s difficult to understand why I saw the opposite in this 
model. Perhaps it reflects something unreliable about my myofibre isolating 
procedure, which might also explain the problems I had with caffeine and 4-
chloro-m-cresol stimulation. 
2.4.2 Mitochondrial phenotype 
To characterise the bioenergetic status of this new mouse sub-line, I 
measured resting Δm, NADH levels and O2 consumption in isolated HET 
myofibres. No significant differences were found in any of these 
measurements, suggesting that the I4895T mutation in RyR1 does not 
compromise bioenergetic function on a mixed genetic background. This is 
consistent with the observation that this sub-line does not show an ‘EC 
uncoupled’ RyR1 phenotype. To date, these bioenergetic parameters have 
not been assessed in human or mouse models expressing the RyR1 I4895T 
mutation. As mitochondrial energy production is closely linked to cytosolic 
Ca2+ signalling (see Introduction 1.4.1), I would expect mitochondrial 
metabolism to be reduced in models showing an ‘EC uncoupled’ RyR1 
phenotype.  
Mitochondrial function was also characterised by immunoblotting for 
OXPHOS subunits in fast-twitch and slow-twitch HET muscle. This showed 
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that there was a significant decrease in the expression of Complex III and IV 
subunits in fast-twitch EDL muscle. Given that type I fibres are more affected 
in human CCD (ENGEL et al. 1961; Telerman-Toppet et al. 1973; Isaacs et 
al. 1975), I would have expected to see a more of a defect in the soleus 
rather than the EDL muscle. A possible explanation for this discrepancy 
maybe because mice are physiologically more dependent on fast-twitch 
muscle activity (Close 1972). There was certainly a trend for reduced 
expression of all complex subunits in both fast-twitch and slow-twitch HET 
muscle, but the degree of variability between mice made this statistically non-
significant. Reduced complex subunit expression might suggest that HET 
muscles have smaller mitochondrial populations, which would correspond 
with the presence of cores (though I found no visual evidence of cores or 
mitochondrial displacement in the HET fibres). A reduction in mitochondrial 
number could be the result of diminished mitochondrial biogenesis, but this 
did not seem to be the case as TFAM protein levels were similar between 
WT and HET muscles. An alternative explanation is that the mitochondria are 
being turned over quicker in the HET muscles; this idea could be explored in 
future by assessing the activity of proteins involved in autophagy/mitophagy. 
As mitochondria move towards physiological Ca2+ signals (Yi et al. 2004), it 
would also be interesting to observe mitochondrial trafficking in muscles 
affected by cores; perhaps mitochondria are re-located from the cores, rather 
than being destroyed. 
2.4.3 Evaluation of I4895T mouse models 
Although the I4895T mutation in RyR1 is known to result in ‘EC uncoupling’ 
and reduced Ca2+ ion permeation (Zvaritch et al. 2009; Loy et al. 2011), I 
was unable to identify such a defect in primary cells derived from this mouse 
sub-line, which greatly limits its significance in core myopathy research. In 
contrast to the severely affected congenic mice produced by Zvaritch et al., 
this sub-line appeared quite healthy and never showed any sign of physical 
muscle dysfunction (though they were usually culled before reaching a year 
old). It seems that successive breeding to a C57BL/6J background has 
drastically diluted the disease phenotype as well as the functional RyR1 
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phenotype of the mouse, which would explain why mitochondrial function is 
mostly unaffected. Perhaps the mice and/or cell models need to be put under 
physiological stress to reveal a phenotype, so I suggest that any future work 
using this mouse sub-line explores this idea. With hindsight, histological 
analysis of skeletal muscle from these mice would have been beneficial in 
determining whether they have a core myopathy; this should also be included 
in future work using this sub-line.  
The association between genetic background and phenotype in the I4895T 
mice closely reflects the variable disease presentation seen in heterozygous 
individuals from human families carrying the analogous I4898T mutation 
(Lynch et al. 1999; Monnier et al. 2001) and across the core myopathy 
spectrum as a whole. In contrast to human CCD, type I fibre predominance is 
not a feature of mice expressing the RyR1 I4895T mutation (Zvaritch et al. 
2009). Nevertheless, the human disease is somewhat replicated through the 
preferential involvement of type I fibres, where greater structural defects and 
z-line streaming have been reported (Boncompagni et al. 2010). The 
congenic I4895T mouse sub-line also presented with minicores and nemaline 
rods, which have been observed in a few human CCD cases but - somewhat 
strangely - never with humans expressing the analogous I4898T mutation 
(Zvaritch et al. 2009). 
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Chapter 3 The effect of the STAC3 W284S mutation on 
intracellular Ca2+ signalling and bioenergetics 
3.1 Introduction 
As part of a whole exome sequencing (WES) project on congenital myopathy 
patients, a mutation in STAC3 was identified in a male teenager with King-
Denborough Syndrome (KDS) (Zaharieva et al. 2014). KDS is a rare 
condition characterised by malignant hyperthermia susceptibility (MHS), 
delayed motor development, short stature, skeletal abnormalities and a 
variety of dysmorphic features such as ptosis, malar hypoplasia 
(underdeveloped cheekbones) and low-set ears (Dowling et al. 2011). The 
patient in the WES study specifically presented with severe scoliosis, 
learning difficulties, sickle cell disease with recurrent crises and had 
experienced a malignant hyperthermia reaction during a previous anaesthetic 
induction. Interestingly, his muscle biopsy sample also showed core-like 
changes. 
Since mutations in RYR1 have been associated with KDS (D’Arcy et al. 
2008; Dowling et al. 2011), the patient had previously undergone RYR1 
screening but the results came back negative. Subsequent whole exome 
sequencing analysis identified a homozygous missense mutation (c.851G>C; 
rs140291094) in the STAC3 gene (Zaharieva et al. 2014). STAC3 is a poorly 
characterised adaptor protein that has been shown to have a role in EC 
coupling and skeletal muscle development (see Introduction 1.5 & 1.6, 
respectively). At the amino acid level, the patient’s mutation corresponds to a 
W284S change, which is situated in the first SH3 domain of STAC3 and so 
affects its binding specificity (Horstick et al. 2013). This could affect its ability 
to chaperone the principal DHPR subunit, CaV1.1, to the t-tubule membrane, 
according to a recent study (Polster et al. 2015). 
The W284S mutation in STAC3 is known to cause NAM (see Introduction 
1.7) but has never before been associated with core formation. In this 
chapter I will assess the impact that the STAC3 mutation has on Ca2+ 
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signalling and mitochondrial function in skin fibroblasts derived from the 
patient described above. Although STAC3 is predominantly expressed in 
skeletal muscle, preliminary characterisation of these fibroblasts will be the 
first step towards a longer project using MyoD-transduced or iPSC-derived 
myotubes (discussed in 3.4.4). It is useful to know the properties of 
fibroblasts before converting them into a muscle model and to see how Ca2+ 
signalling changes specifically with differentiation. 
  
  97 
3.2 Methods 
3.2.1 Chemicals 
All chemicals were purchased from Sigma unless otherwise stated. 
3.2.2 Cell culture 
Primary human fibroblasts were obtained from the Biobank at the MRC 
Centre for Neuromuscular Disease, London. Two control samples with no 
known neuromuscular disease were age-matched to the affected individual. 
Fibroblasts were cultured in high glucose (4.5g/L) DMEM with Glutamax, 
supplemented with 10% FBS, 50 units/mL penicillin and 50ug/mL 
streptomycin (hereafter referred to as 1% PS) (all from Invitrogen). 
3.2.3 Cytosolic Ca2+ imaging 
Cells were plated on 22mm glass coverslips and measurements were carried 
out in RB. Cells were loaded with 5μM indo-1 AM (Molecular Probes) for 
30min at RT before being washed with RB and imaged (excitation at 351nm, 
emission simultaneously detected at 400nm and 475nm) on a Zeiss 510 UV-
VIS CSLM using a 40x objective and a 37°C heated stage. 
ImageJ (NIH) was used for image analysis. Background was subtracted from 
both 400nm and 475nm images and regions of interest (ROIs) were drawn 
around individual cells. 400nm/475nm ratio was used to illustrate cytosolic 
Ca2+ levels in each cell. Resting indo-1 ratio was defined as the average ratio 
over the first 24 secs before 10μM histamine addition. indo-1 was 
calculated as the difference between the resting ratio and the peak ratio 
following histamine stimulation. 
3.2.4 Measurements of resting mitochondrial membrane potential 
Fibroblasts were equilibrated with RB containing 25nM TMRM for 15 mins at 
37°C. Confocal images were then acquired on a Zeiss 510 UV-VIS CLSM 
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using a 40x oil objective. RB containing only 25nM TMRM was present 
throughout imaging. Fluorescence was excited at 535nm and measured at 
>560nm.  
ImageJ was used for image analysis. ROIs were drawn around individual 
cells and images were thresholded to quantify the mean of mitochondria-
localised signal intensities within each ROI. Identical acquisition settings and 
threshold values were used in repeat experiments.  
3.2.5 Respirometry of intact cells 
Cells were trypsinised and resuspended at 1 million cells/mL in DMEM 
buffered with 20mM HEPES, supplemented with 5.5mM glucose, 2mM 
glutamine and 1mM pyruvate. Respiration rates were measured at 37°C with 
the High-Resolution Oxygraph (Oroboros Oxygraph-2k). Once resting rate 
had stabilised, 2.5μM oligomycin A was added to measure leak respiration, 
1μM FCCP to determine maximal oxidative capacity and 2.5μM antimycin A 
to measure non-mitochondrial (background) O2 consumption. Each of these 
respiratory states was defined as the average value over a user-defined 
region of stabilised signal (Figure 3.1). 
3.2.6 Statistics 
Data for both control cell lines was pooled together and compared with data 
for the STAC3 W284S cell line. Values are presented as mean ± standard 
error. Statistical analysis was performed using Prism 6 (GraphPad software). 
Unpaired two tail t-tests were applied to test significance to a P value of 0.05. 
Significant differences are indicated with asterisks (* if P<0.05, ** if P<0.01, 
*** if P<0.001, **** if P<0.0001). N indicates total number of cells measured 
unless otherwise stated. 
  
  
 
 
Figure 3.1: Example of O2 consumption measurements of intact cells 
Blue line indicates O2 concentration inside the chamber, while the red line shows O2 flux per million cells.  After adding the cell suspension, the 
chambers were allowed to acclimatise until a stable signal was achieved (Basal/resting state). 2.5μM oligomycin was added to induce the leak 
state, followed by titrations of 1μM FCCP to reach the maximal respiratory rate. A final addition of 2.5μM Antimycin A was used to measure non-
mitochondrial respiration (NMR). Green bars indicate regions over which average respiratory state values were calculated.
9
9
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3.3 Results 
3.3.1 The W284S mutation in STAC3 increases histamine-induced 
Ca2+ release 
Previous studies have shown that STAC3 plays a role in EC coupling 
(Horstick et al. 2013; Nelson et al. 2013). Although the EC coupling 
machinery is only present in muscle tissue, it was thought that the STAC3 
W284S fibroblasts might reveal a disorder in general Ca2+ homeostasis in the 
patient. To visualise intracellular Ca2+ levels, control and STAC3 W284S 
fibroblasts were loaded with indo-1 AM. Like fura-2, indo-1 is a ratiometric 
Ca2+ indicator that is not affected by loading conditions or bleaching. While 
fura-2 shows a shift in its excitation spectra when it binds Ca2+, indo-1 shows 
a shift in its emission spectra, from about 475nm without Ca2+ to about 
400nm with Ca2+ (Figure 3.2). This means that only one excitation laser is 
required for indo-1, which allows for faster acquisition times and a more 
accurate description of intracellular Ca2+ release.  
 Figure 3.2: Example of indo-1 Ca2+ measurements 
When excited at 350nm, indo-1 emits fluorescence at 400nm (blue) and 475nm 
(green). An increase in [Ca2+]c is observed as an increase in fluorescence at 400nm 
and a decrease in fluorescence at 475nm, which corresponds to an increase in 
indo-1 ratio (right-hand y axis, black trace). 
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Quantification of average indo-1 ratio showed that histamine evoked 
significantly more Ca2+ release into the cytosol of the STAC3 W284S cells 
(0.775 ± 0.0996) than in controls (0.423 ± 0.0391) (P=0.0003), although there 
was a lot of cell-to-cell variability (Figure 3.3a & c). Some of the STAC3 
W284S cells also demonstrated a considerable amount of oscillatory activity 
post-histamine addition (Figure 3.3a). This suggests that the STAC3 
mutation is somehow having a global effect on Ca2+ signalling in the patient. 
Seeing as this patient has an MHS phenotype, and MHS is associated with 
an increase in SR leak (see section 1.4), I also measured the average resting 
indo1 ratio of the fibroblast populations. This showed that although the 
STAC3 W284S cells tended to have higher resting cytosolic Ca2+ levels 
(0.429 ± 0.0531) than control cells (0.325 ± 0.0258), the difference was not 
statistically significant (P=0.0555) (Figure 3.3b). 
  
 
Figure 3.3: Intracellular Ca2+ 
signals are elevated in 
STAC3 W284S fibroblasts 
Control (blue) and STAC3 
W284S (red) fibroblasts were 
loaded with indo-1 AM and 
stimulated with 10μM 
histamine (a). Coloured trace 
illustrates average response of 
all cells (grey traces). Average 
indo-1 ratio prior to stimulation 
was used as a measure of 
resting cytosolic Ca2+ 
concentration (b). indo-1 was 
calculated as the difference 
between the average resting 
indo1 ratio and the peak ratio 
following histamine addition 
(c). n>35 cells measured over 
3 different experimental days.
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3.3.2 Mitochondrial depolarisation in STAC3 W284S fibroblasts 
Δm is a key bioenergetic parameter that gives an indication of mitchondrial 
function. To assess whether Δm was affected by the STAC3 W284S 
mutation, control and STAC3 W284S fibroblasts were imaged in the 
presence of TMRM (Figure 3.4a). STAC3 W284S cells had significantly 
reduced TMRM fluorescence (0.867 ± 0.0163) compared to controls (1.001 ± 
0.0124) (P<0.0001) (Figure 3.4b), which shows that their mitochondria are 
slightly depolarised i.e. Δm is more positive so less dye is accumulated.   
 
 
 
 
 
 
 
 
 
Figure 3.4: Mitochondrial depolarisation in resting STAC3 W284S fibroblasts 
Representative confocal images of TMRM staining in control and STAC3 W284S 
fibroblasts (a). Average TMRM intensity was quantified and normalised to the mean 
control intensity (b). n>118 cells from 3 independent experiments. Scale bars 10μm. 
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3.3.3 Mitochondrial O2 consumption is unchanged in STAC3 W284S 
fibroblasts 
As Δm is crucial for maintaining the physiological function of the electron 
transport chain, high-resolution respirometry measurements were carried out. 
No significant differences were observed in mitochondrial O2 consumption in 
the resting (P=0.946), leak (P=0.499) and maximal states (P=0.352) (Figure 
3.5). 
  Basal Leak Maximal 
Control 31.8 33.2 28.7 3.5 5.2 3.5 - 62.2 54.0 
STAC3 
W284S 
36.2 29.2 28.8 2.6 4.3 3.7 - 62.0 64.4 
 
 
 
 
 
Figure 3.5: Mitochondrial O2 consumption in STAC3 W284S cells is similar to 
controls 
O2 consumption of intact cells in the basal state, leak state (2.5μM oligomycin 
present) and maximal state (1μM FCCP present) were measured using high-
resolution respirometry (see Figure 3.1 for example measurement). Raw 
measurements (pmol s-1 million cells-1) from each experimental day are shown in the 
table. The mean averages of these measurements are shown in the bar graph (error 
bars SEM). n=3 independent experiments (except for maximal measurements, 
where n=2 as one experiment was prematurely terminated by addition of FCCP that 
may have been contaminated with Antimycin A). 
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3.4 Discussion 
In this chapter I have characterised Ca2+ homeostasis and mitochondrial 
function in fibroblasts from an individual with a mutation in STAC3, with the 
intention of providing preliminary data for a future project using fibroblast-
derived myotubes. STAC3 is a relatively new player in the regulation of EC 
coupling but its association with Native American Myopathy, and now KDS 
and core myopathy, highlight its importance in skeletal muscle health. While 
it may not be surprising that a defect in EC coupling results in muscle 
disease, it is interesting to see that a mutation in STAC3, like RYR1, can 
have an effect on the mitochondria that leads to core formation. 
3.4.1 Ca2+ homeostasis in STAC3 W284S fibroblasts 
While resting cytosolic Ca2+ levels were similar to controls, histamine-induced 
Ca2+ release was significantly higher in the STAC3 W284S fibroblasts. This 
suggests that, despite STAC3 being predominantly expressed in skeletal 
muscle, its physiological function may be important for Ca2+ regulation across 
the body. Although it is difficult to envisage a physiological purpose for 
communication between the skin and skeletal muscle, Ca2+ waves can 
propagate between dissimilar cell types (Sanderson et al. 1994), so perhaps 
the primary Ca2+ defect in skeletal muscle has caused compensatory 
changes in Ca2+ regulation in the skin. It will be interesting to see whether 
Ca2+ signals produced by future myotube models compare to my results from 
the fibroblast precursors, or whether they recapitulate the reduced skeletal 
muscle Ca2+ transients observed in the STAC3 W284S zebrafish model 
(Horstick et al. 2013). 
3.4.2 Mitochondrial function in STAC3 W284S fibroblasts 
Confocal imaging with TMRM showed that the mitochondrial population was 
slightly depolarised in the STAC3 W284S fibroblasts. As mitochondrial Ca2+ 
uptake is driven by the Δm, depolarisation may reduce the Ca
2+ buffering 
ability of the mitochondria, giving a possible explanation for the increased 
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cytosolic Ca2+ transients observed upon histamine stimulation. Due to limited 
time and resources, I did not investigate mitochondrial Ca2+ uptake in the 
fibroblasts but this is something that should be measured in future myotube 
models using either genetically engineered Ca2+ indicators (Hill et al. 2014), 
or cationic dyes such as rhod-2 AM (Davidson & Duchen 2012). If 
mitochondrial depolarisation were also observed in STAC3 W284S 
myotubes, then I would expect to see a reduction in mitochondrial Ca2+ 
accumulation. This could result in a metabolic deficit, which would 
significantly contribute to the muscle weakness experienced by the patient. 
Respirometry measurements showed that the STAC3 W284S cells behaved 
similarly to controls in terms of basal, leak or maximal mitochondrial O2 
consumption. This was surprising as I expected mitochondrial depolarisation 
to mean one of two things: more proton leak from the matrix i.e. increased O2 
consumption under the oligomycin-induced leak state, or a lack of proton 
pumping from the matrix to the IMS i.e. a reduction in the activity of 
respiratory chain complexes and a reduction in overall O2 consumption. 
Again due to time limitations, I could not investigate this discrepancy further 
but these measurements should certainly be repeated in future myotube 
models. As mitochondrial depolarisation can signify respiratory chain 
inhibition and ATP depletion, assays for ATP production and OXPHOS 
complex activity should also be carried out. 
3.4.3 Expression of STAC3 in fibroblasts 
The first published study on STAC3 showed that it is abundant in the skin as 
well as fast and slow-twitch muscles of Atlantic salmon (Bower et al. 2012). 
Although subsequent studies have not tested STAC3 expression in the skin, 
they show that STAC3 is predominantly expressed in skeletal muscle 
(Reinholt et al. 2013; Horstick et al. 2013; Nelson et al. 2013; Zhang et al. 
2014). Recently it has been shown that STAC3 is required for efficient 
membrane trafficking of the muscle-specific CaV1.1 subunit of the DHPR 
(Polster et al. 2015); this again suggests that STAC3 is a skeletal muscle 
specific isoform. 
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Being the only available model at the time, skin fibroblasts were selected for 
these experiments with the aim of providing preliminary data towards a 
longer project using MyoD-transduced or iPSC-derived myotubes. It is useful 
to know the properties of fibroblasts before converting them into a muscle 
model and to see how Ca2+ signalling changes specifically with 
differentiation. However, with hindsight, whether STAC3 is expressed in this 
fibroblast model should have been determined prior to characterisation. This 
would help to confirm whether the changes in Ca2+ signalling and 
mitochondrial function I have observed are actually due to the mutation in 
STAC3. Without this knowledge, it is difficult to interpret my results; the 
observed differences may have been due to genetic variation between 
individual patient donors, rather than the STAC3 mutation. 
3.4.4 Developing a skeletal muscle model 
To fully understand the pathological consequences of the STAC3 W284S 
mutation, a skeletal muscle cell model needs to be established. To avoid the 
use of animals and also open up the possibility of a future therapy, it would 
be ideal to use cells derived from the patient himself. While it is possible to 
establish primary myoblast cell lines from patients with muscle disease 
(Mamchaoui et al. 2011), the process of obtaining a muscle biopsy is 
invasive and can be painful for the patient, particularly if the patient is a child 
(Skram et al. 2009). This particular patient also has a history of malignant 
hyperthermia, which increases the risk associated with anaesthetic 
procedures. If histopathological and biochemical analysis is also to be 
performed from one biopsy, the amount of muscle remaining for cell culture 
may be somewhat limited. Once isolated, primary skeletal muscle cells have 
a short proliferative lifespan and limited myogenic potential (Lauren Cornall 
2012). Immortalisation can solve this problem, though it is important to 
adequately characterise an immortalised skeletal muscle cell line to ensure it 
replicates the physiology of the original tissue and retains the phenotypic 
traits of the donor cells (Lauren Cornall 2012). 
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Seeing as we already have fibroblasts from the patient, it might be better to 
convert them into skeletal muscle cells. One way to do this is to directly 
transform the fibroblasts into myoblasts by using a viral vector system to 
force the expression of the myogenic ‘master switch’, MyoD (Weintraub et al. 
1989). If this approach was successful, it would be interesting to see if the 
W284S mutation has any effect on myogenic differentiation, as has been 
previously reported in KD studies (Bower et al. 2012; Ge et al. 2014). 
Another approach would be to revert the fibroblasts back to pluripotency, 
resulting in iPSCs that can then be differentiated to a skeletal muscle fate 
(Takahashi & Yamanaka 2006). The iPSCs could also be differentiated into 
neuronal cells, which might give an insight into why this patient also has 
learning difficulties. Once MyoD transduction or reprogramming has been 
carried out, it will be important to check that the resulting myogenic cells are 
fully differentiated and behave like mature muscle i.e. they express DHPR 
and RyR1 and can be stimulated to produce contractile Ca2+ transients. 
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Chapter 4 Exploring the physiological consequences of 
MICU1 deficiency in fibroblasts 
4.1 Introduction 
While the MCU KO mouse may lack an obvious phenotype, the physiological 
importance of mitochondrial Ca2+ handling has been highlighted by our 
discovery of the first human disease to be directly associated with 
dysfunctional mitochondrial Ca2+ uptake (Logan et al. 2014). In collaboration 
with clinicians, we identified 15 individuals lacking in MICU1 who presented 
with a novel brain and muscle disorder as infants or young children. 
Characteristic features included muscle weakness, elevated serum creatine 
kinase levels, learning difficulties and progressive extrapyramidal motor 
disturbances (Logan et al. 2014). Features associated with mitochondrial 
disease were also reported in some cases, including ataxia, microcephaly, 
opthalmaplegia, ptosis, optic atrophy and axonal peripheral neuropathy. 
Available muscle biopsies showed myopathic features including clusters of 
regenerating fibres and minicores (Figure 4.1). 
 
 
 
 
 
 
Figure 4.1: Patients with mutations in MICU1 present with minicores 
Quadriceps biopsy from a patient at 10.7 years of age stained with NADH 
tetrazolium reductase (blue). Minicores are indicated with arrows. Scale bar 50μm. 
Adapted from (Logan et al. 2014). 
Figure removed due to copyright restrictions 
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While 11 individuals from 5 UK families had a splice acceptor site mutation, 
c.1078-1G>C, the remaining 4 individuals from 2 unrelated Dutch families 
had a different homozygous mutation affecting a splice donor site, 
c.741+1G>A (Logan et al. 2014). Sequencing of cDNA from the 15 subjects 
revealed intronic insertions causing frameshifts, which resulted in a 
significant loss of MICU1 mRNA and a complete loss of the protein. 
In line with the objectives set out in 1.6, the aim of this chapter is to 
characterise intracellular Ca2+ homeostasis and mitochondrial function in 
primary fibroblast cell lines derived from two unrelated teenagers carrying the 
c.1078-1G>C mutation (hereafter referred to as ΔMICU1). This will give an 
insight into the physiological consequences of the absence of MICU1, which 
will also help to understand the core myopathy pathology in these patients. 
While some of the data in this chapter has been published (Logan et al. 
2014), the rest of the dataset shows the follow-up project.  
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4.2 Methods 
4.2.1 Chemicals 
All chemicals were purchased from Sigma unless otherwise stated. 
4.2.2 Cell culture 
Primary human fibroblasts were obtained from the MRC Centre for 
Neuromuscular Disease Biobank, London. Two control samples with no 
known neuromuscular disease were age-matched to two ΔMICU1 patients. 
Fibroblasts were cultured in high glucose (4.5g/L) DMEM with Glutamax, 
supplemented with 10% FBS, 50 units/mL penicillin and 50μg/mL 
streptomycin (hereafter referred to as 1% PS) (all from Invitrogen). Where 
galactose conditions are indicated, fibroblasts were cultured in zero glucose 
DMEM with L-glutamine (Invitrogen), 10% FBS (Invitrogen), 1mM sodium 
pyruvate (Sigma), 0.1% w/v (5.5mM) galactose (MP Biomedicals) and 1% PS 
(Invitrogen). 
4.2.3 Mitochondrial Ca2+ measurements with aequorin 
Fibroblasts were seeded in white 96 well plates (50,000 cells/well) and 
transduced for 48hrs with an adenovirus expressing mitochondria-targeted 
luminescent aequorin (mtAEQ) under cytomegalovirus (CMV) control 
(Ainscow & Rutter 2001). The mAEQ adenoviral construct was produced 
using the AdEasy system (Stratagene) by Professor Guy Rutter (Imperial 
College London). Prior to assay, cells were reconstituted with 5μM 
coelenterazine (Invitrogen) for 2hrs at 37°C. Mitochondrial signals induced by 
10μM histamine were measured in a plate reader (Fluostar Optima, BMG 
Labtech) using a luminescence optic with 3mm diameter light guide. Assays 
were carried out at 37°C. 1mM digitonin was used to generate a saturating 
concentration of Ca2+ inside the cells and thus give the maximum light 
intensity. Luminescence values were converted into Ca2+ concentration with 
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a mathematical algorithm that uses the maximum light intensity value and 
parameters based on the affinity of the aequorin used (Brini et al. 1995).  
4.2.4 Measurements of resting Δm 
Fibroblasts plated on 22mm glass coverslips were equilibrated with RB 
containing 25nM TMRM for 15 mins at 37°C. Confocal z stacks were then 
acquired on a Zeiss 700 CLSM using a 40x oil objective and a 37°C stage. 
RB containing only 25nM TMRM was present throughout imaging. 
Fluorescence was excited at 555nm and measured at >560nm.  
ImageJ was used for image analysis. Maximum intensity projections were 
used for quantification to avoid bias in the focal plane. ROIs were drawn 
around individual cells and images were thresholded to quantify the mean of 
mitochondria-localised signal intensities within each cell. Identical acquisition 
settings and threshold values were used in repeat experiments. 
4.2.5 Cytosolic Ca2+ measurements of cell populations 
Fibroblasts were seeded in black 96 well plates (50,000 cells/well) and 
loaded with RB containing 5μM Fluo-4 AM, 0.002% pluronic acid and 1mM 
probenecid for 30mins at RT. For measurements of histamine-evoked Ca2+ 
release, cells were washed with RB, pre-treated with 0.1% DMSO or 1μM 
FCCP (to eradicate mitochondrial Ca2+ uptake) for 10mins and then assayed 
at 37°C on a plate reader (Fluostar Optima, BMG Labtech) using 
fluorescence optics and light guide with 485BP12 excitation and Em520 
emission filters. 10μM histamine was injected to induce a cytoplasmic Ca2+ 
signal followed by 2μM ionomycin, which provided a maximum fluorescence 
reading. To assess intracellular Ca2+ store content, a similar plate reader set 
up was used but cells were present in Ca2+ free RB supplemented with 
200μM EGTA and 2μM ionomycin was injected. 
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Background (measured in an empty well with RB) corrected fluorescence 
intensities were calibrated into Ca2+ concentration using the following 
equation (Maravall et al. 2000): 
[Ca2+] = Kd x (F / Fmax – 1/Rf) / (1- F/Fmax) 
Where Kd = 350nM, Fmax is the maximum fluorescence after ionomycin 
application, Rf = 100. F is fluorescence as measured in these experiments. 
4.2.6 Confocal imaging of mitochondrial Ca2+ levels 
Cells plated on 22mm glass coverslips were loaded with RB containing 5μM 
rhod-2 AM or rhod-FF AM (both Molecular Probes) and 0.002% pluronic acid. 
Images were acquired on a Zeiss 700 CLSM (excitation at 555nm, emission 
at >560nm) using a 40x objective and a 37°C stage.  
ImageJ was used for image analysis. ROIs were drawn around individual 
cells and images were thresholded to quantify the mean of mitochondria-
localised signal intensities within each cell. Identical acquisition settings and 
threshold values were used in repeat experiments. 
4.2.7 High content imaging of basal mitochondrial Ca2+ levels 
Control and ΔMICU1 cells were seeded in 96 well imaging plates (BD 
Biosciences) and transduced for 4hrs with an adenovirus expressing wild 
type (WT) MICU1-HA and GFP (gift from Rizzuto lab, Padua). The following 
day cells were loaded in RB with rhod-2 AM (5μM; 30min at RT and then 
replaced with dye free RB), and 2μg/mL Hoecsht 33342 (present throughout) 
to label nuclei for cell counting. Cells were imaged on an ImageXpress Micro 
XL high-content imaging system (Molecular Devices) using a custom protocol 
to image three wavelengths (Lumencor solid-state illumination with Semrock 
(Brightline) filters (nm) ex377/50 em447/60 for Hoechst 33342, ex472/30 
em520/35 nm for GFP, and ex531/40 em593/40 for detection of Rhod-2). 
Nine fields per well were imaged using a 40x objective, binning 1 (full 
resolution) with a Complementary Metal-Oxide Semiconductor (CMOS) 
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detector. Acquisition was performed using MetaXpress software (Molecular 
Devices) and analysis was carried out using the proprietary Multi-Wavelength 
Scoring Application Module within this software. The Hoecsht signal was 
used to create a nuclear mask and thus allow cell identification, while the 
GFP signal was used to create a green cytosolic mask (Figure 4.2). Green 
areas larger than 400μm2 that also possessed a nucleus were scored as 
GFP-positive cells (Figure 4.2). The rhod-2 signal was separated into nuclear 
and cytosolic signals, with the nuclear signal being assumed to represent 
pure cytosolic signal with minimal mitochondrial interference. A ratio between 
the two was then used to detect specific mitochondrial signal. Outliers 
resulting from imaging artefacts were excluded by applying a maximum 
threshold for rhod-2 intensities. 
Figure 4.2: High-throughput analysis of the effect of MICU1 expression on 
basal [Ca2+]m 
Figure removed due to copyright restrictions 
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Demonstration of the workflow of the Multi-Wavelength Scoring Application Module, 
which was used to quantify basal mitochondrial rhod-2 intensities in cells infected 
with adenovirus expressing WT MICU1-GFP. Adapted from (Logan et al. 2014). 
4.2.8 Rates of cellular ROS production 
Cells were imaged in the presence of 5μM dihydroethidium (DHE) (Molecular 
Probes) on a Zeiss 510 UV-VIS CSLM using a 40x objective and a 37°C 
stage. Blue fluorescence of the reduced form of DHE was excited at 351nm 
and emission detected between 435-485nm. Oxidised DHE was excited at 
543nm and emission detected >560nm. After background subtraction, a ratio 
of oxidised / reduced DHE fluorescence was calculated and the rate of 
change in this ratio was interpreted as the rate of ROS production. The first 
minute of measurements were excluded to allow for loading of the dye.  
4.2.9 Western blotting 
Following relevant drug treatment and/or media changes, fibroblasts were 
washed with PBS, scraped and centrifuged.  Cell pellets were then lysed in 
RIPA buffer (150mM NaCl, 0.5% sodium deoxycholic acid, 0.1% SDS, 1% 
Triton X-100, 50mM Tris pH8, 1mM PMSF, PhosSTOP phosphatase 
inhibitors (Roche)) for 30 mins on ice. Samples were subsequently 
centrifuged at 16,000g at 4’C and protein concentrations determined using 
Pierce BCA assay (Thermo Scientific). 
40μg of protein was boiled at 95°C for 5 mins in NuPAGE 4X LDS sample 
buffer (Invitrogen) containing 5% β-mercapethanol. Proteins were separated 
using 4-12% NuPAGE Bis-Tris gels (Invitrogen) with MOPS running buffer 
(Invitrogen) and transferred onto nitrocellulose membranes using NuPAGE 
transfer buffer (Invitrogen) supplemented with 20% methanol. Membranes 
were washed with TBS-T and blocked with 3% BSA in TBS-T for 1 hr at RT, 
before being incubated with primary antibody solution overnight at 4°C. 
Following 3 x 10 min washes in TBS-T, membranes were incubated with 
secondary antibody solution for 1-1.5 hours at RT. After 3 x 5 min washes in 
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TBS-T, the membranes were developed using Amersham ECL reagent (GE 
Healthcare) and imaged with a ChemiDoc system (BioRad).  
Densitometry analysis was carried out using ImageJ. 
Primary antibodies used were anti-DRP1 (mouse, Abcam; 1:1000), anti-
phospho DRP1 (Ser637) (rabbit, NEB; 1:1000), anti-LC3b (rabbit, Cell 
Signaling; 1:2000), anti-β-actin (mouse, Santa Cruz; 1:2000), anti-PDH E1α 
(mouse, Invitrogen; 1:1000) and anti-phospho PDH E1α (Ser293) (rabbit, 
Novus Biologicals; 1:1000). Secondary antibodies used were anti-mouse and 
anti-rabbit (both from Thermo Scientific and diluted 1:4000). 
4.2.10 PDH phosphorylation state 
To minimise variability relating to substrate supply, protein samples were 
made approximately 2hrs after refreshing the culture media. Culture plates 
were also snap frozen at -80°C before scraping to minimise any subsequent 
kinase and phosphatase activity. Western blotting for phosphorylated PDH 
(pPDH) was carried out first and then the same membrane was washed and 
re-probed overnight for total PDH. The proportion of pPDH was then 
expressed as average intensity of pPDH band / average intensity of total 
PDH band.  
4.2.11 Respirometry of intact cells 
Cells were trypsinised and resuspended at 1 million cells/mL in DMEM 
buffered with 20mM HEPES, supplemented with 5.5mM glucose (or 5.5mM 
galactose for galactose-grown cells), 2mM glutamine and 1mM pyruvate. 
Respiration rates were measured at 37°C with the High-Resolution Oxygraph 
(Oroboros Oxygraph-2k). Once resting rate had stabilised, 10μM histamine 
was added to induce a Ca2+-dependent rise in O2 consumption. After 
returning to resting rate, 2.5μM oligomycin A was added to measure leak 
respiration, 1μM FCCP to determine maximal oxidative capacity and 2.5μM 
antimycin A to measure non-mitochondrial (background) O2 consumption. 
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Each of these respiratory states was defined as the average value over a 
user-defined region of stabilised signal (for example see Figure 3.1). 
4.2.12 ATP luminescence measurements 
Cells were seeded in white 96 well plates (20,000 cells / well) and the next 
day were incubated with one of the following treatments for 1hr at 37°C: 
1uL/mL DMSO, 5μM oligomycin A, 1mM iodoacetic acid (IAA), 10μM CGP-
37157 or 10mM 2-deoxyglucose (DG). The cells were allowed to come to RT 
before incubating with CellTiter-Glo® Reagent (Promega) for 10mins. 
Luminescence values proportional to ATP content were measured in a plate 
reader (Fluostar Optima, BMG Labtech) using a luminescence optic with 
3mm diameter light guide. 
4.2.13 Mitochondrial morphology scoring 
Mitochondrial morphology was assessed by eye using images collected from 
TMRM and Rhod-2 imaging (see 4.3.10). Cells in which <50% of 
mitochondria were elongated were scored as cells containing fragmented 
mitochondria. 
4.2.14 Measurements of single cell cytoplasmic Ca2+ transients 
Spontaneous cytoplasmic Ca2+ transients were measured by loading cells 
with 5μM fluo-4 AM (Molecular Probes) for 25min at RT before washing with 
RB and imaging (excitation at 488nm, emission at >520nm) on a Zeiss 700 
CLSM. After 10min, 1μM FCCP was added to eradicate mitochondrial Ca2+ 
uptake. A spontaneous transient was defined as an increase in fluo-4 
intensity that was at least 25% greater than baseline intensity. A cell showing 
at least one of these transients was scored as ‘spontaneously active’. 
4.2.15 DRP1 phosphorylation state 
Western blotting for phosphorylated DRP1 (pDRP1) was carried out first and 
then the same membrane was washed and re-probed overnight for total 
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DRP1. The proportion of pDRP1 was then expressed as average intensity of 
pDRP1 band / average intensity of total DRP1 doublet. 
4.2.16 Assessing autophagy flux 
1hr after the culture media was refreshed, fibroblasts were treated with 
1uL/mL DMSO or 100nM Bafilomycin A1 for 5 hrs at 37°C. Samples were 
then processed for western blotting as in 4.2.9 and probed for LC3 
expression. 
4.2.17 Statistics 
Data for both control cell lines was pooled together and compared with 
similarly pooled data for both ΔMICU1 cell lines. Values are presented as 
mean ± standard error. N numbers indicate number of independent repeat 
experiments unless otherwise indicated. 
Statistical analysis was performed using Prism 6 (GraphPad software). 
Where the means of two independent groups were being compared e.g. 
control group v ΔMICU1 group, unpaired two tail t-tests were applied to test 
significance to a P value of 0.05. Where the means of three or more 
independent groups were being compared, one-way analysis of variance 
(ANOVA) was used. When the effect of two different independent variables 
was being measured e.g. cell line and drug treatment, two-way ANOVA was 
used. I considered using repeated measures ANOVA for repeated 
measurements on the same cell line but decided it was unsuitable as my 
measurements were never conducted on exactly the same sample of cells 
i.e. the passage number varied between experiments or the cells were grown 
in different tissue culture plates. If the same sample of cells had been 
measured multiple times e.g. in a time course experiment then repeated 
measures testing would be more appropriate.  
When several comparisons between groups were being made, post hoc 
Tukey tests were used to correct for multiple testing. 
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4.3 Results 
4.3.1 Loss of MICU1 leads to accelerated mitochondrial Ca2+ uptake 
Given the gatekeeping role of MICU1 in mitochondrial Ca2+ uptake, my first 
question was to find out what effect the loss of MICU1 had on mitochondrial 
Ca
2+ 
levels in response to a physiological cytosolic Ca
2+ 
rise (induced by 
histamine, an agonist that triggers IP3-mediated Ca
2+ 
release from internal 
stores). Control and ΔMICU1 fibroblasts were transduced with an adenovirus 
encoding for mitochondrial-targeted aequorin (mtAEQ), a Ca2+ sensitive 
photoprotein that can be used to measure matrix Ca2+ concentrations in 
intact cells. Stimulating the mtAEQ-expressing cells with 10μM histamine 
(Figure 4.3a) showed no significant difference in peak [Ca2+]m 
(P=0.616)(Figure 4.3b) but the half time to peak was significantly reduced in 
the ΔMICU1 cells (2.57 ± 0.132 secs) compared to controls (3.097 ± 0.162 
secs) (P=0.030) (Fig 4.3c). Similarly with 50μM histamine, the half time to 
peak was significantly reduced in the ΔMICU1 cells (2.03 ± 0.049 secs) 
compared to controls (2.45 ± 0.184 secs) (P=0.0492)(Figure 4.3c) but there 
was no significant change in peak [Ca2+]m (P=0.858)(Figure 4.3b). 
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Figure 4.3: ΔMICU1 cells show a significantly faster rate of rise in [Ca2+]m  
Representative traces of mtAEQ measurements of cell populations (50,000 cells per 
well of a 96 well plate) (a). Maximum matrix concentrations in response to 10μM and 
50μM histamine were quantified (b). The rate of mitochondrial Ca2+ uptake (c) was 
calculated as the time taken to reach half the maximal concentration i.e. the half 
time to peak. n=6 replicates pooled from both cell lines (2 control and 2 ΔMICU1 cell 
lines were measured on 3 experimental days). At least 3 wells were measured per 
cell line per day. Therefore values shown are mean of means for each replicate. 
Errors bars show SEM.  
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4.3.2 Accelerated mitochondrial Ca2+ uptake in the ΔMICU1 cells was 
not due to altered Δm or intracellular Ca
2+ store content 
 As well as being a key determinant of respiratory chain activity, Δm is the 
driving force for mitochondrial Ca2+ uptake. To see if an increase in Δm was 
responsible for the accelerated uptake observed with mtAEQ, control and 
ΔMICU1 cells were imaged in the presence of TMRM. Quantification of 
average steady state TMRM intensity, however, showed no significant 
difference in Δm between control and ΔMICU1 cells (P=0.370) (Figure 
4.4a).  
Another factor that could influence mitochondrial Ca2+ uptake is the amount 
of Ca2+ stored in the ER. Mitochondria tend to localise at Ca2+ release sites 
of the ER, so if the loss of MICU1 somehow caused an increase in ER store 
Ca2+, the mitochondria could be exposed to higher Ca2+ fluxes during store 
release and thus exhibit altered uptake kinetics. ER store content can be 
measured using the SERCA inhibitor, thapsigargin, which prevents Ca2+ 
pumping into the ER and so causes ER depletion. Unfortunately, 
thapsigargin did not seem to be a reliable stimulus in my cytosolic Ca2+ plate 
reader assays (outlined in 4.2.5). Instead I decided to use ionomycin, which 
non-specifically triggers release from intracellular Ca2+ stores. This showed 
that there was no significant difference (P=0.0739) in intracellular Ca2+ 
content between control (3.627 ± 0.4893) and ΔMICU1 cells (4.610 ± 0.2714) 
(Figure 4.4b). However it is worth keeping in mind that ionomycin is a potent 
ionophore, which can also affect the mitochondria (Abramov & Duchen 
2003). 
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Figure 4.4: Accelerated mitochondrial Ca2+ uptake was not due to altered 
mitochondrial membrane potential or intracellular Ca2+ store content 
Average TMRM fluorescence of ΔMICU1 fibroblasts was normalised to control 
average on each experimental day (a). n=6 replicates pooled from both cell lines (2 
control and 2 ΔMICU1 cell lines were measured on 3 experimental days). At least 
37 cells were measured per cell line per day. Therefore values shown are mean of 
means for each replicate. Errors bars show SEM. 
Intracellular Ca2+ store content was measured in fluo-4 loaded cell populations 
(50,000 cells per well of a 96 well plate) (b). Maximum fluo-4 fluorescence after 2μM 
ionomycin application was normalised to resting fluorescence and used to signify 
intracellular Ca2+ store content. n ≥ 9 wells measured over 3 experimental days. 
Therefore values shown are the mean of all wells measured. Error bars show SEM. 
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4.3.3 Loss of MICU1 results in reduced cytoplasmic Ca2+ signals and 
increased mitochondrial Ca2+ buffering 
Since mitochondria buffer cytoplasmic Ca2+ signals, the magnitude of a rise 
in [Ca2+]c can influence mitochondrial Ca
2+ uptake. To measure the 
characteristics of agonist-induced cytosolic Ca2+ signals, populations of fluo-
4 loaded cells were stimulated with 10μM histamine in a plate reader assay 
(Figure 4.5a). This showed that peak cytoplasmic Ca2+ concentration was 
significantly reduced in the ΔMICU1 cells (786.3 ± 89.73 nM) compared to 
controls (1104 ± 81.13 nM) (P=0.0203) (Figure 4.5b). This was likely to be 
due to increased mitochondrial buffering, since pre-treating the cells with 
FCCP, an uncoupler that prevents mitochondrial Ca2+ uptake, prevented this 
effect (P=0.862) (Figure 4.5c).  
Figure 4.5: ΔMICU1 cells have increased mitochondrial buffering capacity 
Representative traces of cytosolic Ca2+ measurements of fluo-4 loaded cell 
populations incubated with DMSO as a control treatment (a). Maximum cytoplasmic 
Ca2+ concentrations in response to 10μM histamine were quantified in DMSO-
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treated (a) and FCCP-treated cells (b). n ≥ 9 independent wells measured over 3 
experimental days. Values shown are the mean of all wells measured. Error bars 
show SEM. 
4.3.4 The loss of MICU1 leads to chronic activation of the MCU at 
resting cytosolic Ca2+ concentrations 
To find out what effect the absence of MICU1 had on basal mitochondrial 
Ca2+ levels, control and ΔMICU1 fibroblasts were labelled with rhod-2 AM, a 
Ca2+ indicator that partitions between the cytosol and the mitochondria in 
response to Δm due to the net positive charge of the AM ester. Rhod-2 
fluorescence is uniform across the cell (Figure 4.6A) until intracellular Ca2+ 
flux is stimulated. In resting ΔMICU1 cells, the fluorescent signal was bright 
in the mitochondria, even before stimulation (Figure 4.6B). This is consistent 
with the gatekeeping function of the protein and shows that mitochondrial 
Ca2+ concentrations at rest are elevated in the absence of MICU1. 
 
Figure 4.6: A loss of MICU1 caused mitochondrial Ca2+ loading at rest 
Representative confocal image of rhod-2 labelled control (A) and ΔMICU1 (B) 
fibroblasts. Scale bar 20μm. 
  
Figure removed due to copyright restrictions 
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To verify that this phenotype was due to the lack of MICU1, the WT protein 
was re-expressed in the ΔMICU1 cells; subsequent rhod-2 imaging showed 
that this caused a small but significant reduction in mitochondrial Ca2+ 
content (Figure 4.7). Interestingly, this reduction was also observed in control 
cells in which MICU1 was overexpressed, suggesting that excessive 
expression of MICU1 can disturb mitochondrial Ca2+ homeostasis (Figure 
4.7).  
 
 
 
 
 
 
 
Figure 4.7: Overexpression of WT MICU1 caused a reduction in mitochondrial 
Ca2+ concentration 
Cells transduced with MICU1-GFP expressing adenovirus were loaded with rhod-2 
and imaged using a high throughput imaging system (for analysis see section 4.2.7). 
Values are normalized to the average mitochondrial rhod-2 signal of non-transduced 
control cells. NT = Non-transduced i.e. no viral treatment, + = positively transduced 
i.e. GFP expressing, - = not successfully transduced i.e. no GFP expression. n=4 
independent wells on the same imaging plate. For comparison of means one-way 
ANOVA with post hoc Tukey tests were used. This gave the following adjusted P 
values: Control NT vs ΔMICU1 NT (*P=0.0343), Control NT vs Control + 
(***P=0.0003), Control – vs Control + (***P=0.0005), ΔMICU1 NT vs ΔMICU1 + 
(***P=0.0001), ΔMICU1 – vs ΔMICU1 + (*P=0.0118). 
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4.3.5 The absence of MICU1 in fibroblasts does not affect cellular 
ROS production 
MICU1 deficiency has previously been shown to result in [Ca2+]m-dependent 
ROS overproduction (Mallilankaraman, Doonan, et al. 2012; Hoffman et al. 
2013). To assess whether MICU1 loss results in oxidative stress, control and 
ΔMICU1 fibroblasts were imaged in the presence of fluorescent superoxide 
indicator DHE and average rates of dye oxidation were calculated (Figure 
4.8a). This showed no significant difference in the rate of ROS production 
between control and ΔMICU1 cells (P=0.466) (Figure 4.8b). 
 
 
 
 
Figure 4.8: The effect of MICU1 loss on cellular ROS production 
Representative trace of DHE oxidation in control and ΔMICU1 cells (a). FOX 
indicates the blue fluorescence intensity emitted by oxidated DHE, while FRED 
indicates the red fluorescence intensity emitted by reduced DHE. Rate of ROS 
production was calculated as the change in FOX / FRED over time (shown in grey). 
Average rates of ROS production were normalised to average control rate on each 
experimental day (b). n=6 replicates pooled from both cell lines (2 control and 2 
ΔMICU1 cell lines were measured on 3 experimental days). At least 8 cells were 
measured per cell line per day. Therefore values shown are mean of means for 
each replicate. Errors bars show SEM. 
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4.3.6 The absence of MICU1 in glycolytic fibroblasts does not cause 
bioenergetic dysfunction 
It is important to establish the bioenergetic consequences of altered MICU1 
expression. Measuring O2 consumption within intact cells can give an 
indication of electron transport chain functionality and cellular bioenergetics. 
As an increase in mitochondrial matrix Ca2+ concentration increases the 
supply of NADH and FADH2 through citric acid cycle activation, one might 
expect to observe increased basal O2 consumption in the ΔMICU1 
fibroblasts. Measurements using a high-resolution respirometer, however, did 
not show any significant difference in basal mitochondrial O2 consumption 
between control and ΔMICU1 cells (P=0.232) (Figure 4.9a). There were also 
no significant differences in average leak (P=0.267) or in maximal respiration 
values (P=0.210) (Figure 4.9a). Previous studies described a greater 
increase in O2 consumption during stimulation of mitochondrial Ca
2+ uptake 
in MICU1 KD cells than in controls (Mallilankaraman, Doonan, et al. 2012; 
Csordás et al. 2013). In contrast, my measurements showed that histamine-
stimulated O2 consumption was similar between control and ΔMICU1 cells 
(P=0.972) (Figure 4.9b). 
To assess the impact of chronic mitochondrial Ca2+ loading on ATP 
production, ATP levels in control and ΔMICU1 fibroblasts were measured 
using a commercial luminescence assay kit. In keeping with the respirometry 
data, there was no significant difference in resting ATP levels between 
ΔMICU1 cells and controls (P=0.999) (Figure 4.9c). The lack of effect of 
treatment with complex V inhibitor, oligomycin, revealed that both control and 
ΔMICU1 fibroblasts do not rely on oxidative phosphorylation for ATP 
production (Control: DMSO v oligomycin P=0.999, ΔMICU1: DMSO v 
oligomycin P=0.999) (Figure 4.9c). Treatment with glyceraldehyde-3-
phosphate dehydrogenase inhibitor, iodoacetic acid (IAA), caused a large 
reduction in ATP levels in both populations of cells, confirming that these 
fibroblasts make most of their ATP via glycolysis (Control: DMSO v IAA 
P<0.0001, ΔMICU1: DMSO v oligomycin P<0.0001) (Figure 4.9c). 
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Although it is clear from my respirometry data that these primary fibroblasts 
do respire aerobically, their basal rates of O2 consumption were relatively low 
compared to their maximal capacities and treatment with ATP synthase 
inhibitor, oligomycin, had no effect on [ATP]. This suggests that mitochondrial 
oxidative phosphorylation in skin fibroblasts in culture plays a minimal role in 
energy homeostasis, which is not particularly useful when studying a 
mitochondrial protein that indirectly regulates mitochondrial metabolism. If 
these cells can be forced to use their mitochondria, perhaps a bioenergetic 
defect will be unveiled in the ΔMICU1 cells. 
Figure 4.9: The effect of MICU1 loss on mitochondrial energy metabolism 
O2 consumption of intact control and ΔMICU1 cells in the basal state, leakage state 
(2.5μM oligomycin present) and maximal state (1μM FCCP present) were measured 
using high-resolution respirometry (a). The effect of 10μM histamine on basal 
respiration was also measured (b). Control and ΔMICU1 fibroblast populations were 
pre-treated with DMSO, 5μM oligomycin or 1mM IAA and processed via a 
commercial ATP assay kit, which gave a luminescence readout proportional to ATP 
content (c). n=6 replicates pooled from both cell lines (2 control and 2 ΔMICU1 cell 
lines were measured on 3 experimental days). Asterisks in (c) indicate statistical 
comparison with corresponding DMSO control. As two different variables (cell line 
and drug treatment) were being measured in (c), two-way ANOVA with post hoc 
Tukey tests were used.  
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4.3.7 ΔMICU1 fibroblasts cultured in galactose are more dependent 
on mitochondrial ATP production 
 One way to force cells to have an increased reliance on mitochondrial ATP 
production experimentally is to replace glucose with galactose in the culture 
medium. Galactose is metabolised into pyruvate via glycolysis, though at a 
much slower rate than its structural isomer, glucose (Robinson et al. 1992). 
As there are no catabolic processes to directly metabolise galactose, it is first 
converted to galactose-1-phosphate by galactokinase (Berg et al. 2002). 
Galactose-1-phosphate then acquires a uridyl group from uridine 
disphosphate (UDP) glucose, which is an intermediate in glycogen chain 
synthesis (Figure 4.10) (Berg et al. 2002). The resulting products are UDP-
galactose, which is subsequently epimerised to regenerate UDP-glucose, 
and glucose-1-phosphate, which is isomerised by phosphoglucomutase to 
produce glycolytic intermediate glucose-6-phosphate (Figure 4.10). 
 
 
 
 
 
 
 
 
 
Figure 4.10: Generation of glucose-6-phosphate from galactose 
Diagram reproduced from section 16.1.11 in (Berg et al. 2002). 
Figure removed due to copyright restrictions 
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The slow metabolism of galactose to glucose-1-phosphate is not sufficient for 
cells to produce the bulk of their ATP requirements by glycolysis (Robinson 
et al. 1992). This forces cells to switch to oxidative metabolism and to use 
glutamine as the major energy source (Reitzer et al. 1979). The immediate 
product of glutamine metabolism is glutamate, which can be converted to α-
ketoglutarate by three different enzymes (Figure 4.11).  
 
Figure 4.11: Glutaminolysis pathways 
Glutaminolysis partly uses reaction steps from the citric acid cycle (blue) and the 
malate-aspartate shuttle (red). GLDH = Glutamate dehydrogenase, GOT = 
Glutamate oxaloacetate transaminase (also alanine transaminase), GPT = 
Glutamate pyruvate transaminase (also aspartate transaminase). 
Different types of cells grown in galactose show a significantly higher O2 
consumption rate compared to cells grown in high glucose conditions 
(Rossignol 2004; Marroquin et al. 2007; Shulga et al. 2010; MacVicar & Lane 
2014; Aguer et al. 2011). In addition, lower amounts of lactate and pyruvate 
accumulate in the media of galactose-grown cells, indicating that the majority 
of ATP production is from the mitochondrial oxidation of pyruvate and not 
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from glycolysis (Robinson 1996). The more aerobic state of galactose-grown 
cells is also thought to be due to changes in mitochondrial structure and an 
increase in mitochondrial oxidative capacity, as evidenced by increased 
OXPHOS protein expression and mitochondrial enzymatic activities 
(Rossignol 2004).  
To verify that galactose growth conditions had resulted in a more oxidative 
phenotype, O2 consumption was measured in control and ΔMICU1 
fibroblasts that had been cultured in galactose for at least two weeks. 
Although galactose-cultured cells tended to show higher rates of O2 
consumption than glucose-grown cells, the differences were not statistically 
significant in either basal (Control: glucose v galactose P=0.717, ΔMICU1: 
glucose v galactose P=0.737), leak (Control: glucose v galactose P=0.998, 
ΔMICU1: glucose v galactose P=0.991), or maximal states (Control: glucose 
v galactose P=0.145, ΔMICU1: glucose v galactose P=0.0911) (Figure 
4.12a). Despite this slight trend towards increased mitochondrial activity, the 
galactose-grown control and ΔMICU1 cells still behaved in a similar way as 
no significant differences could be detected in basal (P=0.836), leak 
(P=0.999) or maximal respiration values (P=0.302) (Figure 4.12a). Similar to 
previous glucose results, there was also no change in histamine-stimulated 
O2 consumption between galactose-grown control and ΔMICU1 cells 
(P=0.875) (Figure 4.12b). 
Figure 4.12: Mitochondrial O2 consumption is normal in galactose-grown 
ΔMICU1 fibroblasts 
High-resolution respirometry was used to measure O2 consumption of glucose 
(unpatterned) or galactose (patterned) grown control (blue) and ΔMICU1 (red) cells 
in the basal state, leakage state (2.5μM oligomycin present) and maximal state 
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(1μM FCCP present) (a). The effect of 10μM histamine on basal respiration was 
also measured (b). Statistical differences were tested using two-way ANOVA with 
post hoc Tukey correction. n=6 replicates pooled from both cell lines (2 control and 
2 ΔMICU1 cell lines were measured on 3 experimental days).  
To assess whether galactose had successfully caused a metabolic shift from 
glycolytic to mitochondrial ATP production, ATP levels were analysed in 
galactose-grown cells treated with DMSO, oligomycin and IAA. Growth in 
galactose caused the ΔMICU1 cells to become more sensitive to oligomycin 
(***P<0.001), indicating that more mitochondrial ATP production was taking 
place than in glucose-grown ΔMICU1 cells (Figure 4.13a). A similar trend in 
increased oligomycin sensitivity was seen in the galactose-grown control 
cells, however, this was not significant (P=0.157) (Figure 4.13a). This 
suggests that, under oxidative conditions, ΔMICU1 cells are more reliant on 
their mitochondria for ATP production.  
IAA treatment caused a large significant decrease in ATP levels in all 
galactose-grown cells, meaning glycolysis was still highly active 
(***P<0.0001) (Figure 4.13a). Including 10mM 2-deoxyglucose (DG) in the 
1hr treatments confirmed that galactose-grown cells were producing the bulk 
of their ATP from the glycolytic breakdown of galactose (***P<0.0001) 
(Figure 4.13b). 
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Figure 4.13: ΔMICU1 cells produce more mitochondrial ATP than controls 
when grown in galactose 
Control and ΔMICU1 fibroblasts grown in glucose or galactose were pre-treated with 
DMSO, 5μM oligomycin and 1mM IAA before being processed via a commercial 
ATP assay kit (a). 10mM 2-deoxyglucose treatment was also included in the assays 
of galactose-grown cells (b). Luminescence readout is proportional to ATP content. 
Asterisks in (a) indicate statistical comparison with corresponding DMSO control. 
Statistical differences were tested using two-way ANOVA with post hoc Tukey 
correction. n=6 replicates pooled from both cell lines (2 control and 2 ΔMICU1 cell 
lines were measured on 3 experimental days).   
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4.3.8 The loss of MICU1 is associated with increased PDH activity 
The loss of MICU1 causes the MCU to be constitutively active and the 
mitochondria become Ca2+ loaded even at resting [Ca2+]c. A rise in [Ca
2+]m 
increases the activity of three mitochondrial dehydrogenases, including PDH 
(see Introduction Figure 1.7), so the activity of these enzymes should be 
increased in the ΔMICU1 cells. To get an indication of its activity, the 
phosphorylation status of PDH was assessed using western blotting (Figure 
4.14a). To account for possible differences in the amount of enzyme present 
in each cell line, the ratio of pPDH intensity to total PDH intensity was 
quantified. In keeping with elevated resting [Ca2+]m and enhanced Ca
2+-
activated PDP activity, the pPDH/PDH ratio was significantly reduced in 
ΔMICU1 cells (0.4828 ± 0.0972) compared to controls (1.00 ± 0.129) 
(P=0.0064) (Figure 4.14b). This is in agreement with our group’s published 
data showing that MICU1 loss results in increased levels of NADH at rest 
(Logan et al. 2014). 
 
Figure 4.14: PDH is hypophosphorylated in ΔMICU1 cells 
Whole cell lysates from galactose-cultured control and ΔMICU1 cells were 
immunoblotted for pPDH (PDH-E1α pS293) and total PDH (PDH-E1α) (a). The ratio 
of band intensities was normalised to the average control ratio on each experimental 
day (b). n=8 replicates pooled from both cell lines (2 control and 2 ΔMICU1 cell lines 
were measured on 4 experimental days).   
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4.3.9 Inhibition of mitochondrial Ca2+ export revealed futile Ca2+ 
cycling in the ΔMICU1 fibroblasts 
An increase in [Ca2+]m should ultimately activate Ca
2+ efflux pathways in the 
mitochondria. Because the ΔMICU1 mitochondria are continually taking up 
Ca2+ at resting [Ca2+]c, it seems inevitable that they are also extruding Ca
2+ 
through increased activation of the NCX and subsequent promotion of 
Na+/H+ exchange (see Introduction figure 1.7). This should offset the PMF 
and reduce ATP generation in the ΔMICU1 cells, though this is not obvious 
due to the increased PDH activation. To test this futile cycling theory, control 
and ΔMICU1 fibroblasts loaded with rhod-FF AM were imaged in the 
presence of NCX inhibitor CGP-37157 (Figure 4.15a & b). Rhod-FF was 
used because it is a lower affinity Ca2+ indicator (Kd=19μM), which should be 
able to pick up large changes in [Ca2+]m that would otherwise saturate rhod-2 
(Kd=570nM). In keeping with what was previously seen with rhod-2, average 
resting rhod-FF intensity was significantly higher in the ΔMICU1 cells (169 ± 
9.30 A.U.) than in controls (122 ± 5.91 A.U.) (P<0.0001) (Figure 4.15c). 
Application of CGP-37157 caused an increase in mitochondrial Ca2+ content 
in the ΔMICU1 cells (1.56 ± 0.0637 fold) that was significantly larger than in 
controls (1.32 ± 0.021 fold) (P=0.0006) (Figure 4.15d). This increase was 
also significantly faster in the ΔMICU1 cells (0.0141 ± 0.00317 fold increase 
per min) than in control cells (0.00415 ± 0.000536 fold increase per min) 
(P=0.0022) (Figure 4.15e).  
Accordingly, I measured cellular [ATP] in control and ΔMICU1 cells that had 
been treated with either DMSO or CGP-357157. This showed that NCX 
inhibition caused a significantly larger change in [ATP] in the ΔMICU1 cells 
(108 ± 1.89%) than in controls (95.6 ± 4.85%) (P=0.04) (Figure 4.15f). 
Although this increase in [ATP] was relatively small (approximately 8%), it is 
consistent with the energetically wasteful mitochondrial Ca2+ cycling in the 
ΔMICU1 cells. 
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Figure 4.15: ΔMICU1 cells show increased mitochondrial Ca2+ uptake when 
NCX-mediated efflux is blocked 
Representative confocal images of galactose-cultured, rhod-FF loaded fibroblasts 
after approximately 7 mins of 10μM CGP-37157 incubation (a). After normalising 
each time point to resting rhod-FF intensity (b), average traces were plotted (c).  
Resting rhod-FF intensity was calculated as the average fluorescence of each cell 
over the first 30 secs; mean cell average is shown in (b). The initial rate of 
normalised increase was analysed as shown in (c) and quantified in (d). The peak of 
normalised rhod-FF intensity was calculated as the maximum value over the entire 
time course (approx. 20mins) and was quantified in (e). n>100 cells from 3 
independent experiments. Control and MICU1-deficient fibroblasts were pre-treated 
with DMSO and 10μM CGP-37157 before having total ATP content quantified (f). 
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Luminescence values were normalised to DMSO treatment i.e. 100% indicates no 
change in ATP. n=3 day averages from 3 independent experiments. 
4.3.10 Mitochondrial networks were fragmented in ΔMICU1 cells 
Imaging resting cells with TMRM (Figure 4.16a) and rhod-2 (Figure 4.6) 
revealed differences in mitochondrial morphology; while the control cells had 
intricate, elongated mitochondrial networks, the ΔMICU1 cells appeared to 
have more rounded, broken up mitochondria. Further quantification showed 
that a significant proportion of ΔMICU1 cells had this fragmented phenotype 
(Figure 4.16b, P=0.0003) (Figure 4.16c, P=0.0041). Quantification of the 
rhod-2 fluorescence in such cells confirmed that the fragmentation was 
associated with increased resting mitochondrial Ca2+ levels (P=0.0099) 
(Figure 4.16d). 
 
 
 
 
 
 
Figure 4.16: Loss of MICU1 affects mitochondrial morphology 
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Representative confocal image of glucose-cultured fibroblasts co-loaded with fluo-4 
and TMRM (a). The number of cells with fragmented mitochondria was quantified 
from TMRM (b) and rhod-2 (c) images. After morphology scoring, the intensity of 
each cell was measured and normalised to the average intensity of all ‘connected’ 
cells on each experimental day (d). n=6 replicates pooled from both cell lines (2 
control and 2 ΔMICU1 cell lines were measured on 3 experimental days). At least 
10 cells were measured per cell line per day. Therefore values shown are mean of 
means for each replicate.  
 
Although a significant proportion of ΔMICU1 cells displayed a fragmented, 
Ca2+ loaded mitochondrial phenotype, not all of the cell population were 
affected in this way (Figure 4.16b & c). This heterogeneity could reflect the 
Ca2+ signalling history of each cell; a rise in [Ca2+]m far outlasts the initiating 
cytosolic Ca2+ signal (Boitier et al. 1999), so a cell that shows spontaneous 
[Ca2+]c fluctuations might be more likely have a higher resting [Ca
2+]m than a 
less active cell. In support of this, the fibroblasts showed sporadic [Ca2+]c 
transients that varied considerably within the population (Figure 4.17a). The 
frequency of these spontaneous transients was quantified, and was found to 
be no different between ΔMICU1 and control cells (P=0.456) (Figure 4.17b). 
Abolishing mitochondrial Ca2+ uptake with FCCP significantly increased the 
frequency of spontaneous transients in both control (P=0.0377) and ΔMICU1 
cells (P=0.0497) (Figure 4.17b), which is consistent with the view that the 
mitochondria regulate local Ca2+ and the propagation of signals (Boitier et al. 
1999). There was also no significant difference between the number of 
spontaneously active cells in control and ΔMICU1 cell populations (P=0.156) 
(Figure 4.17c). 
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Figure 4.17: Control and ΔMICU1 fibroblasts showed spontaneous [Ca2+]c 
activity 
Spontaneous Ca2+ transients were measured in fluo-4 loaded cells using confocal 
microscopy. Representative traces from an imaging field of ΔMICU1 cells (a). 
Frequency of spontaneous Ca2+ transients (b) and the number of spontaneously 
active cells (c) was quantified. n=6 replicates pooled from both cell lines (2 control 
and 2 ΔMICU1 cell lines were measured on 3 experimental days). At least 5 cells 
were measured per cell line per day. Therefore values shown are mean of means 
for each replicate. 
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4.3.11 Mitochondrial fragmentation in the ΔMICU1 cells may be due to 
increased DRP1 activity  
A significant number of ΔMICU1 fibroblasts had a fragmented mitochondrial 
network (Figure 4.16). To see whether this phenotype was the result of 
increased mitochondrial fission, the phosphorylation status of S637 
(inhibitory phosphorylation site) of DRP1 was assessed using western 
blotting (Figure 4.18a). To account for possible differences in the amount of 
DRP1 protein in each cell line, the ratio of pDRP1 intensity to total DRP1 
intensity was quantified. The pDRP1/DRP1 ratio was significantly reduced in 
the ΔMICU1 cells (0.394 ± 0.0620) when compared to controls (1.00 ± 
0.0807) (P<0.0001) (Figure 4.18b), suggesting that DRP1 was more active 
and mitochondrial fission may have been dominant. 
 
Figure 4.18: Reduced DRP1 S637 phosphorylation in ΔMICU1 cells 
Whole cell lysates from galactose-cultured control and ΔMICU1 cells were 
immunoblotted for pDRP1 (S637) and total DRP1 (a). The ratio of band intensities 
was normalised to the average control ratio on each experimental day (b). n=8 
replicates pooled from both cell lines (2 control and 2 ΔMICU1 cell lines were 
measured on 4 experimental days).  
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4.3.12 The loss of MICU1 does not alter autophagy flux 
Since mitochondrial fission is a prerequisite for mitophagy, the ΔMICU1 cells 
maybe activating autophagy as a way to eliminate their fragmented, Ca2+ 
loaded mitochondria. On the other hand, the permanent presence of 
fragmented mitochondria might suggest that autophagy is being inhibited or 
is defective in some way. To assess autophagic flux under basal conditions, 
the amount of LC3-II was measured in DMSO and bafilomycin treated control 
and ΔMICU1 fibroblasts (Figure 4.19a). As expected, vacuolar H+ ATPase 
and autophagy inhibitor bafilomycin significantly increased the level of LC3-II 
in both control (P=0.001) and ΔMICU1 cells (P<0.0001) (Figure 4.19b). 
However there was no significant difference (P=0.827) in basal LC3-II levels 
between control (0.172 ± 0.0186) and ΔMICU1 cells (0.262 ± 0.0142) (Figure 
4.19b). There was also no significant difference (P=0.0509) in LC3-II levels 
after bafilomycin treatment between control (0.760 ± 0.0455) and ΔMICU1 
cells (1.05 ± 0.0329) (Figure 4.19b). 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  142 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.19: Autophagy is not altered in ΔMICU1 cells 
Galactose-cultured control and ΔMICU1 cells were treated with 1uL/mL DMSO (NT) 
or 100nM bafilomycin A1 (BAF) for 5hrs before having total protein extracted and 
immunoblotted for LC3 (a). Intensity of the LC3-II band at 14kDa was normalised to 
b-actin loading control (b). Statistical differences were analysed using two-way 
ANOVA with Tukey post hoc correction. n=6 replicates pooled from both cell lines (2 
control and 2 ΔMICU1 cell lines were measured on 3 experimental days).  
  
  143 
4.4 Discussion 
In this chapter, I have presented a range of data showing the status of 
cellular bioenergetics and Ca2+ homeostasis in fibroblasts derived from 
patients lacking the MICU1 protein. My results agree with the established 
theory that MICU1 acts as a gatekeeper of the MCU by setting an 
intracellular threshold concentration for mitochondrial Ca2+ uptake 
(Mallilankaraman, Doonan, et al. 2012; Csordás et al. 2013). However, there 
are discrepancies between my work and parts of the literature, which I will 
now review in conjunction with the aims set out at the start of this thesis (see 
Introduction 1.6). 
4.4.1 Ca2+ homeostasis in ΔMICU1 fibroblasts 
It is evident that authors of the first MICU1 KD study were mistaken in their 
conclusion that MICU1 is essential for mitochondrial Ca2+ uptake. In 
agreement with the work of many others, my aequorin data proves that the 
mitochondria of ΔMICU1 cells are capable of taking up Ca2+. It is not clear 
why Perocchi et al. observed the opposite result but it may be due to 
technical and analytical differences. Like Mallilankaraman et al. but in 
contrast to Csordas et al., I found that a lack of MICU1 does not affect the 
peak mitochondrial Ca2+ concentration reached during ER Ca2+ release, but 
does increase mitochondrial Ca2+ load at resting cytosolic concentrations and 
after spontaneous, low frequency, cytoplasmic Ca2+ transients. In addition, I 
found evidence of accelerated mitochondrial Ca2+ uptake, which has not 
been reported in previous KD studies. These results demonstrate the 
function of MICU1 in restricting mitochondrial Ca2+ uptake to a sigmoidal 
dependence on [Ca2+]c (Figure 4.20). Without MICU1 there is no threshold 
for uptake and sigmoidicity is lost, meaning mitochondria are Ca2+-loaded at 
rest and uptake occurs in a more linear fashion (Figure 4.20). Although the 
sigmoidal dependence of mitochondrial Ca2+ uptake on [Ca2+]c has been 
known about for a long time, its physiological importance is only truly 
appreciated now that this ΔMICU1 patient cohort has been discovered. 
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Figure 4.20: Schematic illustration of the sigmoidal dependence of 
mitochondrial Ca2+ uptake on cytosolic Ca2+ concentration 
The loss of MICU1 alleviates the threshold for uptake, meaning mitochondria are 
Ca2+ loaded at rest and uptake occurs in a more linear fashion. Figure based on 
data from (Csordás et al. 2013). 
Cell population measurements revealed that cytoplasmic Ca2+ signals were 
reduced in ΔMICU1 fibroblasts due to enhanced mitochondrial Ca2+ 
buffering. Given the importance of Ca2+ signalling for muscle contraction and 
synaptic transmission, this enhanced mitochondrial buffering capacity might 
explain why the muscle and brain are primarily affected in these patients. 
While it might be surprising that the patients do not have a cardiomyopathy, 
the heart has a much lower MICU1:MCU expression ratio (De Stefani et al. 
2011), which suggests that the threshold concentration for mitochondrial 
Ca2+ uptake is much lower in the heart. In theory, this makes physiological 
sense, as it is crucial that heart mitochondria make enough ATP to support 
beat-by-beat contractions. 
4.4.2 Bioenergetic consequences of MICU1 loss 
Despite having a chronically active MCU, the ΔMICU1 fibroblasts showed no 
differences in steady state Δm, O2 consumption or ATP levels; this was 
surprising, as I expected an increase in mitochondrial matrix Ca2+ 
concentration to activate the citric acid cycle and increase ATP production. 
On the other hand, my results are in agreement with previous MICU1 KD 
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studies, where no changes in Δm, resting O2 consumption or ATP levels 
have ever been reported. The only discrepancy concerns Ca2+-enhanced 
respiration; in contrast with Mallilankaraman et al., I found no difference in O2 
consumption between control and ΔMICU1 cells after stimulation with 10μM 
histamine. However, this result is in keeping with our group’s observation that 
MICU1 loss does not affect NADH levels after 10μM histamine addition 
(Logan et al. 2014). Furthermore, these results are in agreement with my 
aequorin data, which showed that a lack of MICU1 does not affect peak 
[Ca2+]m after stimulation with 10μM histamine. Mallilankaraman et al. did not 
measure peak [Ca2+]m during 10μM histamine stimulation but perhaps it was 
elevated in their MICU1 KD model, thus explaining why an increase in Ca2+-
enhanced respiration was observed. 
Measuring ATP levels after treatment with OXPHOS or glycolysis inhibitors 
revealed that both control and ΔMICU1 fibroblasts were heavily relying on 
glycolysis for ATP production. As MICU1 is a mitochondrial protein that 
indirectly regulates mitochondrial metabolism, I concluded that a glycolytic 
fibroblast model was not particularly useful for investigating the bioenergetic 
consequences of MICU1; I decided to switch to galactose culture conditions 
to see if this would reveal a bioenergetic defect in the ΔMICU1 cells. 
Although basal ATP levels were similar in galactose-grown ΔMICU1 cells 
and controls, oligomycin treatment showed that the mitochondria of the 
ΔMICU1 cells were making a bigger contribution to ATP production; this may 
be attributed to the fact that PDH was hypophosphorylated and therefore 
more active in these cells. However, this increase in oxidative 
phosphorylation in the ΔMICU1 cells did not correspond with a significant 
increase in O2 consumption. I can only assume that this is because the 
sensitivity and resolution of the Oroboros respirometer is below that required 
for these fibroblasts with relatively low overall O2 flow. 
According to the literature, growing cells in galactose causes a metabolic 
switch from glycolysis to oxidative glutamine metabolism. This is true for the 
primary human fibroblasts I have tested; when the cells were grown in 
galactose, there was a trend for an increase in respiratory rates and a 
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significant increase in mitochondrial ATP production. However, treatment 
with glycolysis inhibitor 2DG showed that the fibroblasts were still producing 
the bulk of their ATP through glycolysis i.e. by breaking down the galactose 
into glucose-6-phosphate. This highlights the need for caution when using 
galactose as a growth substrate; although it is widely accepted that galactose 
increases cellular oxidative capacity, how well it can achieve this may vary 
between cell types. Even though mitochondrial ATP synthesis was higher in 
the ΔMICU1 cells, 2DG still caused a significantly large drop in [ATP]; this 
suggests that the ΔMICU1 cells still rely on the glycolytic production of 
pyruvate, which is used as an anaplerotic substrate for the citric acid cycle, in 
addition to glutamine use. Indeed, PDH is hypophosphorylated in the 
ΔMICU1 cells, which could lead to higher flux of pyruvate into the citric acid 
cycle.  
An increase in [Ca2+]m inevitably leads to the activation of efflux pathways. 
When mitochondrial Ca2+ export was blocked in the ΔMICU1 cells, [Ca2+]m 
increased at a much higher rate than in controls. This suggests that under 
resting conditions a futile mitochondrial Ca2+ cycle is maintained in the 
ΔMICU1 cells, which ultimately undermines their bioenergetic capacity and 
might explain why overall [ATP] is not increased; the increased activity of 
PDH is essentially offset by the increased activity of the NCX in conjunction 
with the Na+/H+ exchanger (Figure 4.21). In agreement with this, [ATP] was 
higher in ΔMICU1 cells than controls after pre-treatment with the NCX 
inhibitor, CGP-37157. However, a proton influx independent of the ATP 
synthase should effectively uncouple the mitochondrial membrane and either 
decrease Δm or increase O2 consumption (to maintain Δm) (Figure 4.21). 
Uncoupling should also cause an increase in the amount of leak respiration 
i.e. O2 consumption in the presence of oligomycin. Since I have not observed 
any of these particular changes, my data are not fully consistent with this 
futile cycle model. I suspect that O2 consumption is in fact increased in the 
absence of MICU1 but this change is below the resolution of the Oroboros 
respirometer. I also observed a lot of day-to-day variability in these 
measurements, which might suggest that further optimisation is required, or 
perhaps that a different respirometry method should be used. 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.21: Schematic illustrating the bioenergetic cost of mitochondrial Ca2+ accumulation in the MICU1-deficient cells 
The loss of MICU1 means the MCU is constitutively active and resting [Ca2+]m is increased. This activates the mitochondrial Na
+/Ca2+ 
exchanger (NCX) and causes a futile Ca2+ cycle. Increased [Ca2+]m also activates the pyruvate dehydrogenase complex (PDHC) and increases 
NADH production. This increased NADH supply should increase respiratory chain activity and thus O2 consumption, but this has not been 
observed in the ΔMICU1 fibroblast model.
1
4
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4.4.3 Mitochondrial morphology is altered in ΔMICU1 fibroblasts 
Although the ΔMICU1 fibroblasts do not seem to be energetically 
compromised, there is certainly evidence of mitochondrial stress through the 
fragmented phenotype shown by approximately 40-50% of the cell 
population. This mitochondrial fragmentation was associated with increased 
resting [Ca2+]m and could be somewhat reversed by the viral expression of 
WT MICU1 protein (Logan et al. 2014). Although MICU1 deficiency has 
never before been linked to altered mitochondrial morphology, 
pharmacologically induced mitochondrial Ca2+ overload has been shown to 
cause mitochondrial fission in prostate cancer cells (Kaddour-Djebbar et al. 
2010). However, it is not clear why or how increased [Ca2+]m is associated 
with mitochondrial fragmentation in the ΔMICU1 fibroblasts, particularly as 
they do not seem to suffer from energetic dysfunction or increased oxidative 
stress. Mitochondrial fragmentation is usually an early apoptotic event but 
increased fission does not necessarily result in cell death (Youle & Karbowski 
2005) and I have not observed reduced viability while culturing these cells. It 
is worth keeping in mind that not all of the ΔMICU1 fibroblasts display 
fragmented, Ca2+ loaded mitochondria at rest, and even within the same cell 
the mitochondria can vary in appearance and [Ca2+]m. This heterogeneity 
may reflect the different Ca2+ signalling histories of each cell and each 
mitochondrion; for example, a cell that has undergone frequent spontaneous 
activity may be more likely to have Ca2+ loaded mitochondria at rest. 
Moreover, if these mitochondria were positioned close to Ca2+ release sites 
at the time of a signal, they may be even more likely to have higher resting 
[Ca2+]m. 
To gain a better understanding of the molecular mechanism behind the 
increased fragmentation in the ΔMICU1 fibroblasts, I investigated DRP1 
activation by quantifying the amount of phosphorylation of its inhibitory S637 
site. I found that this S637 site was hypophosphorylated in the MICU1-
deficient cells, indicating that increased DRP1 activity was behind the 
fragmented phenotype. Dephosphorylation of the S637 site is carried out by 
the cytosolic phosphatase, calcineurin, which is activated during a sustained 
  149 
rise in intracellular Ca2+ levels (Cereghetti et al. 2008). Such a pathological 
Ca2+ rise could occur following mitochondrial depolarisation but my 
measurements of Ca2+ transients after FCCP treatment showed this not to be 
the case in the ΔMICU1 cells (Figure 4.5c). Although it is not clear exactly 
how DRP1-dependent fission is activated in the ΔMICU1 cells, it could be an 
important cellular adaptation. It has been previously shown that DRP1-
dependent fission protects against Ca2+-mediated apoptosis by blocking 
intra-mitochondrial Ca2+ waves (Szabadkai et al. 2004). This means that 
fragmented mitochondria are less exposed to substantial [Ca2+]m elevations, 
which seems crucial for ΔMICU1 mitochondria that already have elevated 
basal [Ca2+]m. As a collective population the ΔMICU1 cells do not show 
reduced agonist-induced mitochondrial Ca2+ uptake, but perhaps on a single 
cell level the [Ca2+]m responses vary according to mitochondrial morphology. 
Since mitophagy is associated with mitochondrial fission, I tested to see 
whether basal levels of autophagy were altered in the ΔMICU1 cells. This did 
not appear to be the case, as the relative amount of the autophagic marker 
LC3-II after 5 hrs of DMSO or bafilomycin treatment was similar between 
control and ΔMICU1 cells. This is in agreement with the results of a previous 
study of MICU1 KD in HeLa cells (Mallilankaraman, Doonan, et al. 2012). 
While increased [Ca2+]m appears to have no effect on autophagy, a reduction 
in [Ca2+]m is thought to increase autophagy through AMPK activation (Rizzuto 
et al. 2012; Cárdenas & Foskett 2012). This theory, however, has been 
recently challenged by the creation of an MCU KO mouse, which showed no 
alteration in basal metabolism (Pan et al. 2013). 
4.4.4 Future work 
Previous work has shown that MICU1 KD enhances sensitivity to cell death 
(Mallilankaraman, Doonan, et al. 2012; Csordás et al. 2013). Time limitations 
meant that I could not test this in the ΔMICU1 cells but I would expect that 
their elevated resting [Ca2+]m would make them vulnerable to cell death 
through ‘priming’ of the mPTP. As it is difficult to experimentally observe 
mPTP opening in whole cells (personal observations within our group), this 
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theory should be tested by carrying out Ca2+ retention capacity (CRC) assays 
on isolated ΔMICU1 mitochondria (ideally from a muscle sample). This 
involves sequentially adding Ca2+ to a mixture of mitochondria and 
membrane impermeable fluorescent Ca2+ indicator; the mitochondria will take 
up and buffer this Ca2+ (resulting in a decrease in fluorescence signal) until 
the threshold for mPTP opening is reached and Δm is lost (causing an 
increase in fluorescence signal). 
The molecular makeup of the mitochondrial calcium uniporter complex is still 
yet to be fully understood but many different proteins appear to be involved. I 
have focussed on the physiological role of MICU1 in this project but it would 
be interesting to investigate its relationship with other proteins residing in the 
mitochondrial calcium uniporter complex. The relationship between MCU, 
MICU1 and MICU2 is perhaps of most interest, given the present 
disagreements in the literature. Mootha et al. have suggested that MICU1 
and MICU2 are both gatekeepers of the MCU and are functionally non-
redundant (Kamer & Mootha 2014). However, Patron et al. have presented 
evidence that MICU2 is the gatekeeper and MICU1 is an activator of the 
MCU; in their paper they show that MICU2 relies on MICU1 for stability, 
which means that a loss of MICU1 also results in a loss of MICU2 and 
therefore a lack of MCU regulation (Patron et al. 2014). When the data in this 
chapter was evaluated for publication, a peer reviewer asked whether MICU2 
expression was altered in the ΔMICU1 fibroblasts. Interestingly, MICU2 
protein was missing in the ΔMICU1 fibroblasts, but returned to normal levels 
when MICU1 was re-expressed (Figure 4.22). This supports the theory that 
MICU2 relies on MICU1 for stability, but does not alter the conclusion that the 
observed phenotype is the primary consequence of MICU1 deficiency.  
Although the ΔMICU1 fibroblasts have shed some light on the general 
mechanism of mitochondrial Ca2+ handling, they have been unable to tell us 
much about the pathological process that has occurred (and might still be 
occurring) in the patients. A ΔMICU1 skeletal muscle model will need to be 
established in order to fully understand how and why minicores develop. The 
best option might be to make iPSCs from the patient fibroblasts, as these can 
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then be differentiated into neurons as well as skeletal muscle. It would then 
be interesting to know the effect of MICU1 deficiency on EC coupling, and 
whether there are any parallels to disease mechanisms proposed by other 
core myopathy models.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.22: MICU1, MICU2 and MCU expression levels in ΔMICU1 fibroblasts 
Left four lanes show non-transfected cells, the middle and right four lanes show 
cells transduced with GFP and HA-tagged MICU1 expressing adenoviral constructs, 
respectively. Anti-HA antibody shows the presence of exogenous MICU1. 
Expression of mitochondrial protein Tom20 was measured as a loading control. 
Figure kindly provided by the Rizzuto lab, Padova. 
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Chapter 5 Final conclusions 
5.1 Summary of findings 
The aim of this thesis has been to explore the possibility that mitochondria 
are contributing to core myopathy pathology by suffering from Ca2+-related 
dysfunction. To test this theory, I assessed intracellular Ca2+ homeostasis 
and its possible effect on mitochondrial function in three core myopathy 
models with mutations in different proteins involved in muscle Ca2+ 
homeostasis. 
The first model, which was discussed in Chapter 2, was a knockin mouse 
with a heterozygous RYR1 mutation that is associated with CCD in humans. 
Myotubes and myofibres originating from this mouse were used as cell 
models, reflecting immature and mature skeletal muscle cells, respectively. 
Unfortunately, both of these cell models failed to demonstrate the reduced 
cytosolic Ca2+ signals that this ‘EC uncoupled’ mutation is supposed to cause 
(Avila et al. 2001; Boncompagni et al. 2010; Loy et al. 2011). Despite the 
genetic alteration in RYR1, there appeared to be no functional alteration in 
the behaviour of the RyR1 channel and consequently, no significant 
mitochondrial dysfunction was observed. These results were attributed to the 
fact that this particular mouse sub-line was maintained on a mixed genetic 
background that had never been explored before. I concluded that 
successive breeding to a C57BL/6J background had drastically diluted the 
disease phenotype, as well as the functional RyR1 phenotype observed in 
the founder 129S2/SvPasCrl sub-line (Zvaritch et al. 2009). Although these 
findings significantly limit the value of this mouse sub-line for studying core 
myopathy pathology, it is interesting that genetic background has such a 
strong influence on the mouse phenotype; this may explain the variable 
disease severity also seen in humans. 
In chapter 3 I described the first case of a core myopathy caused by a 
mutation in STAC3. Fibroblasts originating from this individual were 
characterised in terms of Ca2+ signalling and mitochondrial function, with the 
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purpose of providing preliminary data before a patient-specific muscle model 
is established. Histamine-induced Ca2+ release was significantly higher in the 
patient fibroblasts than in controls, which confirms that STAC3 has a role in 
general Ca2+ homeostasis but is difficult to interpret further, as fibroblasts do 
not express the EC coupling machinery that STAC3 is associated with. 
Although the mitochondrial population in the patient cells was slightly 
depolarised, O2 consumption was not affected; this discrepancy should be 
investigated further in future skeletal muscle models. 
In Chapter 4 I studied fibroblasts derived from individuals with loss-of-
function mutations in MICU1. These cells displayed a striking mitochondrial 
phenotype; their mitochondria were largely fragmented and Ca2+-loaded, 
even at basal unstimulated cytosolic Ca2+ concentrations. The sigmoidal 
dependence of mitochondrial Ca2+ uptake on [Ca2+]c was also lost in these 
cells, which is consistent with the previously characterised gatekeeping 
function of MICU1. Despite chronic activation of the MCU and increased 
activation of Ca2+-sensitive PDH, the ΔMICU1 fibroblasts showed no change 
in Δm, basal O2 consumption or ATP levels. The cells appear to have 
developed compensatory mechanisms to deal with such mitochondrial 
stress, which is perhaps reflected in the slow progression of clinical features 
in affected individuals (Logan et al. 2014; Bhosale et al. 2015). Interrupting 
mitochondrial Ca2+ efflux in these cells revealed some evidence of a futile 
Ca2+ cycle, where ongoing mitochondrial Ca2+ uptake at rest activates Na+-H+ 
exchange and effectively wastes PMF on balancing [Ca2+]m rather than 
producing ATP. This shows that mitochondrial Ca2+ accumulation carries an 
energetic cost; although this may not be so obvious in this glycolytic 
fibroblast model, it is clearly evident in the cell types primarily affected by the 
mutation i.e. muscle and neurons. The physiological role of MICU1 appears 
to be as a signal-to-noise discriminator, filtering out cell noise and restricting 
uptake to only robust Ca2+ signals, thus allowing energy demand to be 
coupled to oxidative metabolism (Bhosale et al. 2015).  
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5.2 Does mitochondrial dysfunction contribute to core myopathy 
pathology? 
I found no indication of mitochondrial dysfunction in the RYR1 I4895T mouse 
sub-line but given that there was also no evidence of RyR1 uncoupling or 
core formation, I think it is difficult to consider this particular sub-line as a 
core myopathy model. Although the same could be said about the skin 
fibroblasts I have studied, the fact that they are derived from core myopathy 
patients themselves gives them some value in answering the proposed 
question. The data collected on STAC3 W284S fibroblasts offers preliminary 
evidence of mitochondrial dysfunction inflicted by Ca2+ deregulation, though 
a lot more work is required to fully understand the patient disease pathology. 
The characterisation of fibroblasts from MICU1-deficient patients clearly 
demonstrates mitochondrial involvement in core pathology; the patients’ 
disease is primarily caused by the loss of a protein that regulates 
mitochondrial Ca2+ uptake, resulting in obvious mitochondrial stress through 
fragmentation and basal Ca2+ loading. Although there was evidence of an 
energetically wasteful mitochondrial Ca2+ cycle in these ΔMICU1 cells, the 
overall degree of bioenergetic dysfunction was relatively mild, which was 
probably due to the glycolytic nature of this fibroblast model. A ΔMICU1 
skeletal muscle model will now need to be developed to fully understand the 
patient disease pathology. 
In this thesis I have shown that defective mitochondrial Ca2+ handling has a 
role in core myopathy pathology, though many questions remain about how 
exactly this leads to muscle weakness and core formation; the genetic and 
phenotypic variability across the core myopathy spectrum makes it seem 
likely that several pathological mechanisms exist. Nevertheless, mitochondria 
are clearly an integral part of skeletal muscle Ca2+ homeostasis and should 
not be overlooked in future core myopathy research.  
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